Revvity (RVTY) 10-K 27 Feb 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 23, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Registrant Name	PERKINELMER INC
Entity Central Index Key	31,791
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2017
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		110,504,347
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 7,366,225,026

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Revenue
Product revenue	$ 1,477,414	$ 1,396,896	$ 1,395,102
Service revenue	779,568	718,621	709,721
Total revenue	2,256,982	2,115,517	2,104,823
Cost of product revenue	708,685	664,803	696,461
Cost of service revenue	475,266	437,361	444,131
Selling, general and administrative expenses	616,167	600,885	587,219
Research and development expenses	139,404	124,278	112,539
Restructuring and contract termination charges, net	12,657	5,124	13,547
Operating income from continuing operations	304,803	283,066	250,926
Interest and other expense, net	8,085	38,998	42,119
Income from continuing operations before income taxes	296,718	244,068	208,807
Provision for income taxes	139,828	28,362	20,022
Income from continuing operations	156,890	215,706	188,785
Income from discontinued operations before income taxes	650	22,229	35,205
Gain (loss) on disposition of discontinued operations before income taxes	179,615	619	(28)
Provision for income taxes on discontinued operations and dispositions	44,522	4,255	11,537
Income from discontinued operations and dispositions	135,743	18,593	23,640
Net income	$ 292,633	$ 234,299	$ 212,425
Basic earnings per share:
Income from continuing operations	$ 1.43	$ 1.97	$ 1.68
Income from discontinued operations and dispositions	1.24	0.17	0.21
Net income	2.67	2.14	1.89
Diluted earnings per share:
Income from continuing operations	1.42	1.96	1.67
Income from discontinued operations and dispositions	1.22	0.17	0.21
Net income	$ 2.64	$ 2.12	$ 1.87

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Net income	$ 292,633	$ 234,299	$ 212,425
Other comprehensive income (loss)
Foreign currency translation adjustments	54,341	(54,077)	(70,178)
Unrecognized prior service costs, net of tax	(77)	(860)	(316)
Unrealized gains (losses) on securities, net of tax	79	32	(262)
Other comprehensive income (loss)	54,343	(54,905)	(70,756)
Comprehensive income	$ 346,976	$ 179,394	$ 141,669

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Jan. 01, 2017
Current assets:
Cash and cash equivalents	$ 202,134	$ 359,265
Accounts receivable, net	552,304	425,588
Inventories	351,675	246,847
Other current assets	93,842	99,246
Current assets of discontinued operations	0	58,985
Total current assets	1,199,955	1,189,931
Property, plant and equipment, net	298,066	145,494
Intangible assets, net	1,346,940	420,224
Goodwill	3,002,198	2,247,966
Other assets, net	244,304	204,679
Long-term assets of discontinued operations	0	68,389
Total assets	6,091,463	4,276,683
Current liabilities:
Current portion of long-term debt	217,306	1,172
Accounts payable	222,093	168,033
Accrued restructuring and contract termination costs	8,759	7,479
Accrued expenses and other current liabilities	500,642	399,700
Current liabilities of discontinued operations	2,102	26,971
Total current liabilities	950,902	603,355
Long-term debt	1,788,803	1,045,254
Long-term liabilities	848,570	459,544
Long-term liabilities of discontinued operations	0	14,960
Total liabilities	3,588,275	2,123,113
Commitments and contingencies (see Notes 13 and 16)
Stockholders' equity:
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 110,361,000 and 109,617,000 shares at December 31, 2017 and January 1, 2017, respectively	110,361	109,617
Capital in excess of par value	58,828	26,130
Retained earnings	2,380,517	2,118,684
Accumulated other comprehensive income	(46,518)	(100,861)
Total stockholders' equity	2,503,188	2,153,570
Total liabilities and stockholders' equity	$ 6,091,463	$ 4,276,683

Consolidated Balance Sheet Pare

Consolidated Balance Sheet Parenthetical - $ / shares	Dec. 31, 2017	Jan. 01, 2017
Balance Sheet Parenthetical [Abstract]
Preferred stock, par value	$ 1	$ 1
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 1	$ 1
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	110,361,000	109,617,000
Common stock, outstanding	110,361,000	109,617,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock Amount [Member]	Capital In Excess of Par Value [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning Balance at Dec. 28, 2014	$ 2,042,102	$ 112,481	$ 94,276	$ 1,810,545	$ 24,800
Net income	212,425			212,425
Other comprehensive income (loss)	(70,756)				(70,756)
Dividends	(31,539)			(31,539)
Exercise of employee stock options and related income tax benefits	17,340	849	16,491
Issuance of common stock for employee benefit plans	3,686	78	3,608
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	76,439	1,595	74,844
Issuance of common stock for long-term incentive program	9,319	221	9,098
Stock compensation	4,303	0	4,303	0	0
Ending Balance at Jan. 03, 2016	2,110,441	112,034	52,932	1,991,431	(45,956)
Net income	234,299		0	234,299
Other comprehensive income (loss)	(54,905)				(54,905)
Dividends	(30,629)			(30,629)	0
Exercise of employee stock options and related income tax benefits	14,418	576	13,842
Issuance of common stock for employee benefit plans	2,463	50	2,413
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	151,801	3,275	58,058	90,468
Issuance of common stock for long-term incentive program	10,425	232	10,193
Stock compensation	4,631	0	4,631	0	0
Ending Balance at Jan. 01, 2017	2,153,570	109,617	26,130	2,118,684	(100,861)
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Info Retrospectively Adjusted	14,228	0	177	14,051	0
Net income	292,633			292,633
Other comprehensive income (loss)	54,343				54,343
Dividends	(30,800)			(30,800)
Exercise of employee stock options and related income tax benefits	18,004	578	17,426
Issuance of common stock for employee benefit plans	2,467	37	2,430
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	4,367	79	4,288
Issuance of common stock for long-term incentive program	12,353	208	12,145
Stock compensation	4,985	0	4,985	0	0
Ending Balance at Dec. 31, 2017	$ 2,503,188	$ 110,361	$ 58,828	$ 2,380,517	$ (46,518)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Operating activities:
Net income	$ 292,633	$ 234,299	$ 212,425
Income from discontinued operations and dispositions, net of income taxes	(135,743)	(18,593)	(23,640)
Income from continuing operations	156,890	215,706	188,785
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and contract termination charges, net	12,657	5,124	13,547
Depreciation and amortization	105,000	99,972	105,364
Stock-based compensation	25,421	17,158	17,278
Pension and other postretirement (benefits) expense	(10,439)	14,511	9,381
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	2,162	16,183	0
Deferred taxes	28,854	(4,549)	(9,602)
Deferred Income Tax Expense (Benefit), Continuing Operations, Discontinuing Operations	28,854	(6,526)	(6,571)
Contingencies and Non-Cash Tax Matters	182	(291)	(5,342)
Amortization of deferred debt issuance costs, interest rate hedge and accretion of discounts	2,592	2,137	1,496
Losses (gains) on disposition of businesses and assets, net	309	(5,562)	0
Amortization of acquired inventory revaluation	6,188	396	7,275
Excess tax benefit from exercise of common stock options	0	0	(2,435)
Changes in assets and liabilities which (used) provided cash, excluding effects from companies purchased and divested:
Accounts receivable, net	(36,633)	(18,960)	4,061
Inventories, net	(17,923)	6,752	(27,931)
Accounts payable	34,331	30,716	(10,897)
Accrued expenses and other	(17,436)	(53,540)	(30,177)
Net cash provided by operating activities of continuing operations	292,155	323,776	263,834
Net cash (used in) provided by operating activities of discontinued operations	(3,702)	26,839	23,264
Net cash provided by operating activities	288,453	350,615	287,098
Investing activities:
Capital expenditures	(39,089)	(31,702)	(28,218)
Proceeds from Derivative Instrument, Investing Activities	36,541	0	0
Payments to Acquire Investments	(10,783)	0	0
Proceeds from Divestiture of Businesses	1,100	21,000	0
Changes in restricted cash balances	17,218	(16,959)	59
Proceeds from surrender of life insurance policies	45	44	757
Activity related to acquisitions, net of cash and cash equivalents acquired	(1,527,183)	(71,924)	(72,040)
Net cash used in investing activities of continuing operations	(1,522,151)	(99,541)	(99,442)
Net cash provided by (used in) investing activities of discontinued operations	272,779	(1,302)	(1,414)
Net cash used in investing activities	(1,249,372)	(100,843)	(100,856)
Financing activities:
Payments on revolving credit facility	(235,965)	(902,507)	(485,000)
Proceeds from revolving credit facility	1,060,952	420,507	451,000
Proceeds from sale of senior debt	0	546,190	0
Payments of debt financing costs	0	(7,868)	0
Net payments on other credit facilities	(2,831)	(1,096)	(1,072)
Settlement of cash flow hedges	(13,824)	(1,900)	18,706
Payments for acquisition-related contingent consideration	(8,940)	(155)	(103)
Excess tax benefit from exercise of common stock options	0	0	2,435
Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options	18,004	14,418	14,905
Purchases of common stock	(3,834)	(151,801)	(76,439)
Dividends paid	(30,793)	(30,799)	(31,571)
Net cash provided by (used in) financing activities of continuing operations	782,769	(115,011)	(107,139)
Net cash used in financing activities of discontinued operations	(533)	0	0
Net cash provided by (used in) financing activities	782,236	(115,011)	(107,139)
Effect of exchange rate changes on cash and cash equivalents	21,552	(13,428)	(15,992)
Net (decrease) increase in cash and cash equivalents	(157,131)	121,333	63,111
Cash and cash equivalents at beginning of year	359,265	237,932	174,821
Cash and cash equivalents at end of year	202,134	359,265	237,932
Supplemental disclosures of cash flow information
Interest	35,780	30,718	31,741
Income taxes	$ 77,607	$ 43,549	$ 49,275

Nature of Operations and Accoun

Nature of Operations and Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Nature of Operations and Accounting Policies	Nature of Operations and Accounting Policies Nature of Operations: PerkinElmer, Inc. is a leading provider of products, services and solutions to the diagnostics, research, environmental, industrial, food and laboratory services markets. Through its advanced technologies and differentiated solutions, critical issues are addressed that help to improve lives and the world around us. The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation. The Company has two operating segments: Discovery & Analytical Solutions and Diagnostics. The Company's Discovery & Analytical Solutions segment focuses on service and innovating for customers spanning the environmental, food, industrial, life sciences research and laboratory services markets. The Company's Diagnostics segment is targeted towards meeting the needs of clinically-oriented customers, especially within the growing areas of reproductive health, emerging market diagnostics and applied genomics. The Company's fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. Each of the fiscal years ended December 31, 2017 (" fiscal year 2017 ") and January 1, 2017 (" fiscal year 2016 ") included 52 weeks. The fiscal year ended January 3, 2016 (" fiscal year 2015 ") included 53 weeks. The additional week in fiscal year 2015 has been reflected in the Company's third quarter. The fiscal year ending December 30, 2018 will include 52 weeks. Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Revenue Recognition: The Company’s product revenue is recorded when persuasive evidence of an arrangement exists, delivery has occurred, the price to the buyer is fixed or determinable, and collectability is reasonably assured. For products that include installation, and if the installation meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and installation revenue is recognized when the installation is complete. For revenue that includes customer-specified acceptance criteria, revenue is recognized after the acceptance criteria have been met. Certain of the Company’s products require specialized installation. Revenue for these products is deferred until installation is completed. Revenue from services is deferred and recognized over the contractual period, or as services are rendered. In limited circumstances, the Company has arrangements that include multiple elements that are delivered at different points of time, such as revenue from products and services with a remaining service or storage component, including cord blood processing and storage. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by a selling-price hierarchy. A deliverable in an arrangement qualifies as a separate unit of accounting if the delivered item has value to the customer on a stand-alone basis. A delivered item that does not qualify as a separate unit of accounting is combined with the other undelivered items in the arrangement and revenue is recognized for those combined deliverables as a single unit of accounting. The selling price used for each deliverable is based upon vendor-specific objective evidence ("VSOE") if such evidence is available, third-party evidence ("TPE") if VSOE is not available, and management's best estimate of selling price ("BESP") if neither VSOE nor TPE are available. TPE is the price of the Company's or any competitor's largely interchangeable products or services in stand-alone sales to similarly-situated customers. BESP is the price at which the Company would sell the deliverable if it were sold regularly on a stand-alone basis, considering market conditions and entity-specific factors. Revenue from software licenses and services was 4% of the Company's total revenue for fiscal year 2017 , and 5% for each of fiscal years 2016 and 2015 . The Company sells its software licenses with maintenance services and, in some cases, also with consulting services. For the undelivered elements, the Company determines VSOE of fair value to be the price charged when the undelivered element is sold separately. The Company determines VSOE for maintenance sold in connection with a software license based on the stated renewal rate method. The Company determines VSOE for consulting services by reference to the amount charged for similar engagements on a stand-alone basis. The Company recognizes revenue from software licenses sold together with maintenance and/or consulting services upon shipment using the residual method, provided that the above criteria have been met. If VSOE of fair value for the undelivered elements cannot be established, the Company defers all revenue from the arrangement until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered, or if the only undelivered element is maintenance, then the Company recognizes the entire fee ratably over the maintenance period. The Company recognizes revenue from the grant of certain intellectual property rights for patented technologies it owns. These rights typically include a combination of the following: the grant of a non-exclusive, retroactive and future license to patented technologies, a covenant-not-to-sue, the release of the licensee from certain claims, and the dismissal of any pending litigation. The intellectual property rights granted may be perpetual in nature, extending until the expiration of the related patents, or can be granted for a defined timeframe. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by the selling-price hierarchy. In the case where the agreement includes the dismissal of any pending litigation, the Company allocates between revenue and litigation settlement using the residual method. The Company recognizes revenue when the earnings process is complete and upon the execution of the agreement, when collectability is reasonably assured, or upon receipt of the minimum upfront fee for term agreement renewals, and when all other revenue recognition criteria have been met. Service revenues represent the Company’s service offerings including service contracts, field service including related time and materials, diagnostic testing, cord blood processing and storage, and training. Service revenues are recognized as the service is performed. Revenues for service contracts and storage contracts are recognized over the contract period. The Company sells products and accessories predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. Sales incentives related to distributor revenue are also the same as those for end-user customers. Warranty Costs : The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period. Shipping and Handling Costs: The Company reports shipping and handling revenue in revenue, to the extent they are billed to customers, and the associated costs in cost of product revenue. Inventories : Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements. Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings. The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense. See Note 6 below for additional details. Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 7 years. Certain tooling costs are capitalized and amortized over a 3 -year life, while repairs and maintenance costs are expensed. Asset Retirement Obligations : The Company records obligations associated with its lease obligations, the retirement of tangible long-lived assets and the associated asset retirement costs in accordance with authoritative guidance on asset retirement obligations. The Company reviews legal obligations associated with the retirement of long-lived assets that result from contractual obligations or the acquisition, construction, development and/or normal use of the assets. If it is determined that a legal obligation exists, regardless of whether the obligation is conditional on a future event, the fair value of the liability for an asset retirement obligation is recognized in the period in which it is incurred, if a reasonable estimate of fair value can be made. The fair value of the liability is added to the carrying amount of the associated asset, and this additional carrying amount is depreciated over the life of the asset. The difference between the gross expected future cash flow and its present value is accreted over the life of the related lease as interest expense. The amounts recorded in the consolidated financial statements are not material to any year presented. Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company immediately recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company's fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds. Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive (loss) income, a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net. Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. Measurement period adjustments are made in the period in which the amounts are determined and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed. Goodwill and Other Intangible Assets: The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of a trade name that is not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships, and purchased technologies, which are being amortized over their estimated useful lives. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. In January 2017, the Company early adopted Accounting Standards Update No. 2017-04, Intangibles-Goodwill and Other Topic (Topic 350), Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). ASU 2017-04 amends Topic 350 by eliminating Step 2 from the goodwill impairment test and requires an entity to perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which the carrying value exceeds the reporting unit's fair value but not to exceed the total amount of goodwill allocated to that reporting unit. The Company will apply the provisions of ASU 2017-04 in its interim or annual goodwill impairment tests prospectively. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized . In addition, the Company evaluates the remaining useful life of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Amortizing intangible assets are reviewed for impairment when indicators of impairment are present. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 12 below for additional details. Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 18 below. Marketable Securities and Investments: The cost of securities sold is based on the specific identification method. If securities are classified as available for sale, the Company records these investments at their fair values with unrealized gains and losses included in accumulated other comprehensive (loss) income. Under the cost method of accounting, equity investments in private companies are carried at cost and are adjusted for other-than-temporary declines in fair value, additional investments or distributions. Cash and Cash Equivalents: The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments. Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted. Research and Development: Research and development costs are expensed as incurred. The fair value of acquired IPR&D costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned. Restructuring Charges: In recent fiscal years, the Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of its operations with its growth strategy, the integration of its business units and its productivity initiatives. In connection with these initiatives, the Company has recorded restructuring charges, as more fully described in Note 4 below. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Costs related to lease terminations are recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceases use. Comprehensive Income: Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income. Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive (loss) income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements. The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of Accumulated Other Comprehensive Income ("AOCI"), as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815), Targeted Improvements to Accounting for Hedging Activities ("ASU 2017-12") , which amends the hedge accounting recognition and presentation requirements in Topic 815. ASU 2017-12 makes targeted changes to the existing hedge accounting model to better align an entity’s financial reporting for hedging relationships with the entity’s risk management activities, and to reduce the complexity of, and simplify the application of, the hedge accounting model. Specifically, ASU 2017-12 expands the types of transactions eligible for hedge accounting, eliminates the requirement to separately measure and present hedge ineffectiveness, simplifies the way assessments of hedge ineffectiveness may be performed, relaxes the documentation requirements for entering into hedging positions, provides targeted improvements to fair value hedges of interest rate risk, and permits an entity to exclude the change in the fair value of cross-currency basis spreads in currency swaps from the assessment of hedge effectiveness. The standard also requires entities to provide new disclosures about the impact fair value and cash flow hedges have on their income statements and about cumulative basis adjustments arising from fair value hedges. The provisions of this guidance are to be applied using a modified retrospective approach to existing hedging relationships as of the adoption date. However, the transition provisions allow for certain elections at the date of adoption and entities may choose to apply any of the provided elections. ASU 2017-12 is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The Company early adopted the provisions of this guidance beginning after December 31, 2017. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In May 2017, the FASB issued Accounting Standards Update No. 2017-09, Compensation - Stock Compensation (Topic 718), Scope of Modification Accounting ("ASU 2017-09") , which amends the scope of modification accounting for share-based payment arrangements. ASU 2017-09 provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under Topic 718. Specifically, an entity would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. If an entity modifies its awards and concludes that it is not required to apply modification accounting under the standard, it must still consider whether the modification affects its application of other guidance. Additionally, if a significant modification does not result in incremental compensation cost, entities are required to disclose the “lack of” incremental compensation cost resulting from such significant modification. The standard also removes the guidance in Topic 718 stating that modification accounting is not required when an entity adds an antidilution provision as long as that modification is not made in contemplation of an equity restructuring. The provisions of this guidance are to be applied on a prospective basis to awards modified on or after the effective date. ASU 2017-09 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In March 2017, the FASB issued Accounting Standards Update No. 2017-07, Compensation - Retirement Benefits (Topic 715), Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost ("ASU 2017-07") , which amends the requirements in Topic 715 related to the income statement presentation of the components of net periodic benefit cost for an entity’s sponsored defined benefit pension and other postretirement plans. ASU 2017-07 requires entities to (1) disaggregate the current-service-cost component from the other components of net benefit cost (the “other components”) and present it with other current employee compensation costs in their income statements and (2) present the other components elsewhere in their income statements and outside of income from operations, and disclose the income statement lines that contain the other components if they are not presented on appropriately described separate lines. Additionally, the standard requires that only the service-cost component of net benefit cost is eligible for capitalization (e.g., as part of inventory or property, plant, and equipment). The change in income statement presentation requires retrospective application, while the change in capitalized benefit cost is to be applied prospectively. ASU 2017-07 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The standard provides a practical expedient that permits entities to use the components of cost disclosed in prior years as a basis for the retrospective application of the new income statement presentation. Entities need to disclose the use of the practical expedient. The Company is evaluating the requirements of this guidance. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In January 2017, the FASB issued ASU 2017-04 , Intangibles-Goodwill and Other Topic (Topic 350), Simplifying the Test for Goodwill Impairment ("ASU 2017-04") , which amends Topic 350 to simplify the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 requires that an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize the impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider the income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring th

Business Combinations and Asset

Business Combinations and Asset Purchases	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Business Combinations and Asset Purchases	Business Combinations Acquisitions in fiscal year 2017 Acquisition of EUROIMMUN Medizinische Labordiagnostika AG. During fiscal year 2017 , the Company completed the acquisition of 99.98% of the outstanding stock of EUROIMMUN Medizinische Labordiagnostika AG (“EUROIMMUN”) for aggregate consideration of €1.2 billion (equivalent to $1.4 billion at December 19, 2017, the time of closing). The purchase price was funded by borrowings from the Company's senior unsecured revolving credit facility and senior unsecured term loan credit facility of $710.0 million and $200.0 million , respectively, and available cash on hand of $503.8 million . EUROIMMUN is based in Lübeck, Germany, has approximately 2,400 employees, and is recognized as a global leader in autoimmune testing and an emerging force in infectious disease and allergy testing. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired. As a result of the acquisition, the Company recorded goodwill of $614.8 million , which is not tax deductible, and intangible assets of $897.4 million . The Company has reported the operations for this acquisition within the results of the Company's Diagnostics segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of this acquisition had a weighted average amortization period of 16.1 years . Other acquisitions in 2017. During fiscal year 2017 , the Company also completed the acquisition of two other businesses for aggregate consideration of $142.1 million . The acquired businesses were Tulip Diagnostics Private Limited (“Tulip”), which was acquired for total consideration of $127.3 million in cash and one other business acquired for total consideration of $14.8 million in cash. The Company has a potential obligation to pay the former shareholders of Tulip up to INR 1.6 billion in additional consideration over a two year period, which is currently equivalent to $25.2 million , and is accounted for as compensation expense in the Company's financial statements over a two year period and is excluded from the purchase price allocation shown below. The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations of Tulip within the results of the Company's Diagnostics segment and the other acquired business within the results of the Company's Discovery & Analytical Solutions segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 11.8 years . The total purchase price for the acquisitions in fiscal year 2017 have been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: EUROIMMUN 2017 Other (In thousands) Fair value of business combination: Cash payments $ 1,413,780 $ 140,861 Other liability — 1,273 Less: cash acquired (25,018 ) (2,439 ) Total $ 1,388,762 $ 139,695 Identifiable assets acquired and liabilities assumed: Current assets $ 121,174 $ 16,268 Property, plant and equipment 129,964 11,356 Other assets 49,944 1,691 Identifiable intangible assets: Core technology 160,000 12,400 Trade names 36,000 3,000 Customer relationships 700,000 43,700 In-process research and development ("IPR&D") 1,400 — Goodwill 614,759 75,453 Deferred taxes (275,491 ) (15,414 ) Liabilities assumed (87,631 ) (8,759 ) Debt assumed (61,357 ) — Total $ 1,388,762 $ 139,695 EUROIMMUN's revenue and net loss for the period from the acquisition date to December 31, 2017 were $13.5 million and $1.0 million , respectively. The following unaudited pro forma information presents the combined financial results for the Company and EUROIMMUN as if the acquisition of EUROIMMUN had been completed at the beginning of fiscal year 2016: December 31, January 1, (In thousands, except per share data) Pro Forma Statement of Operations Information (Unaudited): Revenue $ 2,562,580 $ 2,379,176 Income from continuing operations 143,459 156,210 Basic earnings per share: Income from continuing operations $ 1.31 $ 1.43 Diluted earnings per share: Income from continuing operations $ 1.29 $ 1.42 The unaudited pro forma information for fiscal years 2017 and 2016 have been calculated after applying the Company's accounting policies and the impact of acquisition date fair value adjustments. The fiscal year 2017 unaudited pro forma income from continuing operations was adjusted to exclude approximately $9.8 million of acquisition-related transaction costs. The fiscal year 2016 pro forma income from continuing operations was adjusted to include these acquisition-related transaction costs and the nonrecurring expenses related to the fair value adjustments. These pro forma condensed consolidated financial results have been prepared for comparative purposes only and include certain adjustments, such as fair value adjustment to inventory, increased interest expense on debt obtained to finance the transaction, and increased amortization for the fair value of acquired intangible assets. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities. Acquisitions in fiscal year 2016 During fiscal year 2016 , the Company completed the acquisition of two businesses for total consideration of $72.3 million in cash. The acquired businesses were Bioo Scientific Corporation, which was acquired for total consideration of $63.5 million in cash and one other business acquired for total consideration of $8.8 million in cash. The excess of the purchase prices over the fair values of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired. As a result of the acquisitions, the Company recorded goodwill of $43.1 million , which is not tax deductible, and intangible assets of $22.1 million . The Company has reported the operations for these acquisitions within the results of the Company's Diagnostics and Discovery & Analytical Solutions segments from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 9.4 years . The total purchase price for the acquisitions in fiscal year 2016 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2016 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 72,497 Working capital and other adjustments (261 ) Less: cash acquired (2,152 ) Total $ 70,084 Identifiable assets acquired and liabilities assumed: Current assets $ 7,153 Property, plant and equipment 7,542 Identifiable intangible assets: Core technology 6,600 Trade names 570 Customer relationships 14,900 Goodwill 43,072 Deferred taxes (7,768 ) Liabilities assumed (1,985 ) Total $ 70,084 Acquisitions in fiscal year 2015 During fiscal year 2015, the Company completed the acquisition of five businesses for total consideration of $77.1 million in cash. The acquired businesses included Vanadis Diagnostics AB (“Vanadis”), which was acquired for total consideration of $35.1 million in cash, as further described in Note 21 below, and other acquisitions for aggregate consideration of $42.0 million in cash. At the time of closing, the Company had a potential obligation to pay the shareholders of Vanadis additional contingent consideration of up to $93.0 million , with an estimated fair value of $56.9 million . The excess of the purchase prices over the fair values of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, of which $9.2 million is tax deductible. The Company has reported the operations for all of these acquisitions within the results of the Company’s Diagnostics and Discovery & Analytical Solutions segments from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology and trade names, acquired as part of these acquisitions had a weighted average amortization period of 9 years . The total purchase price for the acquisitions in fiscal year 2015 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2015 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 75,285 Contingent consideration 56,878 Working capital and other adjustments 1,832 Less: cash acquired (3,864 ) Total $ 130,131 Identifiable assets acquired and liabilities assumed: Current assets $ 2,551 Property, plant and equipment 998 Identifiable intangible assets: Core technology 15,759 Trade names 200 Licenses 116 Customer relationships 3,073 IPR&D 75,700 Goodwill 53,112 Deferred taxes (18,528 ) Liabilities assumed (2,850 ) Total $ 130,131 The Company does not consider the acquisitions completed during fiscal years 2017, 2016 and 2015 , with the exception of the EUROIMMUN acquisition, to be material to its consolidated results of operations; therefore, the Company is only presenting pro forma financial information of operations for the EUROIMMUN acquisition. The aggregate revenue for the acquisitions, with the exception of EUROIMMUN, completed during fiscal year 2017 for the period from their acquisition dates to December 31, 2017 was $38.5 million and the results of operations were no t material. The aggregate revenue and results of operations for the acquisitions completed during fiscal years 2016 and 2015 for the period from their respective acquisition dates to December 31, 2017 and January 1, 2017 were minimal. The Company has also determined that the presentation of the results of operations for each of those acquisitions, from the date of acquisition, is impracticable due to the integration of the operations upon acquisition. As of December 31, 2017 , the allocations of purchase prices for acquisitions completed in fiscal years 2016 and 2015 were final. The preliminary allocations of the purchase prices for acquisitions completed in fiscal year 2017 were based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete its valuations within the measurement periods, which are up to one year from the respective acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. These adjustments will be made in the periods in which the amounts are determined and the cumulative effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition dates. All changes that do not qualify as adjustments made during the measurement periods are also included in current period earnings. During fiscal year 2017 , the Company obtained information relevant to determining the fair values of certain tangible and intangible assets acquired, and liabilities assumed, related to recent acquisitions and adjusted its purchase price allocations. Based on this information, for the Bioo acquisition, the Company recognized an increase in intangible assets of $2.2 million , a decrease in deferred tax liabilities of $0.5 million , a decrease in current assets of $0.1 million , and a decrease in goodwill of $2.6 million , and for the Tulip acquisition, the Company recognized an increase in property and equipment of $1.7 million , with a corresponding decrease in goodwill. Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. As of December 31, 2017 , the Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $83.0 million . As of December 31, 2017 , the Company has recorded contingent consideration obligations of $65.3 million , of which $52.2 million was recorded in accrued expenses and other current liabilities, and $13.1 million was recorded in long-term liabilities. As of January 1, 2017 , the Company has recorded contingent consideration obligations of $63.2 million , of which $15.4 million was recorded in accrued expenses and other current liabilities, and $47.8 million was recorded in long-term liabilities. The expected maximum earnout period for acquisitions with open contingency periods does not exceed 1.75 years from the respective acquisition dates, and the remaining weighted average expected earnout period at December 31, 2017 was 11 months. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional contingent consideration which would be recognized as a component of operating expenses from continuing operations. In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of deferred revenue assumed with its acquisitions. The estimated fair value of deferred revenue is determined by the legal performance obligation at the date of acquisition, and is generally based on the nature of the activities to be performed and the related costs to be incurred after the acquisition date. The fair value of an assumed liability related to deferred revenue is estimated based on the current market cost of fulfilling the obligation, plus a normal profit margin thereon. The estimated costs to fulfill the deferred revenue are based on the historical direct costs related to providing the services. The Company does not include any costs associated with selling effort, research and development, or the related margins on these costs. In most acquisitions, profit associated with selling effort is excluded because the acquired businesses would have concluded the selling effort on the support contracts prior to the acquisition date. The estimated research and development costs are not included in the fair value determination, as these costs are not deemed to represent a legal obligation at the time of acquisition. The sum of the costs and operating income approximates, in theory, the amount that the Company would be required to pay a third-party to assume the obligation. Total transaction costs related to acquisition and divestiture activities for fiscal years 2017, 2016 and 2015 were $10.8 million , $1.2 million and $0.7 million , respectively. These transaction costs were expensed as incurred and recorded in selling, general and administrative expenses in the Company's consolidated statements of operations.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Disposition of Businesses and Assets As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. When the discontinued operations represented a strategic shift that will have a major effect on the Company's operations and financial statements, the Company has accounted for these businesses as discontinued operations and accordingly, has presented the results of operations and related cash flows as discontinued operations. Any business deemed to be a discontinued operation prior to the adoption of ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of An Entity, continues to be reported as a discontinued operation, and the results of operations and related cash flows are presented as discontinued operations for all periods presented. Any remaining assets and liabilities of these businesses have been presented separately, and are reflected within assets and liabilities from discontinued operations in the accompanying consolidated balance sheets as of December 31, 2017 and January 1, 2017 . The Company recorded the following pre-tax gains and losses, which have been reported as a net gain or loss on disposition of discontinued operations during the three fiscal years ended: December 31, January 1, January 3, (In thousands) Gain on disposition of the Medical Imaging business $ 179,615 $ — $ — Gain (loss) on disposition of Technical Services business — 1,753 (28 ) Loss on disposition of Fluid Sciences Segment — (1,134 ) — Gain (loss) on disposition of discontinued operations before income taxes $ 179,615 $ 619 $ (28 ) On May 1, 2017 (the "Closing Date"), the Company completed the sale of its Medical Imaging business to Varex Imaging Corporation ("Varex") pursuant to the terms of the Master Purchase and Sale Agreement, dated December 21, 2016 (the “Agreement”), by and between the Company and Varian Medical Systems, Inc. ("Varian") and the subsequent Assignment and Assumption Agreement, dated January 27, 2017, between Varian and Varex, pursuant to which Varian assigned its rights under the Agreement to Varex. On the Closing Date, the Company received consideration of approximately $277.4 million for the sale of the Medical Imaging business. During fiscal year 2017, the Company paid Varex $4.2 million to settle a post-closing working capital adjustment. During fiscal year 2017, the Company recorded a pre-tax gain of $179.6 million and income tax expense of $43.1 million related to the sale of the Medical Imaging business in discontinued operations and dispositions. The corresponding tax liability was recorded within the other tax liabilities in the consolidated balance sheet, and the Company expects to utilize tax attributes to minimize the tax liability. Following the closing, the Company is providing certain customary transitional services during a period of up to 12 months . Commercial transactions between the parties following the closing of the transaction are not expected to be significant. The Company presented its Medical Imaging business as discontinued operations in the Company's consolidated financial statements for fiscal years 2016 and 2015. The results of discontinued operations during fiscal year 2017 include the results of the Medical Imaging business through April 30, 2017. During fiscal year 2017, the Company sold Suzhou PerkinElmer Medical Laboratory Co., Ltd. for aggregate consideration of $2.3 million , recognizing a pre-tax loss of $1.1 million . The pre-tax loss recognized in fiscal year 2017 is included in interest and other expense, net in the consolidated statement of operations. Suzhou PerkinElmer Medical Laboratory Co., Ltd. was a component of the Company's Diagnostics segment. The divestiture of Suzhou PerkinElmer Medical Laboratory Co., Ltd. has not been classified as a discontinued operation in this Form 10-K because the disposition does not represent a strategic shift that will have a major effect on the Company's operations and financial statements. During fiscal year 2016 , the Company sold PerkinElmer Labs, Inc. for cash consideration of $20.0 million , recognizing a pre-tax gain of $7.1 million . The sale generated a capital loss for tax purposes of $7.3 million , which resulted in an income tax benefit of $2.5 million that was recognized as a discrete benefit during the second quarter of 2016. During fiscal year 2017 , the Company recognized an additional pre-tax gain of $1.1 million relating to the earn-out consideration received from the buyer. PerkinElmer Labs, Inc. was a component of the Company's Diagnostics segment. The pre-tax gain recognized in fiscal years 2017 and 2016 is included in interest and other expense, net in the consolidated statement of operations. The divestiture of PerkinElmer Labs, Inc. has not been classified as a discontinued operation in this Form 10-K because the disposition does not represent a strategic shift that will have a major effect on the Company's operations and financial statements. During fiscal year 2016 , the Company entered into a letter of intent to contribute certain assets to an academic institution in the United Kingdom. The Company recognized a pre-tax loss of $1.6 million related to the write-off of assets in the second quarter of 2016 which is included in interest and other expense, net in the consolidated statement of operations. In August 1999, the Company sold the assets of its Technical Service business. The Company recorded pre-tax gains (losses) of $1.8 million in fiscal year 2016 and $(0.03) million in fiscal year 2015 for a contingency related to this business. These gains (losses) were recognized as a gain (loss) on disposition of discontinued operations before income taxes. The summary pre-tax operating results of the discontinued operations were as follows during the three fiscal years ended: December 31, January 1, January 3, (In thousands) Revenue $ 44,343 $ 146,217 $ 158,128 Cost of revenue 32,933 95,395 97,777 Selling, general and administrative expenses 5,869 13,657 11,712 Research and development expenses 4,891 14,368 13,391 Restructuring and contract termination charges, net — 568 43 Income from discontinued operations before income taxes $ 650 $ 22,229 $ 35,205 The Company recorded a tax provision of $44.5 million , $4.3 million and $11.5 million on discontinued operations and dispositions in fiscal years 2017, 2016 and 2015 , respectively. The carrying amounts of the major classes of assets and liabilities included in discontinued operations as of December 31, 2017 and January 1, 2017 consisted of the following: December 31, January 1, (In thousands) Current assets of discontinued operations: Accounts receivables $ — $ 28,400 Inventories — 26,977 Prepaid income taxes — 425 Other current assets — 3,183 Total current assets of discontinued operations — 58,985 Property, plant and equipment — 25,219 Intangible assets — 3,292 Goodwill — 38,794 Other assets, net — 1,084 Long-term assets of discontinued operations — 68,389 Total assets of discontinued operations $ — $ 127,374 Current liabilities of discontinued operations: Accounts payable $ — $ 16,770 Accrued restructuring and contract termination charges — 209 Accrued expenses and other current liabilities 2,102 9,992 Total current liabilities of discontinued operations 2,102 26,971 Deferred income taxes — 7,851 Long-term liabilities — 7,109 Total long-term liabilities — 14,960 Total liabilities of discontinued operations $ 2,102 $ 41,931

Restructuring and Contract Term

Restructuring and Contract Termination Charges, Net	12 Months Ended
	Dec. 31, 2017
Restructuring and Related Activities [Abstract]
Restructuring and Contract Termination Charges, Net	Restructuring and Contract Termination Charges, Net The Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of the Company's operations with its growth strategy, the integration of its business units and its productivity initiatives. The current portion of restructuring and contract termination charges is recorded in accrued restructuring and contract termination charges and the long-term portion of restructuring and contract termination charges is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges, net, as applicable, and are included as a component of income from continuing operations. The Company implemented a restructuring plan in each of the fourth and third quarters of fiscal year 2017 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q4 2017 Plan and "Q3 2017 Plan", respectively). The Company implemented a restructuring plan in the first quarter of fiscal year 2017 consisting of workforce reductions and the closure of excess facility space principally intended to focus resources on higher growth end markets (the "Q1 2017 Plan"). The Company implemented a restructuring plan in the third quarter of fiscal year 2016 consisting of workforce reductions principally intended to focus resources on higher growth product lines (the "Q3 2016 Plan"). The Company implemented a restructuring plan in the second quarter of fiscal year 2016 consisting of workforce reductions principally intended to focus resources on higher growth end markets (the "Q2 2016 Plan"). The Company implemented a restructuring plan in the fourth quarter of fiscal year 2015 consisting of workforce reductions and the closure of excess facility space principally intended to focus resources on higher growth end markets (the "Q4 2015 Plan"). The Company implemented a restructuring plan in the second quarter of fiscal year 2015 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q2 2015 Plan"). All other previous restructuring plans were workforce reductions or the closure of excess facility space principally intended to integrate the Company's businesses in order to realign operations, reduce costs, achieve operational efficiencies and shift resources into geographic regions and end markets that are more consistent with the Company's growth strategy (the "Previous Plans"). The following table summarizes the number of employees reduced, the initial restructuring or contract termination charges by operating segment, and the dates by which payments were substantially completed, or the expected dates by which payments will be substantially completed, for restructuring actions implemented during fiscal years 2017, 2016 and 2015 in continuing operations: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Diagnostics Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Severance Excess Facility (In thousands, except headcount data) Q4 2017 Plan 29 $ 255 $ 1,680 $ — $ — $ 1,935 Q1 FY2019 — Q3 2017 Plan 27 1,021 1,321 — — 2,342 Q4 FY2018 — Q1 2017 Plan 90 1,631 5,000 33 33 6,697 Q2 FY2018 Q2 FY2018 Q3 2016 Plan 22 41 1,779 — — 1,820 Q4 FY2017 — Q2 2016 Plan 72 561 4,106 — — 4,667 Q3 FY2017 — Q4 2015 Plan 174 1,315 9,980 — 285 11,580 Q1 FY2017 Q4 FY2017 Q2 2015 Plan 95 673 5,290 — — 5,963 Q2 FY2016 — The Company expects to make payments under the Previous Plans for remaining residual lease obligations, with terms varying in length, through fiscal year 2022 . The Company also has terminated various contractual commitments in connection with certain disposal activities and has recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to the Company. The Company recorded additional pre-tax charges of $3.6 million , $0.1 million and $0.1 million in the Discovery & Analytical Solutions segment during fiscal years 2017, 2016 and 2015 , respectively, and $0.5 million during fiscal year 2017 , in the Diagnostics segment as a result of these contract terminations. At December 31, 2017 , the Company had $14.0 million recorded for accrued restructuring and contract termination charges, of which $8.8 million was recorded in short-term accrued restructuring, $2.3 million was recorded in long-term liabilities and $2.9 million was recorded in other reserves. At January 1, 2017 , the Company had $10.5 million recorded for accrued restructuring and contract termination charges, of which $7.5 million was recorded in short-term accrued restructuring and $3.1 million was recorded in long-term liabilities. The following table summarizes the Company's restructuring accrual balances and related activity by restructuring plan, as well as contract termination accrual balances and related activity, during fiscal years 2017, 2016 and 2015 in continuing operations: Balance at December 28, 2014 2015 Charges and Changes in Estimates, Net 2015 Amounts Paid Balance at January 3, 2016 2016 Charges and Changes in Estimates, Net 2016 Amounts Paid Balance at January 1, 2017 2017 Charges and Changes in Estimates, Net 2017 Amounts Paid Balance at December 31, 2017 (In thousands) Severance: Q4 2017 Plan $ — $ — $ — $ — $ — $ — $ — $ 1,935 $ (16 ) $ 1,919 Q3 2017 Plan — — — — — — — 2,342 (270 ) 2,072 Q1 2017 Plan — — — — — — — 6,631 (4,133 ) 2,498 Q3 2016 Plan — — — — 1,820 (612 ) 1,208 (202 ) (1,006 ) — Q2 2016 Plan (1) — — — — 4,667 (3,231 ) 1,436 (829 ) (607 ) — Q4 2015 Plan (2) — 11,295 (925 ) 10,370 (953 ) (8,198 ) 1,219 (1,066 ) (153 ) — Q2 2015 Plan — 5,423 (4,322 ) 1,101 (533 ) (370 ) 198 (198 ) — — Facility: Q1 2017 Plan — — — — — — — 66 (33 ) 33 Q4 2015 Plan — 285 (26 ) 259 — (248 ) 11 — — 11 Previous Plans (3) 23,522 (3,539 ) (9,695 ) 10,288 35 (3,971 ) 6,352 727 (2,691 ) 4,388 Restructuring 23,522 13,464 (14,968 ) 22,018 5,036 (16,630 ) 10,424 9,406 (8,909 ) 10,921 Contract Termination 304 83 (255 ) 132 88 (103 ) 117 3,251 (320 ) 3,048 Total Restructuring and Contract Termination $ 23,826 $ 13,547 $ (15,223 ) $ 22,150 $ 5,124 $ (16,733 ) $ 10,541 $ 12,657 $ (9,229 ) $ 13,969 ____________________________ (1) During fiscal year 2017 , the Company recognized pre-tax restructuring reversals of $0.4 million each in the Discovery & Analytical Solutions and Diagnostics segments, related to lower than expected costs associated with workforce reductions for the Q2 2016 Plan. (2) During fiscal year 2017 , the Company recognized pre-tax restructuring reversals of $0.5 million each in the Discovery & Analytical Solutions and Diagnostics segments related, to lower than expected costs associated with workforce reductions for the Q4 2015 Plan. (3) During fiscal year 2017 , the Company recognized pre-tax restructuring charges of $0.3 million in the Discovery & Analytical Solutions and $0.4 million in the Diagnostics segments related to change in lease assumptions partially offset by lower than expected costs associated with workforce reductions for the Previous Plans.

Interest and Other Expense (Inc

Interest and Other Expense (Income), Net	12 Months Ended
	Dec. 31, 2017
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and Other Expense, Net Interest and other expense, net, consisted of the following for the fiscal years ended: December 31, January 1, January 3, Interest income $ (2,571 ) $ (702 ) $ (673 ) Interest expense 43,940 41,528 37,997 Losses (gains) on disposition of businesses and assets, net (see Note 3) 309 (5,562 ) — Other (income) expense, net (33,593 ) 3,734 4,795 Total interest and other expense, net $ 8,085 $ 38,998 $ 42,119 Foreign currency transaction (gains) losses were $(29.2) million , $(1.5) million and $25.3 million in fiscal years 2017, 2016 and 2015 , respectively. Net (gains) losses from forward currency hedge contracts were $(4.5) million , $5.4 million and $(20.6) million in fiscal years 2017, 2016 and 2015 , respectively. These amounts were included in other (income) expense, net.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position. The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended: December 31, January 1, January 3, (In thousands) Unrecognized tax benefits, beginning of year $ 29,607 $ 28,143 $ 32,342 Gross increases—tax positions in prior periods 749 1,514 325 Gross decreases—tax positions in prior periods (828 ) (183 ) (2,305 ) Gross increases—current-period tax positions 2,346 3,547 — Settlements (324 ) — (441 ) Lapse of statute of limitations (1,371 ) (4,109 ) (1,077 ) Foreign currency translation adjustments 129 695 (701 ) Unrecognized tax benefits, end of year $ 30,308 $ 29,607 $ 28,143 The Company classifies interest and penalties as a component of income tax expense. At December 31, 2017 and January 1, 2017 , the Company had accrued interest and penalties of $1.9 million and $2.2 million , respectively. During fiscal years 2017, 2016 and 2015 , the Company recognized a net benefit of $0.3 million , $0.1 million and $1.6 million , respectively, for interest and penalties in its total tax provision primarily due to settlements and statutes of limitations that had lapsed. At December 31, 2017 , the Company had gross tax effected unrecognized tax benefits of $30.3 million , of which $28.6 million , if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations. The Company believes that it is reasonably possible that approximately $3.1 million of its uncertain tax positions at December 31, 2017 , including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2010 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as Finland, Germany, Italy, Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction. On December 22, 2017, the President of the United States signed into law tax reform legislation, known as the Tax Cuts and Jobs Act (the "Tax Act"). The Tax Act makes broad and complex changes to the U.S. Internal Revenue Code, which includes reducing the corporate income tax rate from 35% to 21% and implementing a modified territorial tax system that includes a one-time transition tax on deemed repatriated earnings of foreign subsidiaries. Based on currently available information, the Company performed a preliminary analysis of the impacts of the Tax Act and recorded a discrete tax expense of $106.5 million during fiscal year 2017, which comprised of $21.5 million from the remeasurement of certain net deferred tax assets using the lower enacted corporate income tax rate and $85.0 million from the one-time deemed repatriation tax on earnings of foreign subsidiaries, which will be paid over 8 years. The estimated provision incorporates assumptions made based upon the Company’s current interpretation of the Tax Act, and may change as additional clarification and implementation guidance becomes available during 2018. The Company will be subject to the new Global Intangible Low Tax Income ("GILTI") tax rules that are part of the modified territorial tax system imposed by the Tax Act. Because of the complexity of the new rules, the Company continues to evaluate this provision of the Tax Act and the application of ASC 740. Under U.S. GAAP, the Company is allowed to make an accounting policy choice of either (1) treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current-period expense when incurred (the “period cost method”) or (2) factoring such amounts into our measurement of deferred taxes (the “deferred method”). The Company's selection of an accounting policy with respect to the new GILTI tax rules will depend, in part, on analyzing its global income to determine whether it expects to have future U.S. inclusions in taxable income related to GILTI and, if so, what the impact is expected to be. Because whether the Company expects to have future U.S. inclusions in taxable income related to GILTI depends not only on its current structure and estimated future results of global operations, but also on the Company's intent and ability to modify its structure and/or business, the Company is currently unable to reasonably estimate the effect of this provision of the Tax Act. Therefore, the Company has not made any adjustments related to potential GILTI tax in the consolidated financial statements and has not made a policy decision regarding whether to record deferred taxes on GILTI. During fiscal year 2017 , the Company recorded net discrete income tax expense of $98.6 million , of which $106.5 million was a result of the enactment of the Tax Act, partially offset by discrete benefit of $5.1 million related to the recognition of excess tax benefits on stock compensation and the resolution of other tax matters. During fiscal years 2016 and 2015 , the Company recorded net discrete income tax benefits of $9.6 million and $6.4 million , respectively, primarily related to the recognition of excess tax benefits on stock compensation, reversals of uncertain tax position reserves, and resolution of other tax matters. The components of income (loss) from continuing operations before income taxes were as follows for the fiscal years ended: December 31, January 1, January 3, (In thousands) U.S. $ 3,743 $ 39,689 $ (21,510 ) Non-U.S. 292,975 204,379 230,317 Total $ 296,718 $ 244,068 $ 208,807 On a U.S. income tax basis, the Company has reported significant taxable income over the three year period ended December 31, 2017 . The Company has utilized tax attributes to minimize cash taxes paid on that taxable income. The components of the provision for (benefit from) income taxes for continuing operations were as follows: Current Expense (Benefit) Deferred Expense (Benefit) Total (In thousands) Fiscal year ended December 31, 2017 Federal $ 62,003 $ 35,435 $ 97,438 State 3,332 (792 ) 2,540 Non-U.S. 45,639 (5,789 ) 39,850 Total $ 110,974 $ 28,854 $ 139,828 Fiscal year ended January 1, 2017 Federal $ 14 $ 2,994 $ 3,008 State 2,143 (575 ) 1,568 Non-U.S. 30,754 (6,968 ) 23,786 Total $ 32,911 $ (4,549 ) $ 28,362 Fiscal year ended January 3, 2016 Federal $ (10,952 ) $ (4,794 ) $ (15,746 ) State 2,613 (2,563 ) 50 Non-U.S. 37,963 (2,245 ) 35,718 Total $ 29,624 $ (9,602 ) $ 20,022 The total provision for income taxes included in the consolidated financial statements is as follows for the fiscal years ended: December 31, January 1, January 3, (In thousands) Continuing operations $ 139,828 $ 28,362 $ 20,022 Discontinued operations 44,522 4,255 11,537 Total $ 184,350 $ 32,617 $ 31,559 A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended: December 31, January 1, January 3, (In thousands) Tax at statutory rate $ 103,851 $ 85,424 $ 73,082 Non-U.S. rate differential, net (65,836 ) (52,648 ) (47,994 ) U.S. taxation of multinational operations 5,408 6,941 1,732 State income taxes, net 1,810 1,509 80 Prior year tax matters (7,955 ) (9,621 ) (6,387 ) Federal tax credits (8,249 ) (7,189 ) (2,096 ) Change in valuation allowance 1,951 (2,755 ) 2,593 Non-deductible acquisition expense — 5,701 — Impact of federal tax reform 106,538 — — Others, net 2,310 1,000 (988 ) Total $ 139,828 $ 28,362 $ 20,022 The variation in the Company's effective tax rate for each year is primarily a result of the recognition of earnings in foreign jurisdictions, predominantly Singapore, Finland, Netherlands and China, which are taxed at rates lower than the U.S. federal statutory rate, resulting in a benefit from income taxes of $55.9 million in fiscal year 2017 , $48.2 million in fiscal year 2016 and $36.1 million in fiscal year 2015 . These amounts include $10.1 million in fiscal year 2017 , $11.4 million in fiscal year 2016 and $8.3 million in fiscal year 2015 of benefits derived from tax holidays in China and Singapore. The effect of these benefits derived from tax holidays on basic and diluted earnings per share for fiscal year 2017 was $0.09 and $0.09 , respectively, for fiscal year 2016 was $0.10 and $0.10 , respectively, and for fiscal year 2015 was $0.07 and $0.07 , respectively. The tax holiday in one of the Company's subsidiaries in China expired in 2017 and the tax holiday in one other subsidiary in China is scheduled to expire in fiscal year 2019 . The tax holiday in one of the Company's subsidiaries in Singapore is scheduled to expire in fiscal year 2018 . The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of December 31, 2017 and January 1, 2017 were as follows: December 31, January 1, (In thousands) Deferred tax assets: Inventory $ 6,376 $ 10,994 Reserves and accruals 26,657 24,669 Accrued compensation 17,333 26,715 Net operating loss and credit carryforwards 88,503 113,415 Accrued pension 34,682 37,005 Restructuring reserve 2,586 1,954 Deferred revenue 28,478 38,113 Unrealized foreign exchange loss 10,910 — All other, net — 682 Total deferred tax assets 215,525 253,547 Deferred tax liabilities: Postretirement health benefits (3,391 ) (4,785 ) Unrealized foreign exchange gain — (15,730 ) Depreciation and amortization (392,293 ) (130,176 ) All other, net (594 ) — Total deferred tax liabilities (396,278 ) (150,691 ) Valuation allowance (68,895 ) (65,640 ) Net deferred tax (liabilities) assets $ (249,648 ) $ 37,216 The components of net deferred tax (liabilities) assets as of December 31, 2017 and January 1, 2017 were recognized in the consolidated balance sheets as follows: December 31, January 1, (In thousands) Other assets, net $ 67,280 $ 85,312 Long-term liabilities (316,928 ) (48,096 ) Total $ (249,648 ) $ 37,216 At December 31, 2017 , for income tax return purposes, the Company had U.S. federal net operating loss carryforwards of $40.6 million , state net operating loss carryforwards of $198.6 million , foreign net operating loss carryforwards of $263.1 million , state tax credit carryforwards of $6.0 million , general business tax credit carryforwards of $0.1 million , and foreign tax credit carryforwards of $0.1 million . These are subject to expiration in years ranging from 2018 to 2037 , and without expiration for certain foreign net operating loss carryforwards and certain state credit carryforwards. Valuation allowances take into consideration limitations imposed upon the use of the tax attributes and reduce the value of such items to the likely net realizable amount. The Company regularly evaluates positive and negative evidence available to determine if valuation allowances are required or if existing valuation allowances are no longer required. Valuation allowances have been provided on state net operating loss and state tax credit carryforwards and on certain foreign tax attributes that the Company has determined are not more likely than not to be realized. The increase in the valuation allowance of $3.3 million in fiscal year 2017 is primarily due to an increase in tax attributes that the Company does not expect to realize for one of its non-U.S. subsidiaries. The components of net deferred tax (liabilities) assets as of December 31, 2017 and January 1, 2017 were as follows: December 31, January 1, (In thousands) U.S. $ 44,974 $ 52,604 Non-U.S. (294,622 ) (15,388 ) Total $ (249,648 ) $ 37,216 The Company plans to keep its unremitted foreign earnings indefinitely reinvested overseas except for instances where the Company can remit such earnings to the U.S. without an associated net incremental tax cost, such as withholding or state and local taxes. The Company's indefinite reinvestment determination is based on the future operational and capital requirements of its U.S. and non-U.S. operations. As of December 31, 2017 , the amount of foreign earnings that the Company has the intent and ability to keep invested outside the U.S. indefinitely and for which no additional incremental U.S. tax cost has been provided, other than the $85.0 million from the one-time transition tax on deemed repatriation, was approximately $1.4 billion . It is not practical to calculate the unrecognized deferred tax liability related to such incremental tax costs on those earnings.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended: December 31, January 1, January 3, (In thousands) Number of common shares—basic 109,857 109,478 112,507 Effect of dilutive securities: Stock options 708 640 621 Restricted stock awards 294 195 187 Number of common shares—diluted 110,859 110,313 113,315 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 287 458 607 Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Accounts Receivable, Net

Accounts Receivable, Net	12 Months Ended
	Dec. 31, 2017
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]
Accounts Receivable, Net	Accounts Receivable, Net Accounts receivable were net of reserves for doubtful accounts of $31.3 million and $29.2 million as of December 31, 2017 and January 1, 2017 , respectively.

Inventories, Net

Inventories, Net	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventories, Net	Inventories Inventories as of December 31, 2017 and January 1, 2017 consisted of the following: December 31, January 1, (In thousands) Raw materials $ 122,100 $ 79,189 Work in progress 18,452 6,561 Finished goods 211,123 161,097 Total inventories $ 351,675 $ 246,847

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment, at cost, as of December 31, 2017 and January 1, 2017 , consisted of the following: December 31, January 1, (In thousands) Land $ 5,624 $ 4,250 Building and leasehold improvements 262,657 162,780 Machinery and equipment 362,638 260,873 Total property, plant and equipment 630,919 427,903 Accumulated depreciation (332,853 ) (282,409 ) Total property, plant and equipment, net $ 298,066 $ 145,494 Depreciation expense on property, plant and equipment for the fiscal years ended December 31, 2017 , January 1, 2017 and January 3, 2016 was $31.3 million , $28.5 million and $28.7 million , respectively.

Marketable Securities and Inves

Marketable Securities and Investments	12 Months Ended
	Dec. 31, 2017
Marketable Securities [Abstract]
Marketable Securities and Investments	Marketable Securities and Investments Investments as of December 31, 2017 and January 1, 2017 consisted of the following: December 31, January 1, (In thousands) Marketable securities $ 2,208 $ 1,678 Cost method investments 10,783 — $ 12,991 $ 1,678 Marketable securities. Marketable securities include equity and fixed-income securities held to meet obligations associated with the Company’s supplemental executive retirement plan and other deferred compensation plans. The Company has, accordingly, classified these securities as long-term. The net unrealized holding gain and loss on marketable securities, net of deferred income taxes, reported as a component of other comprehensive income (loss) in the statements of stockholders’ equity, were not material in fiscal years 2017 and 2016. The proceeds from the sales of securities and the related gains and losses are not material for any period presented. Marketable securities classified as available for sale as of December 31, 2017 and January 1, 2017 consisted of the following: Market Value Gross Unrealized Holding Cost Gains (Losses) (In thousands) December 31, 2017 Equity securities $ 811 $ 1,161 $ — $ (350 ) Fixed-income securities 22 22 — — Other 1,375 1,438 — (63 ) $ 2,208 $ 2,621 $ — $ (413 ) January 1, 2017 Equity securities $ 598 $ 1,077 $ — $ (479 ) Fixed-income securities 22 22 — — Other 1,058 1,121 — (63 ) $ 1,678 $ 2,220 $ — $ (542 ) Cost method investments. During fiscal year 2017, the Company purchased an approximately 18% equity interest in Nightingale Health Oy ("Nightingale") for total consideration of $ 10.8 million in cash. Nightingale is based in Helsinki, Finland, and engaged in the business of natural and technical research and development including related equipment, software and service business. Nightingale also provides laboratory analysis services. The Company’s investments consist of (i) investments carried at fair value, including available-for-sale securities, and (ii) investments accounted for using the cost method of accounting. The Company regularly reviews its investments for impairment, including when the carrying value of an investment exceeds its market value. If the Company determines that an investment has sustained an other-than-temporary decline in its value, the investment is written down to its fair value by a charge to earnings that is included in Impairment of long-term investments and other assets. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the security in relation to its cost basis, (ii) the financial condition of the investee, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery in the market value of the investment. For investments accounted for using the cost method of accounting, the Company evaluates information available (e.g., budgets, business plans, financial statements, etc.) in addition to quoted market prices, if any, in determining whether an other-than-temporary decline in value exists. Factors indicative of an other-than-temporary decline include recurring operating losses, credit defaults and subsequent rounds of financing at an amount below the cost basis of the Company’s investment.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. The Company performed its annual impairment testing for its reporting units as of January 2, 2017 , its annual impairment date for fiscal year 2017 . The Company concluded based on the first step of the process that there was no goodwill impairment, and that the fair value exceeded the carrying value by more than 20.0% for each reporting unit, except for the Informatics reporting unit which had a fair value exceeding carrying value by less than 20% but more than 10%. The range of the long-term terminal growth rates for the Company’s reporting units was 0.0% to 3.00% for the fiscal year 2017 impairment analysis. The range for the discount rates for the reporting units was 9.0% to 13.5% . Keeping all other variables constant, a 10.0% change in any one of these input assumptions for the various reporting units, except for the Informatics reporting unit, would still allow the Company to conclude, based on the first step of the process, that there was no impairment of goodwill. At January 2, 2017 and January 1, 2018, the Informatics reporting unit, which had a goodwill balance of $217.2 million at December 31, 2017 , had a fair value exceeding carrying value by less than 20% but more than 10% . Informatics is at increased risk of an impairment charge given its ongoing weakness due to a highly competitive industry. Despite the increased risk associated with this reporting unit, the Company does not believe there will be a significant change in the key estimates or assumptions driving the fair value of this reporting unit that would lead to a material impairment charge. The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rates and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The Company corroborates the income approach with a market approach. The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized . In addition, the Company evaluates the remaining useful lives of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful lives and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 2, 2017 , and concluded that there was no impairment of non-amortizing intangible assets. An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. No such events occurred during fiscal year 2017 . The changes in the carrying amount of goodwill for fiscal years 2017 and 2016 are as follows: Discovery & Analytical Solutions Diagnostics Consolidated Balance at January 3, 2016 $ 1,296,724 $ 940,139 $ 2,236,863 Foreign currency translation (16,602 ) (11,873 ) (28,475 ) Acquisitions, earnouts and other 23,814 15,764 39,578 Balance at January 1, 2017 1,303,936 944,030 2,247,966 Foreign currency translation 37,646 29,091 66,737 Acquisitions, earnouts and other 2,653 684,842 687,495 Balance at December 31, 2017 $ 1,344,235 $ 1,657,963 $ 3,002,198 Identifiable intangible asset balances at December 31, 2017 by category and by business segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated Patents $ 28,048 $ 11,911 $ 39,959 Less: Accumulated amortization (24,448 ) (10,637 ) (35,085 ) Net patents 3,600 1,274 4,874 Trade names and trademarks 29,950 51,024 80,974 Less: Accumulated amortization (20,022 ) (8,228 ) (28,250 ) Net trade names and trademarks 9,928 42,796 52,724 Licenses 43,061 10,239 53,300 Less: Accumulated amortization (34,620 ) (8,015 ) (42,635 ) Net licenses 8,441 2,224 10,665 Core technology 230,755 240,985 471,740 Less: Accumulated amortization (186,364 ) (58,552 ) (244,916 ) Net core technology 44,391 182,433 226,824 Customer relationships 233,573 907,938 1,141,511 Less: Accumulated amortization (116,696 ) (126,144 ) (242,840 ) Net customer relationships 116,877 781,794 898,671 IPR&D 5,569 82,456 88,025 Less: Accumulated amortization (4,059 ) (1,368 ) (5,427 ) Net IPR&D 1,510 81,088 82,598 Net amortizable intangible assets 184,747 1,091,609 1,276,356 Non-amortizable intangible assets: Trade name 70,584 — 70,584 Total $ 255,331 $ 1,091,609 $ 1,346,940 Identifiable intangible asset balances at January 1, 2017 by category and business segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated Patents $ 28,001 $ 11,900 $ 39,901 Less: Accumulated amortization (22,852 ) (9,556 ) (32,408 ) Net patents 5,149 2,344 7,493 Trade names and trademarks 28,563 11,523 40,086 Less: Accumulated amortization (15,927 ) (8,090 ) (24,017 ) Net trade names and trademarks 12,636 3,433 16,069 Licenses 49,831 7,936 57,767 Less: Accumulated amortization (38,745 ) (7,762 ) (46,507 ) Net licenses 11,086 174 11,260 Core technology 233,291 70,896 304,187 Less: Accumulated amortization (184,340 ) (49,380 ) (233,720 ) Net core technology 48,951 21,516 70,467 Customer relationships 259,419 123,884 383,303 Less: Accumulated amortization (119,342 ) (93,720 ) (213,062 ) Net customer relationships 140,077 30,164 170,241 IPR&D 5,569 72,946 78,515 Less: Accumulated amortization (3,445 ) (960 ) (4,405 ) Net IPR&D 2,124 71,986 74,110 Net amortizable intangible assets 220,023 129,617 349,640 Non-amortizable intangible assets: Trade name 70,584 — 70,584 Total $ 290,607 $ 129,617 $ 420,224 Total amortization expense related to definite-lived intangible assets was $73.7 million in fiscal year 2017 , $71.5 million in fiscal year 2016 and $76.6 million in fiscal year 2015 . Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $139.1 million in fiscal year 2018 , $145.7 million in fiscal year 2019 , $147.4 million in fiscal year 2020 , $132.0 million in fiscal year 2021 , and $119.8 million in fiscal year 2022 . The Company entered into a strategic agreement in fiscal year 2012 under which it acquired certain intangible assets and received a license to certain core technology for an analytics and data discovery platform, as well as the exclusive right to distribute the platform in certain scientific research and development markets. During fiscal year 2012, the Company paid $6.8 million for net intangible assets and $25.0 million for prepaid royalties. During fiscal year 2013, the Company extended the existing agreement for an additional year. In addition, the Company entered into a new agreement to expand the distribution rights to the clinical and other related markets and acquired additional intangible assets. During fiscal year 2013, the Company paid $7.0 million for net intangible assets and $40.3 million for prepaid royalties. During fiscal year 2016, the Company extended the existing agreement for an additional 3 years and expanded the distribution rights to the related markets. During fiscal year 2016, the Company paid $6.0 million for prepaid royalties related to the extension and new agreement. During the fiscal years 2017 and 2016 , the Company paid $5.1 million and $9.4 million , respectively, for additional prepaid royalties. As of December 31, 2017, we have recorded prepaid royalties of $72.8 million , of which $5.1 million was recorded in other current assets, and $67.7 million was recorded in other assets. The Company expenses royalties as revenue is recognized. These intangible assets are being amortized over their estimated useful lives. The Company has reported the amortization of these intangible assets within the results of the Company's Discovery & Analytical Solutions segment from the execution date.

Debt

Debt	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Debt	Debt Senior Unsecured Revolving Credit Facility. The Company's senior unsecured revolving credit facility provides for $1.0 billion of revolving loans and has an initial maturity of August 11, 2021 . As of December 31, 2017 , undrawn letters of credit in the aggregate amount of $11.4 million were treated as issued and outstanding when calculating the borrowing availability under the senior unsecured revolving credit facility. As of December 31, 2017 , the Company had $363.6 million available for additional borrowing under the facility. The Company uses the senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) an adjusted one-month Libor plus 1.00%. The Eurocurrency margin as of December 31, 2017 was 110 basis points. The weighted average Eurocurrency interest rate as of December 31, 2017 was 1.56%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 2.66%, which was the interest applicable to the borrowings outstanding under the Eurocurrency rate as of December 31, 2017. As of December 31, 2017 , the senior unsecured revolving credit facility had outstanding borrowings of $625.0 million , and $3.3 million of unamortized debt issuance costs. As of January 1, 2017 , the senior unsecured revolving credit facility had no outstanding borrowings, and $4.3 million of unamortized debt issuance costs. The credit agreement for the facility contains affirmative, negative and financial covenants and events of default. The financial covenants include a debt-to-capital ratio that remains applicable for so long as the Company's debt is rated as investment grade. In the event that the Company's debt is not rated as investment grade, the debt-to-capital ratio covenant is replaced with a maximum consolidated leverage ratio covenant and a minimum consolidated interest coverage ratio covenant. Senior Unsecured Term Loan Credit Facility . The Company entered into a senior unsecured term loan credit facility on August 11, 2017 that provides for $200.0 million of term loans and has an initial maturity of twelve months from the date of the initial draw. The Company utilized the senior unsecured term loan facility for the acquisition of EUROIMMUN. The interest rates under the senior unsecured term loan credit facility are based on the Eurocurrency rate or the base rate at the time of the borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) an adjusted one-month Libor plus 1.00%. The Eurocurrency margin as of December 31, 2017 was 110 basis points. The weighted average Eurocurrency interest rate as of December 31, 2017 was 1.56%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 2.66%, which was the interest applicable to the borrowings outstanding under the Eurocurrency rate as of December 31, 2017. As of December 31, 2017 , the senior unsecured term loan credit facility had outstanding borrowings of $200.0 million and has a maturity date of December 18, 2018 . The credit agreement for the facility contains affirmative, negative and financial covenants and events of defaults which are substantially similar to those contained in the senior unsecured revolving credit facility. 5% Senior Unsecured Notes due in 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “2021 Notes”) in a registered public offering and received $496.9 million of net proceeds from the issuance. The 2021 Notes were issued at 99.4% of the principal amount, which resulted in a discount of $3.1 million . As of December 31, 2017 , the 2021 Notes had an aggregate carrying value of $496.6 million , net of $1.4 million of unamortized original issue discount and $2.0 million of unamortized debt issuance costs. As of January 1, 2017 , the 2021 Notes had an aggregate carrying value of $495.8 million , net of $1.7 million of unamortized original issue discount and $2.5 million of unamortized debt issuance costs. The 2021 Notes mature in November 2021 and bear interest at an annual rate of 5% . Interest on the 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest. At any time on or after August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2021 Notes) and a contemporaneous downgrade of the 2021 Notes below investment grade, each holder of 2021 Notes will have the right to require the Company to repurchase such holder's 2021 Notes for 101% of their principal amount, plus accrued and unpaid interest. 1.875% Senior Unsecured Notes due 2026. On July 19, 2016, the Company issued €500.0 million aggregate principal amount of senior unsecured notes due in 2026 (the “2026 Notes”) in a registered public offering and received approximately €492.3 million of net proceeds from the issuance. The 2026 Notes were issued at 99.118% of the principal amount, which resulted in a discount of €4.4 million . The 2026 Notes mature in July 2026 and bear interest at an annual rate of 1.875% . Interest on the 2026 Notes is payable annually on July 19th each year. The proceeds from the 2026 Notes were used to pay in full the outstanding balance of the Company's previous senior unsecured revolving credit facility. As of December 31, 2017 , the 2026 Notes had an aggregate carrying value of $591.7 million , net of $4.7 million of unamortized original issue discount and $4.3 million of unamortized debt issuance costs. As of January 1, 2017 , the 2026 Notes had an aggregate carrying value of $517.8 million , net of $4.5 million of unamortized original issue discount and $4.8 million of unamortized debt issuance costs. Prior to April 19, 2026 (three months prior to their maturity date), the Company may redeem the 2026 Notes in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2026 Notes to be redeemed, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2026 Notes being redeemed, discounted on an annual basis, at the applicable Comparable Government Bond Rate (as defined in the indenture governing the 2026 Notes) plus 35 basis points; plus, in each case, accrued and unpaid interest. In addition, at any time on or after April 19, 2026 (three months prior to their maturity date), the Company may redeem the 2026 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2026 Notes due to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2026 Notes) and a contemporaneous downgrade of the 2026 Notes below investment grade, the Company will, in certain circumstances, make an offer to purchase the 2026 Notes at a price equal to 101% of their principal amount plus any accrued and unpaid interest. Other Debt Facilities. The Company assumed other debt facilities pursuant to the EUROIMMUN acquisition, which includes Euro-denominated bank loans with an aggregate carrying value of €47.6 million (equivalent to $57.2 million ) as of December 31, 2017 . These bank loans are primarily utilized for financing fixed assets and are repaid in monthly or quarterly installments with maturity dates extending to 2031. The bank loans in the aggregate amount of $44.8 million bear fixed interest rates between 1.1% and 7.9% and bank loans in the aggregate amount of $12.4 million bear variable interest rates based on the Euribor rate plus a margin between 1.3% and 1.5% . An aggregate amount of $15.0 million of the bank loans are secured by mortgages on the financed land and buildings and the remaining $42.2 million are unsecured. Certain credit agreements for the unsecured bank loans include financial covenants which are based on an equity ratio or an equity ratio and minimum interest coverage ratio. In addition, the Company has other unsecured revolving credit facilities and a secured bank loan in the amount of $2.7 million and $0.3 million , respectively, as of December 31, 2017 . The unsecured revolving debt facilities bear fixed interest rates between 0.05% and 1.95% and will mature in 2018. The secured bank loan of $0.3 million bears a fixed annual interest rate of 1.95% and is repaid in monthly installments until 2027. Financing Lease Obligations. In fiscal year 2012, the Company entered into agreements with the lessors of certain buildings that the Company is currently occupying and leasing to expand those buildings. The Company provided a portion of the funds needed for the construction of the additions to the buildings, and as a result the Company was considered the owner of the buildings during the construction period. At the end of the construction period, the Company was not reimbursed by the lessors for all of the construction costs. The Company is therefore deemed to have continuing involvement and the leases qualify as financing leases under sale-leaseback accounting guidance, representing debt obligations for the Company and non-cash investing and financing activities. As a result, the Company capitalized $29.3 million in property, plant and equipment, net, representing the fair value of the buildings with a corresponding increase to debt. The Company has also capitalized $11.5 million in additional construction costs necessary to complete the renovations to the buildings, which were funded by the lessors, with a corresponding increase to debt. At December 31, 2017 , the Company had $35.9 million recorded for these financing lease obligations, of which $1.4 million was recorded as short-term debt and $34.5 million was recorded as long-term debt. At January 1, 2017 , the Company had $37.1 million recorded for these financing lease obligations, of which $1.2 million was recorded as short-term debt and $35.9 million was recorded as long-term debt. The buildings are being depreciated on a straight-line basis over the terms of the leases to their estimated residual values, which will equal the remaining financing obligation at the end of the lease term. At the end of the lease term, the remaining balances in property, plant and equipment, net and debt will be reversed against each other. The following table summarizes the maturities of the Company’s indebtedness as of December 31, 2017 : Sr. Unsecured Revolving Credit Facility Maturing 2021 Sr. Unsecured Term Loan Credit Facility 5.0% Sr. Notes Maturing 2021 1.875% Sr. Notes Maturing 2026 Other Debt Facilities Financing Lease Obligations Total (In thousands) 2018 $ — $ 200,000 $ — $ — $ 16,015 $ 1,370 $ 217,385 2019 — — — — 12,974 1,532 14,506 2020 — — — — 7,752 1,597 9,349 2021 625,000 — 500,000 — 9,248 1,664 1,135,912 2022 — — — — 4,664 1,639 6,303 2023 and thereafter — — — 600,700 9,562 28,109 638,371 Total before unamortized discount and debt issuance costs 625,000 200,000 500,000 600,700 60,215 35,911 2,021,826 Unamortized discount and debt issuance costs (3,339 ) — (3,417 ) (8,961 ) — — (15,717 ) Total $ 621,661 $ 200,000 $ 496,583 $ 591,739 $ 60,215 $ 35,911 $ 2,006,109

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2017
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities as of December 31, 2017 and January 1, 2017 consisted of the following: December 31, January 1, (In thousands) Payroll and incentives $ 66,955 $ 61,474 Employee benefits 37,354 31,039 Deferred revenue 159,923 162,987 Federal, non-U.S. and state income taxes 10,800 8,189 Other accrued operating expenses 225,610 136,011 Total accrued expenses and other current liabilities $ 500,642 $ 399,700

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Jan. 01, 2017
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Benefit Plans Savings Plan: The Company has a 401(k) Savings Plan for the benefit of all qualified U.S. employees, with such employees receiving matching contributions in the amount equal to 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits. Savings plan expense was $12.5 million in fiscal year 2017 , and $12.8 million in each of fiscal years 2016 and 2015 . Pension Plans: The Company has a defined benefit pension plan covering certain U.S. employees and non-U.S. pension plans for certain non-U.S. employees. The principal U.S. defined benefit pension plan was closed to new hires effective January 31, 2001, and benefits for those employed by the Company’s former Life Sciences business were frozen as of that date. Plan benefits were frozen as of March 2003 for those employed by the Company’s former Analytical Instruments business and corporate employees. Plan benefits were frozen as of January 31, 2011 for all remaining employees that were still actively accruing in the plan. The plans provide benefits that are based on an employee’s years of service and compensation near retirement. Net periodic pension (credit) cost for U.S. and non-U.S. plans included the following components for fiscal years ended: December 31, January 1, January 3, (In thousands) Service and administrative costs $ 4,951 $ 4,337 $ 4,332 Interest cost 16,707 18,638 20,696 Expected return on plan assets (26,401 ) (24,245 ) (26,021 ) Curtailment gain — — (907 ) Actuarial (gain) loss (7,085 ) 15,890 12,953 Amortization of prior service cost (195 ) (210 ) (238 ) Net periodic pension (credit) cost $ (12,023 ) $ 14,410 $ 10,815 During fiscal year 2014, the Company notified certain employees of its intention to terminate their employment as part of a restructuring plan that the Company implemented during the third quarter of fiscal year 2014. During fiscal year 2015, the termination of these participants decreased the expected future service lives in excess of the curtailment limit for one of the Company's pension plans, which resulted in a curtailment gain. The Company recorded the curtailment gain of $0.8 million during fiscal year 2015. As part of the curtailment, the Company remeasured the assets and liabilities of the plan that had the curtailment based upon current discount rates and the fair value of the pension plan's assets as of the curtailment date, which resulted in an actuarial loss of $0.8 million . The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 31, 2017 and January 1, 2017 . December 31, 2017 January 1, 2017 Non-U.S. U.S. Non-U.S. U.S. (In thousands) Actuarial present value of benefit obligations: Accumulated benefit obligations $ 334,151 $ 308,713 $ 271,127 $ 300,650 Change in benefit obligations: Projected benefit obligations at beginning of year $ 279,522 $ 300,650 $ 276,960 $ 301,416 Service and administrative costs 2,201 2,750 2,262 2,075 Interest cost 4,870 11,836 6,205 12,433 Benefits paid and plan expenses (13,238 ) (20,032 ) (11,940 ) (19,424 ) Participants’ contributions 189 — 209 — Business acquisition (divestiture) 39,293 — (2,955 ) — Plan settlements — — (993 ) — Actuarial (gain) loss (1,486 ) 13,509 38,623 4,150 Effect of exchange rate changes 32,059 — (28,849 ) — Projected benefit obligations at end of year $ 343,410 $ 308,713 $ 279,522 $ 300,650 Change in plan assets: Fair value of plan assets at beginning of year $ 153,281 $ 243,817 $ 150,894 $ 244,693 Actual return on plan assets 15,866 29,642 32,581 18,548 Benefits paid and plan expenses (13,238 ) (20,032 ) (11,940 ) (19,424 ) Employer’s contributions 8,422 — 9,562 — Participants’ contributions 189 — 209 — Plan settlements — — (993 ) — Effect of exchange rate changes 15,216 — (27,032 ) — Fair value of plan assets at end of year $ 179,736 $ 253,427 $ 153,281 $ 243,817 Net liabilities recognized in the consolidated balance sheets $ (163,674 ) $ (55,286 ) $ (126,241 ) $ (56,833 ) Net amounts recognized in the consolidated balance sheets consist of: Noncurrent assets $ 26,591 $ — $ 12,944 $ — Current liabilities (7,017 ) — (6,033 ) — Noncurrent liabilities (183,248 ) (55,286 ) (133,152 ) (56,833 ) Net liabilities recognized in the consolidated balance sheets $ (163,674 ) $ (55,286 ) $ (126,241 ) $ (56,833 ) Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ (457 ) $ — $ (603 ) $ — Actuarial assumptions as of the year-end measurement date: Discount rate 1.99 % 3.56 % 2.06 % 4.06 % Rate of compensation increase 3.50 % None 3.64 % None Actuarial assumptions used to determine net periodic pension cost during the year were as follows: December 31, 2017 January 1, 2017 January 3, 2016 Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Discount rate 2.06 % 4.06 % 2.88 % 4.25 % 2.75 % 4.08 % Rate of compensation increase 3.64 % None 3.26 % None 3.28 % None Expected rate of return on assets 6.00 % 7.25 % 5.30 % 7.25 % 4.60 % 7.25 % The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets: December 31, January 1, (In thousands) Pension Plans with Projected Benefit Obligations in Excess of Plan Assets Projected benefit obligations $ 190,265 $ 139,185 Fair value of plan assets — — Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets Accumulated benefit obligations $ 187,329 $ 136,197 Fair value of plan assets — — Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 31, 2017 and January 1, 2017 , and target asset allocations for fiscal year 2018 are as follows: Target Allocation Percentage of Plan Assets at December 30, 2018 December 31, 2017 January 1, 2017 Asset Category Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Equity securities 45-55% 40-50% 51 % 41 % 48 % 41 % Debt securities 45-55% 50-60% 49 % 59 % 51 % 59 % Other 0-5% 0-5% — % — % 1 % — % Total 100 % 100 % 100 % 100 % 100 % 100 % The Company maintains target allocation percentages among various asset classes based on investment policies established for the pension plans which are designed to maximize the total rate of return (income and appreciation) after inflation within the limits of prudent risk taking, while providing for adequate near-term liquidity for benefit payments. The Company’s expected rate of return on assets assumptions are derived from management’s estimates, as well as other information compiled by management, including studies that utilize customary procedures and techniques. The studies include a review of anticipated future long-term performance of individual asset classes and consideration of the appropriate asset allocation strategy given the anticipated requirements of the plans to determine the average rate of earnings expected on the funds invested to provide for the pension plans benefits. While the study gives appropriate consideration to recent fund performance and historical returns, the assumption is primarily a long-term, prospective rate. The Company's discount rate assumptions are derived from a range of factors, including a yield curve for certain plans, composed of the rates of return on high-quality fixed-income corporate bonds available at the measurement date and the related expected duration for the obligations, and a bond matching approach for certain plans. For the plans in the United States, the Company adopted the updated projection scale, MP-2015, that was published by the Society of Actuaries in 2015, as of January 3, 2016. The adoption of the updated projection scale resulted in a $6.8 million decrease to the projected benefit obligation as of January 3, 2016. During fiscal year 2016, the Society of Actuaries issued an updated projection scale, MP-2016, which reduced the life expectancy used to determine the projected benefit obligation. The Company adopted MP-2016 as of January 1, 2017. The adoption of the updated projection scale resulted in a $5.5 million decrease to the projected benefit obligation at January 1, 2017. During fiscal year 2017, the Society of Actuaries issued an updated projection scale, MP-2017, which reduced the life expectancy used to determine the projected benefit obligation. The Company adopted MP-2017 as of December 31, 2017. The adoption of the updated projection scale resulted in a $2.6 million decrease to the projected benefit obligation at December 31, 2017. The changes to the projected benefit obligations due to the adoption of the mortality base table and projection scale are included within "Actuarial loss (gain)" in the Change in Benefit Obligations for fiscal years 2017 and 2016 above . The target allocations for plan assets are listed in the above table. Equity securities primarily include investments in large-cap and mid-cap companies located in the United States and abroad, and equity index funds. Debt securities include corporate bonds of companies from diversified industries, high-yield bonds, and U.S. government securities. Other types of investments include investments in non-U.S. government index linked bonds, multi-strategy hedge funds and venture capital funds that follow several different strategies. The fair values of the Company’s pension plan assets as of December 31, 2017 and January 1, 2017 by asset category, classified in the three levels of inputs described in Note 21 to the consolidated financial statements are as follows: Fair Value Measurements at December 31, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 4,307 $ 4,307 $ — $ — Equity Securities: U.S. large-cap 30,008 30,008 — — International large-cap value 32,613 32,613 — — U.S. small mid-cap 2,104 2,104 — — Emerging markets growth 14,348 14,348 — — Equity index funds 90,838 — 90,838 — Domestic real estate funds 1,401 1,401 — — Commodity funds 7,387 7,387 — — Fixed income securities: Non-U.S. Treasury Securities 24,946 — 24,946 — Corporate and U.S. debt instruments 138,948 40,290 98,658 — Corporate bonds 27,571 — 27,571 — High yield bond funds 5,912 5,912 — — Other types of investments: Multi-strategy hedge funds 16,789 — — 16,789 Non-U.S. government index linked bonds 35,991 — 35,991 — Total assets measured at fair value $ 433,163 $ 138,370 $ 278,004 $ 16,789 Fair Value Measurements at January 1, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 6,079 $ 6,079 $ — $ — Equity Securities: U.S. large-cap 25,523 25,523 — — International large-cap value 28,267 28,267 — — U.S. small-cap 1,756 1,756 — — Emerging markets growth 12,144 12,144 — — Equity index funds 74,274 — 74,274 — Domestic real estate funds 1,401 1,401 — — Commodity funds 6,854 6,854 — — Fixed income securities: Non-U.S. Treasury Securities 22,059 — 22,059 — Corporate and U.S. debt instruments 133,406 35,971 97,435 — Corporate bonds 23,906 — 23,906 — High yield bond funds 5,636 5,636 — — Other types of investments: Multi-strategy hedge funds 23,790 — — 23,790 Non-U.S. government index linked bonds 32,003 — 32,003 — Total assets measured at fair value $ 397,098 $ 123,631 $ 249,677 $ 23,790 Valuation Techniques: Valuation techniques utilized need to maximize the use of observable inputs and minimize the use of unobservable inputs. There have been no changes in the methodologies utilized at December 31, 2017 compared to January 1, 2017 . The following is a description of the valuation techniques utilized to measure the fair value of the assets shown in the table above. Equity Securities: Shares of registered investment companies that are publicly traded are categorized as Level 1 assets; they are valued at quoted market prices that represent the net asset value of the fund. These instruments have active markets. Equity index funds are mutual funds that are not publicly traded and are comprised primarily of underlying equity securities that are publicly traded on exchanges. Price quotes for the assets held by these funds are readily observable and available. Equity index funds are categorized as Level 2 assets. Fixed Income Securities: Fixed income mutual funds that are publicly traded are valued at quoted market prices that represent the net asset value of securities held by the fund and are categorized as Level 1 assets. Fixed income index funds that are not publicly traded are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments and are categorized as Level 2 assets. Individual fixed income bonds are categorized as Level 2 assets except where sufficient quoted prices exist in active markets, in which case such securities are categorized as Level 1 assets. These securities are valued using third-party pricing services. These services may use, for example, model-based pricing methods that utilize observable market data as inputs. Broker dealer bids or quotes of securities with similar characteristics may also be used. Other Types of Investments: Non-U.S. government index link bond funds are not publicly traded and are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments. Underlying investments consist of bonds in which payment of income on the principal is related to a specific price index and are categorized as Level 2 assets. Hedge funds, private equity funds and venture capital funds are valued at fair value by using the net asset values provided by the investment managers and are updated, if necessary, using analytical procedures, appraisals, public market data and/or inquiry of the investment managers. The net asset values are determined based upon the fair values of the underlying investments in the funds. These other investments invest primarily in readily available marketable securities and allocate gains, losses, and expense to the investor based on the ownership percentage as described in the fund agreements. They are categorized as Level 3 assets. The Company's policy is to recognize significant transfers between levels at the actual date of the event. A reconciliation of the beginning and ending Level 3 assets for fiscal years 2017, 2016 and 2015 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Venture Capital Funds Multi-strategy Hedge Funds Total (In thousands) Balance at December 28, 2014 $ 1 $ 23,332 $ 23,333 Unrealized gains — 83 83 Balance at January 3, 2016 1 23,415 23,416 Realized losses (1 ) — (1 ) Unrealized gains — 375 375 Balance at January 1, 2017 — 23,790 23,790 Sales — (8,189 ) (8,189 ) Realized gains — 1,542 1,542 Unrealized losses — (354 ) (354 ) Balance at December 31, 2017 $ — $ 16,789 $ 16,789 With respect to plans outside of the United States, the Company expects to contribute $8.8 million in the aggregate during fiscal year 2018. In January 2018, the Company made a voluntary $15.0 million contribution to its defined benefit pension plan in the United States for the plan year 2017. During fiscal year 2017 , the Company contributed $8.4 million , in the aggregate, to pension plans outside of the United States. During fiscal year 2016, the Company made contributions of $9.6 million , in the aggregate, to plans outside of the United States. During fiscal year 2015, the Company contributed $14.9 million , in the aggregate, to plans outside of the United States and $20.0 million to its defined benefit pension plan in the United States. The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Non-U.S. U.S. (In thousands) 2018 $ 11,786 $ 18,593 2019 12,166 18,860 2020 12,566 19,125 2021 13,151 19,392 2022 13,275 19,630 2023-2026 71,963 97,295 The Company also sponsors a supplemental executive retirement plan to provide senior management with benefits in excess of normal pension benefits. Effective July 31, 2000, this plan was closed to new entrants. At December 31, 2017 and January 1, 2017 , the projected benefit obligations were $23.7 million and $21.8 million , respectively. Assets with a fair value of $1.4 million and $1.1 million , segregated in a trust (which is included in marketable securities and investments on the consolidated balance sheets), were available to meet this obligation as of December 31, 2017 and January 1, 2017 , respectively. Pension expenses and income for this plan netted to expense of $3.2 million in fiscal year 2017 , expense of $1.6 million in fiscal year 2016 and income of $1.6 million in fiscal year 2015 . Postretirement Medical Plans: The Company provides healthcare benefits for eligible retired U.S. employees under a comprehensive major medical plan or under health maintenance organizations where available. Eligible U.S. employees qualify for retiree health benefits if they retire directly from the Company and have at least ten years of service. Generally, the major medical plan pays stated percentages of covered expenses after a deductible is met and takes into consideration payments by other group coverage and by Medicare. The plan requires retiree contributions under most circumstances and has provisions for cost-sharing charges. Effective January 1, 2000, this plan was closed to new hires. For employees retiring after 1991, the Company has capped its medical premium contribution based on employees’ years of service. The Company funds the amount allowable under a 401(h) provision in the Company’s defined benefit pension plan. Assets of the plan are primarily equity and debt securities and are available only to pay retiree health benefits. Net periodic postretirement medical benefit (credit) cost included the following components for the fiscal years ended: December 31, January 1, January 3, (In thousands) Service cost $ 92 $ 101 $ 108 Interest cost 125 142 143 Expected return on plan assets (1,114 ) (1,035 ) (1,062 ) Actuarial (gain) loss (741 ) (539 ) 971 Net periodic postretirement medical benefit (credit) cost $ (1,638 ) $ (1,331 ) $ 160 The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of December 31, 2017 and January 1, 2017 . December 31, January 1, (In thousands) Actuarial present value of benefit obligations: Retirees $ 804 $ 907 Active employees eligible to retire 379 423 Other active employees 1,948 2,031 Accumulated benefit obligations at beginning of year 3,131 3,361 Service cost 92 101 Interest cost 125 142 Benefits paid (122 ) (145 ) Actuarial loss (gain) 187 (329 ) Change in accumulated benefit obligations during the year 282 (231 ) Retirees 688 804 Active employees eligible to retire 408 379 Other active employees 2,317 1,948 Accumulated benefit obligations at end of year $ 3,413 $ 3,131 Change in plan assets: Fair value of plan assets at beginning of year $ 15,453 $ 14,353 Actual return on plan assets 1,921 1,100 Fair value of plan assets at end of year $ 17,374 $ 15,453 Net assets recognized in the consolidated balance sheets $ 13,961 $ 12,322 Net amounts recognized in the consolidated balance sheets consist of: Noncurrent assets $ 13,961 $ 12,322 Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — Actuarial assumptions as of the year-end measurement date: Discount rate 3.60 % 4.11 % Actuarial assumptions used to determine net cost during the year are as follows: December 31, January 1, January 3, Discount rate 4.11 % 4.34 % 4.10 % Expected rate of return on assets 7.25 % 7.25 % 7.25 % The Company maintains a master trust for plan assets related to the U.S. defined benefit plans and the U.S. postretirement medical plan. Accordingly, investment policies, target asset allocations and actual asset allocations are the same as those disclosed for the U.S. defined benefit plans. The fair values of the Company’s plan assets at December 31, 2017 and January 1, 2017 by asset category, classified in the three levels of inputs described in Note 21, are as follows: Fair Value Measurements at December 31, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 268 $ 268 $ — $ — Equity Securities: U.S. large-cap 2,057 2,057 — — International large-cap value 2,236 2,236 — — U.S. small mid-cap 144 144 — — Emerging markets growth 984 984 — — Domestic real estate funds 96 96 — — Commodity funds 506 506 — — Fixed income securities: Corporate debt instruments 9,526 2,762 6,764 — High yield bond funds 406 406 — — Other types of investments: Multi-strategy hedge funds 1,151 — — 1,151 Total assets measured at fair value $ 17,374 $ 9,459 $ 6,764 $ 1,151 Fair Value Measurements at January 1, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 319 $ 319 $ — $ — Equity Securities: U.S. large-cap 1,618 1,618 — — International large-cap value 1,792 1,792 — — U.S. small mid-cap 111 111 — — Emerging markets growth 770 770 — — Domestic real estate funds 89 89 — — Commodity funds 434 434 — — Fixed income securities: Corporate debt instruments 8,456 2,280 6,176 — High yield bond funds 356 356 — — Other types of investments: Multi-strategy hedge funds 1,508 — — 1,508 Total assets measured at fair value $ 15,453 $ 7,769 $ 6,176 $ 1,508 Valuation Techniques: Valuation techniques are the same as those disclosed for the U.S. defined benefit plans above. A reconciliation of the beginning and ending Level 3 assets for fiscal years 2017, 2016 and 2015 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Multi-strategy Hedge Funds (In thousands) Balance at December 28, 2014 $ 1,341 Unrealized gains 33 Balance at January 3, 2016 1,374 Unrealized gains 134 Balance at January 1, 2017 1,508 Sales (562 ) Realized gains 229 Unrealized losses (24 ) Balance at December 31, 2017 $ 1,151 The Company does no t expect to make any contributions to the postretirement medical plan during fiscal year 2018 . The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Postretirement Medical Plan (In thousands) 2018 $ 147 2019 166 2020 178 2021 195 2022 211 2023-2026 1,153 Deferred Compensation Plans: During fiscal year 1998, the Company implemented a nonqualified deferred compensation plan that provides benefits payable to officers and certain key employees or their designated beneficiaries at specified future dates, or upon retirement or death. The plan was amended to eliminate deferral elections, with the exception of Company 401(k) excess contributions for eligible participants, for plan years beginning January 1, 2011. Benefit payments under the plan are funded by contributions from participants, and for certain participants, contributions by the Company. The obligations related to the deferred compensation plan totaled $1.0 million at December 31, 2017 and $0.9 million at January 1, 2017 .

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company's responsibility is established and when the cost can be reasonably estimated. The Company has accrued $9.4 million and $9.9 million as of December 31, 2017 and January 1, 2017 , respectively, in accrued expenses and other current liabilities, which represents its management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. The Company's environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded. The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these contingencies at December 31, 2017 should not have a material adverse effect on the Company’s consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.

Warranty Reserves

Warranty Reserves	12 Months Ended
	Dec. 31, 2017
Product Warranties Disclosures [Abstract]
Warranty Reserves	Warranty Reserves The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the consolidated balance sheets. A summary of warranty reserve activity for the fiscal years ended December 31, 2017 , January 1, 2017 and January 3, 2016 is as follows: (In thousands) Balance at December 28, 2014 $ 9,593 Provision charged to income 15,792 Payments (14,936 ) Adjustments to previously provided warranties, net (146 ) Foreign currency translation and acquisitions (460 ) Balance at January 3, 2016 9,843 Provision charged to income 14,901 Payments (14,749 ) Adjustments to previously provided warranties, net (850 ) Foreign currency translation and acquisitions (133 ) Balance at January 1, 2017 9,012 Provision charged to income 13,700 Payments (14,245 ) Adjustments to previously provided warranties, net (815 ) Foreign currency translation and acquisitions 1,398 Balance at December 31, 2017 $ 9,050

Stock Plans

Stock Plans	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Plans	Stock Plans Stock-Based Compensation: In addition to the Company’s Employee Stock Purchase Plan, the Company utilizes one stock-based compensation plan, the 2009 Incentive Plan (the “2009 Plan”). Under the 2009 Plan, 10.0 million shares of the Company's common stock are authorized for stock option grants, restricted stock awards, performance restricted stock units, performance units and stock grants as part of the Company’s compensation programs. In addition to shares of the Company’s common stock originally authorized for issuance under the 2009 Plan, the 2009 Plan includes shares of the Company’s common stock previously granted under the Amended and Restated 2001 Incentive Plan and the 2005 Incentive Plan that were canceled or forfeited without the shares being issued. The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s consolidated statements of operations for fiscal years 2017, 2016 and 2015 : December 31, January 1, January 3, (In thousands) Cost of product and service revenue $ 1,254 $ 1,031 $ 1,272 Research and development expenses 1,389 902 526 Selling, general and administrative expenses 22,778 15,225 15,480 Total stock-based compensation expense $ 25,421 $ 17,158 $ 17,278 The total income tax benefit recognized in the consolidated statements of operations for stock-based compensation was $14.5 million in fiscal year 2017 , $10.5 million in fiscal year 2016 and $5.8 million in fiscal year 2015 . Stock-based compensation costs capitalized as part of inventory were $0.3 million as of each of December 31, 2017 and January 1, 2017 . Stock Options: The Company has granted options to purchase common shares at prices equal to the market price of the common shares on the date the option is granted. Conditions of vesting are determined at the time of grant. Options are generally exercisable in equal annual installments over a period of three years, and will generally expire seven years after the date of grant. Options replaced in association with business combination transactions are generally issued with the same terms of the respective plans under which they were originally issued. The fair value of each option grant is estimated using the Black-Scholes option pricing model. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical and implied volatility of the Company’s stock. The average expected life was based on the contractual term of the option and historic exercise experience. The risk-free interest rate is based on United States Treasury zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended: December 31, January 1, January 3, Risk-free interest rate 2.0 % 1.7 % 1.3 % Expected dividend yield 0.4 % 0.6 % 0.6 % Expected lives 5 years 5 years 5 years Expected stock volatility 22.4 % 25.2 % 26.5 % The following table summarizes stock option activity for the fiscal year ended December 31, 2017 : December 31, 2017 Number of Shares Weighted- Average Exercise Price (Shares in thousands) Outstanding at beginning of year 2,287 $ 37.64 Granted 464 53.94 Exercised (578 ) 31.16 Forfeited (19 ) 50.86 Outstanding at end of year 2,154 $ 42.77 Exercisable at end of year 1,229 $ 37.79 The aggregate intrinsic value for stock options outstanding at December 31, 2017 was $65.4 million with a weighted-average remaining contractual term of 4.0 years. The aggregate intrinsic value for stock options exercisable at December 31, 2017 was $43.4 million with a weighted-average remaining contractual term of 2.9 years. At December 31, 2017 , there were 2.2 million stock options that were vested, and expected to vest in the future, with an aggregate intrinsic value of $65.4 million and a weighted-average remaining contractual term of 4.1 years. The weighted-average per-share grant-date fair value of options granted during fiscal years 2017, 2016 and 2015 was $11.83 , $10.20 , and $11.02 , respectively. The total intrinsic value of options exercised during fiscal years 2017, 2016 and 2015 was $17.6 million , $16.6 million , and $25.9 million , respectively. Cash received from option exercises for fiscal years 2017, 2016 and 2015 was $18.0 million , $14.4 million , and $14.9 million , respectively. The total compensation expense recognized related to the Company’s outstanding options was $4.7 million in fiscal year 2017 , $4.4 million in fiscal year 2016 and $4.1 million in fiscal year 2015 . There was $6.0 million of total unrecognized compensation cost related to nonvested stock options granted as of December 31, 2017 . This cost is expected to be recognized over a weighted-average period of 2.0 years. Restricted Stock Awards: The Company has awarded shares of restricted stock and restricted stock units to certain employees and non-employee directors at no cost to them, which cannot be sold, assigned, transferred or pledged during the restriction period. The restricted stock and restricted stock units vest through the passage of time, assuming continued employment. The fair value of the award at the time of the grant is expensed on a straight line basis primarily in selling, general and administrative expenses over the vesting period, which is generally 3 years. These awards were granted under the Company’s 2009 Plan. Recipients of the restricted stock have the right to vote such shares and receive dividends. The following table summarizes restricted stock award activity for the fiscal year ended December 31, 2017 : December 31, 2017 Number of Shares Weighted- Average Grant- Date Fair Value (Shares in thousands) Nonvested at beginning of year 521 $ 46.48 Granted 231 54.75 Vested (229 ) 46.11 Forfeited (27 ) 50.12 Nonvested at end of year 496 $ 50.30 The fair value of restricted stock awards vested during fiscal years 2017, 2016 and 2015 was $10.6 million , $8.4 million , and $7.8 million , respectively. The total compensation expense recognized related to the restricted stock awards was $10.3 million in fiscal year 2017 , $9.3 million in fiscal year 2016 and $8.4 million in fiscal year 2015 . As of December 31, 2017 , there was $13.2 million of total unrecognized compensation cost, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.3 years. Performance Restricted Stock Units: As part of the Company's executive compensation program, the Company granted 54,337 performance restricted stock units during fiscal year 2017 that will vest based on performance of the Company. The weighted-average per-share grant date fair value of performance restricted stock units granted during fiscal year 2017 was $52.78 . During fiscal year 2017 , no performance restricted stock units were forfeited. The total compensation expense recognized related to the performance restricted stock units was $0.9 million for fiscal year 2017 . As of December 31, 2017 , there were 54,337 performance restricted stock units outstanding. Performance Units: The Company’s performance unit program provides a cash award based on the achievement of specific performance criteria. A target number of units are granted at the beginning of a three-year performance period. The number of units earned at the end of the performance period is determined by multiplying the number of units granted by a performance factor ranging from 0% to 200% . Awards are determined by multiplying the number of units earned by the stock price at the end of the performance period, and are paid in cash and accounted for as a liability based award. The compensation expense associated with these units is recognized over the period that the performance targets are expected to be achieved. The Company granted 49,845 performance units, 72,164 performance units, and 66,509 performance units during fiscal years 2017, 2016 and 2015 , respectively. The weighted-average per-share grant-date fair value of performance units granted during fiscal years 2017, 2016 and 2015 was $52.69 , $42.79 , and $46.83 , respectively. During fiscal years 2017, 2016 and 2015 , 15,139 , 19,584 and 8,860 performance units were forfeited, respectively. The total compensation expense related to performance units was $8.7 million , $2.7 million , and $4.0 million for fiscal years 2017, 2016 and 2015 , respectively. As of December 31, 2017 , there were 164,481 performance units outstanding subject to forfeiture, with a corresponding liability of $11.7 million recorded in accrued expenses and long-term liabilities. Stock Awards: The Company’s stock award program provides an annual equity award to non-employee directors. For fiscal years 2017, 2016 and 2015 , the award equaled the number of shares of the Company’s common stock which has an aggregate fair market value of $100,000 on the date of the award. The stock award is prorated for non-employee directors who serve for only a portion of the year. The compensation expense associated with these stock awards is recognized when the stock award is granted. In fiscal years 2017, 2016 and 2015 , each non-employee director was awarded 1,598 shares, 1,821 shares, and 1,953 shares, respectively. The Company also granted 820 shares to a new non-employee director during fiscal year 2017. The weighted-average per-share grant-date fair value of stock awards granted during fiscal years 2017, 2016 and 2015 was $63.14 , $54.58 , and $51.01 , respectively. The total compensation expense recognized related to these stock awards was $0.8 million in each of fiscal years 2017, 2016 and 2015 . Employee Stock Purchase Plan: In April 1999, the Company’s shareholders approved the 1998 Employee Stock Purchase Plan. In April 2005, the Compensation and Benefits Committee of the Board voted to amend the Employee Stock Purchase Plan, effective July 1, 2005, whereby participating employees have the right to purchase common stock at a price equal to 95% of the closing price on the last day of each six-month offering period. The number of shares which an employee may purchase, subject to certain aggregate limits, is determined by the employee’s voluntary contribution, which may not exceed 10% of the employee’s base compensation. During fiscal year 2017 , the Company issued 36,769 shares of common stock under the Company’s Employee Stock Purchase Plan at a weighted-average price of $67.09 per share. During fiscal year 2016 , the Company issued 49,578 shares under this plan at a weighted-average price of $49.67 per share. During fiscal year 2015 , the Company issued 78,294 shares under this plan at a weighted-average price of $47.08 per share. At December 31, 2017 there remains available for sale to employees an aggregate of 0.9 million shares of the Company’s common stock out of the 5.0 million shares authorized by shareholders for issuance under this plan.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Comprehensive Income: The components of accumulated other comprehensive (loss) income consisted of the following: Foreign Currency Translation Adjustment, net of tax Unrecognized Prior Service Costs, net of tax Unrealized (Losses) Gains on Securities, net of tax Accumulated Other Comprehensive Income (Loss) (In thousands) Balance, December 28, 2014 $ 23,332 $ 1,575 $ (107 ) $ 24,800 Current year change (70,178 ) (316 ) (262 ) (70,756 ) Balance, January 3, 2016 (46,846 ) 1,259 (369 ) (45,956 ) Current year change (54,077 ) (860 ) 32 (54,905 ) Balance, January 1, 2017 (100,923 ) 399 (337 ) (100,861 ) Current year change 54,341 (77 ) 79 54,343 Balance, December 31, 2017 $ (46,582 ) $ 322 $ (258 ) $ (46,518 ) During fiscal years 2017, 2016 and 2015 , pre-tax expense of $0.1 million , $0.9 million , and $0.3 million , respectively, was reclassified from accumulated other comprehensive income into selling, general and administrative expenses as a component of net periodic pension cost. Stock Repurchases: On July 27, 2016, the Board of Directors (the "Board") authorized the Company to repurchase up to 8.0 million shares of common stock under a stock repurchase program (the "Repurchase Program"). The Repurchase Program will expire on July 26, 2018 unless terminated earlier by the Board, and may be suspended or discontinued at any time. During fiscal year 2017 , the Company had no stock repurchases under the Repurchase Program. As of December 31, 2017 , 8.0 million shares remained available for repurchase under the Repurchase Program. In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During fiscal year 2017 , the Company repurchased 78,644 shares of common stock for this purpose at an aggregate cost of $4.4 million . During fiscal year 2016 , the Company repurchased 75,198 shares of common stock for this purpose at an aggregate cost of $3.6 million . During fiscal year 2015 , the Company repurchased 95,129 shares of common stock for this purpose at an aggregate cost of $4.4 million . The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value. Dividends: The Board declared a regular quarterly cash dividend of $0.07 per share in each quarter of fiscal years 2017 and 2016 . At December 31, 2017 , the Company had accrued $7.7 million for a dividend declared on October 27, 2017 for the fourth quarter of fiscal year 2017 that was paid in February 2018 . On January 25, 2018 , the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the first quarter of fiscal year 2018 that will be payable in May 2018 . In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Derivatives And Hedging Activit

Derivatives And Hedging Activities	12 Months Ended
	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging Activities	Derivatives and Hedging Activities The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business. In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months , have no cash requirements until maturity, and are recorded at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s consolidated statement of cash flows. Principal hedged currencies include the British Pound, Euro, Swedish Krona, Japanese Yen and Singapore Dollar. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $212.1 million at December 31, 2017 , $137.5 million at January 1, 2017 , and $127.3 million at January 3, 2016 , and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of fiscal years 2017, 2016 and 2015 . In addition, in connection with certain intercompany loan agreements utilized to finance its acquisitions and stock repurchase program, the Company enters into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies. The Company records these hedges at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from financing activities within the Company’s consolidated statement of cash flows. The outstanding forward exchange contracts designated as economic hedges, which were intended to hedge movements in foreign exchange rates prior to the settlement of certain intercompany loan agreements, included combined Euro notional amounts of €57.2 million and combined U.S. Dollar notional amounts of $1.3 billion as of December 31, 2017 , combined Euro notional amounts of €58.6 million , combined U.S. Dollar notional amounts of $8.7 million and combined Swedish Krona notional amounts of kr969.5 million as of January 1, 2017 , and combined Euro notional amounts of €107.4 million as of January 3, 2016 . The net gains and losses on these derivatives, combined with the gains and losses on the remeasurement of the hedged intercompany loans were not material for each of the fiscal years 2017 and 2016 . The Company paid $13.8 million and $1.9 million during the fiscal years 2017 and 2016 , respectively, from the settlement of these hedges. During fiscal year 2016, the Company designated the 2026 Notes to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges were included in the foreign currency translation component of accumulated other comprehensive income ("AOCI"), which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of December 31, 2017 , the total notional amount of foreign currency denominated debt designated to hedge investments in foreign subsidiaries was €496.1 million . The unrealized foreign exchange loss (gain) recorded in AOCI related to the net investment hedge was $73.0 million and $(23.8) million for the fiscal years 2017 and 2016 , respectively. In January 2018, the Company removed the hedging relationship of its 2026 Notes and investments in certain foreign subsidiaries and recognized $2.1 million of unrealized foreign exchange gain in AOCI. The translation adjustment of the 2026 Notes will be recognized in other (income) expense, net within the Company's consolidated statement of operations prospectively. During fiscal year 2017 , the Company entered into several foreign currency forward contracts to purchase Euros to partly mitigate the currency exchange risk associated with the payment of the Euro-denominated purchase price of EUROIMMUN. These currency forward contracts were not designated as hedging instruments and therefore the change in the derivative fair value was marked to market through the consolidated statement of operations. The foreign currency forward contracts were settled during the fourth quarter of fiscal year 2017 . The Company received $36.5 million from the settlement of these foreign currency forward contracts and recorded a net foreign exchange gain included in other (income) expense, net amounting to $36.5 million for the fiscal year 2017 . The cash flows related to the settlement of these foreign currency forward contracts are included in cash flows from investing activities within the Company’s consolidated statement of cash flows. The Company does no t expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive (loss) income into interest and other expense, net within the next twelve months.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of December 31, 2017 . The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during fiscal years 2017 and 2016 . The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2017 and January 1, 2017 classified in one of the three classifications described above: Fair Value Measurements at December 31, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,208 $ 2,208 $ — $ — Foreign exchange derivative assets 1,431 — 1,431 — Foreign exchange derivative liabilities (23,638 ) — (23,638 ) — Contingent consideration (65,328 ) — — (65,328 ) Fair Value Measurements at January 1, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 1,678 $ 1,678 $ — $ — Foreign exchange derivative assets 1,208 — 1,208 — Foreign exchange derivative liabilities, net (1,370 ) — (1,370 ) — Contingent consideration (63,201 ) — — (63,201 ) Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities. Marketable securities: Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date. Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's consolidated balance sheet on a net basis and are recorded in other assets. As of both December 31, 2017 and January 1, 2017 , none of the master netting arrangements involved collateral. Level 3 Valuation Techniques: The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities. Contingent consideration: Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model. During fiscal year 2015, the Company acquired all the shares of Vanadis. Under the terms of the acquisition, the initial purchase consideration was $32.0 million , net of cash and the Company will be obligated to make potential future milestone payments, based on completion of a proof of concept, regulatory approvals and product sales, of up to $93.0 million ranging from 2016 to 2019. The key assumptions used to determine the fair value of the contingent consideration included projected milestone dates of 2016 to 2019 , discount rates ranging from 3.1% to 11.3% , conditional probabilities of success of each individual milestone ranging from 85% to 95% and cumulative probabilities of success for each individual milestone ranging from 53% to 90% . The fair value of the contingent consideration as of the acquisition date was estimated at $56.9 million . During fiscal year 2017 , the Company updated the fair value of the contingent consideration and recorded a liability of $65.3 million as of December 31, 2017 . The key assumptions used to determine the fair value of the contingent consideration as of December 31, 2017 included projected milestone dates of 2018 to 2019 , discount rates ranging from 2.3% to 8.4% , conditional probabilities of success of each individual milestone ranging from 90% to 95% and cumulative probabilities of success for each individual milestone ranging from 65.8% to 95% . A significant delay in the product development (including projected regulatory milestone) achievement date in isolation could result in a significantly lower fair value measurement; a significant acceleration in the product development (including projected regulatory milestone) achievement date in isolation would not have a material impact on the fair value measurement; a significant change in the discount rate in isolation would not have a material impact on the fair value measurement; and a significant change in the probabilities of success in isolation could result in a significant change in fair value measurement. The fair values of contingent consideration are calculated on a quarterly basis based on a collaborative effort of the Company’s regulatory, research and development, operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving proof of concept, regulatory approvals and revenue targets as compared to initial projections, the impact of market competition and market landscape shifts from non-invasive prenatal testing products, with the impact of such adjustments being recorded in the consolidated statements of operations. As of December 31, 2017 , the Company may have to pay contingent consideration, related to an acquisition with open contingency period, of up to $83.0 million . The expected maximum earnout period for an acquisition with open contingency period do not exceed 1.75 years from the acquisition date, and the remaining weighted average expected earnout period at December 31, 2017 was 11 months. A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: (In thousands) Balance at December 28, 2014 $ (91 ) Additions (57,353 ) Amounts paid and foreign currency translation 113 Change in fair value (included within selling, general and administrative expenses) (19 ) Balance at January 3, 2016 (57,350 ) Additions — Amounts paid and foreign currency translation 332 Reclassified to other current liabilities for milestone achieved 10,000 Change in fair value (included within selling, general and administrative expenses) (16,183 ) Balance at January 1, 2017 (63,201 ) Additions — Amounts paid and foreign currency translation 34 Change in fair value (included within selling, general and administrative expenses) (2,161 ) Balance at December 31, 2017 $ (65,328 ) The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1. As of December 31, 2017 , the Company’s senior unsecured revolving credit facility, which provides for $1.0 billion of revolving loans, had a carrying value of $621.7 million , net of $3.3 million of unamortized debt issuance costs. As of January 1, 2017 , the Company's senior unsecured revolving credit facility had no outstanding borrowings. The interest rate on the Company’s senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during fiscal year 2017 . Consequently, the carrying value approximates fair value and were classified as Level 2. As of December 31, 2017 , the Company’s senior unsecured term loan credit facility, which provides for $200.0 million of term loans, had a carrying value of $200.0 million . The interest rate on the Company’s senior unsecured term loan credit facility will be reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during the fiscal year 2017 . Consequently, the carrying value approximates fair value and were classified as Level 2. The Company's 2021 Notes, with a face value of $500.0 million , had an aggregate carrying value of $496.6 million , net of $1.4 million of unamortized original issue discount and $2.0 million of unamortized debt issuance costs as of December 31, 2017 . The 2021 Notes had an aggregate carrying value of $495.8 million , net of $1.7 million of unamortized original issue discount and $2.5 million of unamortized debt issuance costs as of January 1, 2017 . The 2021 Notes had a fair value of $536.6 million and $539.2 million as of December 31, 2017 and January 1, 2017 , respectively. The fair value of the 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's 2026 Notes, with a face value of €500.0 million , had an aggregate carrying value of $591.7 million , net of $4.7 million of unamortized original issue discount and $4.3 million of unamortized debt issuance costs as of December 31, 2017 . The 2026 Notes had an aggregate carrying value of $517.8 million , net of $4.5 million of unamortized original issue discount and $4.8 million of unamortized debt issuance costs as of January 1, 2017 . The 2026 Notes had a fair value of €508.9 million and €507.5 million as of December 31, 2017 and January 1, 2017 , respectively. The fair value of the 2026 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's financing lease obligations had an aggregate carrying value of $35.9 million and $37.1 million as of December 31, 2017 and January 1, 2017 , respectively. The carrying values of the Company's financing lease obligations approximated their fair value as there has been minimal change in the Company's incremental borrowing rate. As of December 31, 2017 , the 2021 Notes, 2026 Notes and financing lease obligations were classified as Level 2. The Company’s other debt facilities that were assumed from the EUROIMMUN acquisition had an aggregate carrying value of $60.2 million as of December 31, 2017 . The bank loans in the aggregate amount of $47.8 million bear fixed interest rates between 0.05% and 7.9% and bank loans in the aggregate amount of $12.4 million bear variable interest rates based on the Euribor rate plus a margin between 1.25% and 1.5% . The Company had no change in credit standing during fiscal year 2017 . Consequently, the carrying value approximates fair value and were classified as Level 2. As of December 31, 2017 , there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks.

Leases

Leases	12 Months Ended
	Dec. 31, 2017
Leases [Abstract]
Leases	Leases The Company leases certain property and equipment under operating leases. Rental expense charged to continuing operations for fiscal years 2017, 2016 and 2015 amounted to $54.0 million , $52.0 million , and $52.4 million , respectively. Minimum rental commitments under noncancelable operating leases are as follows: $57.0 million in fiscal year 2018 , $37.2 million in fiscal year 2019 , $27.4 million in fiscal year 2020 , $22.0 million in fiscal year 2021 , $13.5 million in fiscal year 2022 and $59.6 million in fiscal year 2023 and thereafter . On August 22, 2013 , the Company sold one of its facilities located in Boston, Massachusetts for net proceeds of $47.6 million . Simultaneously with the closing of the sale of the property, the Company entered into a lease agreement to lease back the property for its continued use. The lease has an initial term of 15 years and the Company has the right to extend the term of the lease for two additional periods of ten years each. The lease is accounted for as an operating lease and at the transaction date the Company had deferred $26.5 million of gains which are being amortized in operating expenses over the initial lease term of 15 years . The Company amortized $1.8 million of the deferred gains related to the lease during each of the fiscal years 2017, 2016 and 2015 . The deferred gains remaining to be amortized were $18.8 million at December 31, 2017 , of which $1.8 million was recorded in accrued expenses and other current liabilities, and $17.0 million was recorded in long-term liabilities. The deferred gains remaining to be amortized were $20.6 million at January 1, 2017 , of which $1.8 million was recorded in accrued expenses and other current liabilities, and $18.8 million was recorded in long-term liabilities.

Industry Segment and Geographic

Industry Segment and Geographic Area Information	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Industry Segment Information	Industry Segment and Geographic Area Information The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1. The principal products and services of the Company's two operating segments are: • Discovery & Analytical Solutions . Provides products and services targeted towards the environmental, industrial, food, life sciences research and laboratory services markets. • Diagnostics . Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, emerging market diagnostics and applied genomics markets. The Diagnostics segment serves the diagnostics market. The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments. During the first quarter of fiscal year 2017, the Company changed the manner in which certain shared functional costs are allocated to the operating segments. Segment financial information relating to the fiscal years ended January 1, 2017 and January 3, 2016 have been retrospectively adjusted to reflect this change to the cost allocation methodology. Accordingly, for the fiscal years ended January 1, 2017 and January 3, 2016 , operating income from continuing operations from the Discovery & Analytical Solutions segment decreased by $10.7 million and $10.9 million , respectively, with corresponding increases in operating income from continuing operations of the Diagnostics segment in both fiscal years. Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended: December 31, January 1, January 3, (In thousands) Discovery & Analytical Solutions Product revenue $ 941,328 $ 934,098 $ 968,034 Service revenue 637,131 578,886 560,385 Total revenue 1,578,459 1,512,984 1,528,419 Operating income from continuing operations (1) 206,688 196,819 162,762 Diagnostics Product revenue 536,086 462,798 427,068 Service revenue 142,437 139,735 149,336 Total revenue 678,523 602,533 576,404 Operating income from continuing operations 149,636 149,577 146,478 Corporate Operating loss from continuing operations (2) (51,521 ) (63,330 ) (58,314 ) Continuing Operations Product revenue 1,477,414 1,396,896 1,395,102 Service revenue 779,568 718,621 709,721 Total revenue 2,256,982 2,115,517 2,104,823 Operating income from continuing operations 304,803 283,066 250,926 Interest and other expense, net (see Note 5) 8,085 38,998 42,119 Income from continuing operations before income taxes $ 296,718 $ 244,068 $ 208,807 ____________________________ (1) Legal costs for a particular case in the Discovery & Analytical Solutions segment were $2.7 million for fiscal year 2017 . (2) Activity related to the mark-to-market adjustment on postretirement benefit plans has been included in the Corporate operating loss from continuing operations, and in the aggregate constituted a pre-tax gain of $2.1 million in fiscal year 2017 , a pre-tax loss of $15.3 million in fiscal year 2016 , and pre-tax loss of $12.4 million in fiscal year 2015 . Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended December 31, 2017 : Depreciation and Amortization Expense Capital Expenditures December 31, January 1, January 3, December 31, January 1, January 3, (In thousands) (In thousands) Discovery & Analytical Solutions $ 72,590 $ 72,484 $ 74,177 $ 26,200 $ 21,486 $ 18,175 Diagnostics 31,204 25,339 29,728 11,262 8,556 6,854 Corporate 1,206 2,149 1,459 1,627 1,660 3,189 Continuing operations $ 105,000 $ 99,972 $ 105,364 $ 39,089 $ 31,702 $ 28,218 Discontinued operations $ 929 $ 6,266 $ 6,643 $ 182 $ 1,302 $ 1,414 Total Assets December 31, January 1, January 3, (In thousands) Discovery & Analytical Solutions $ 2,744,370 $ 2,612,757 $ 2,546,583 Diagnostics 3,314,804 1,505,381 1,459,854 Corporate 32,289 31,171 28,497 Current and long-term assets of discontinued operations — 127,374 131,361 Total assets $ 6,091,463 $ 4,276,683 $ 4,166,295 The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended December 31, 2017 and net long-lived assets based on physical location as of December 31, 2017 and January 1, 2017 : Revenue December 31, January 1, January 3, (In thousands) U.S. $ 837,018 $ 842,364 $ 854,336 International: China 374,931 336,728 296,908 United Kingdom 65,164 65,904 69,081 Germany 91,669 89,839 86,632 India 84,812 43,891 40,239 Italy 77,477 70,948 71,225 France 80,153 71,104 70,665 Japan 76,322 65,980 69,381 Other international 569,436 528,759 546,356 Total international 1,419,964 1,273,153 1,250,487 Total sales $ 2,256,982 $ 2,115,517 $ 2,104,823 Net Long-Lived Assets December 31, January 1, January 3, (In thousands) U.S. $ 210,116 $ 182,186 $ 165,827 International: Germany 88,249 1,292 1,187 China 64,815 36,458 34,494 United Kingdom 28,028 14,638 14,244 India 14,820 2,020 1,508 Finland 14,764 12,295 12,203 Italy 10,334 3,398 2,958 Singapore 9,240 6,820 7,679 Brazil 7,963 1,452 1,225 Netherlands 4,281 4,162 3,835 Sweden 3,869 2,645 1,247 Other international 19,565 7,684 6,619 Total international 265,928 92,864 87,199 Total net long-lived assets $ 476,044 $ 275,050 $ 253,026

Quarterly Financial Information

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (Unaudited)	Quarterly Financial Information (Unaudited) Selected quarterly financial information is as follows for the fiscal years ended: First Quarter Second Quarter Third Quarter Fourth Quarter (1) Year (In thousands, except per share data) December 31, 2017 Revenue $ 514,115 $ 546,962 $ 554,275 $ 641,630 $ 2,256,982 Gross profit 239,611 257,503 268,822 307,095 1,073,031 Restructuring and contract termination charges, net 9,651 — 3,269 (263 ) 12,657 Operating income from continuing operations 51,579 75,997 79,807 97,420 304,803 Income from continuing operations before income taxes 39,983 70,792 105,054 80,889 296,718 Income (loss) from continuing operations 36,062 62,726 96,546 (38,444 ) 156,890 Income (loss) from discontinued operations and dispositions 2,541 141,343 (5,468 ) (2,673 ) 135,743 Net income (loss) 38,603 204,069 91,078 (41,117 ) 292,633 Basic earnings per share: Income (loss) from continuing operations $ 0.33 $ 0.57 $ 0.88 $ (0.35 ) $ 1.43 Income (loss) from discontinued operations and dispositions 0.02 1.29 (0.05 ) (0.02 ) 1.24 Net income (loss) 0.35 1.86 0.83 (0.37 ) 2.67 Diluted earnings per share: Income (loss) from continuing operations $ 0.33 $ 0.57 $ 0.87 $ (0.35 ) $ 1.42 Income (loss) from discontinued operations and dispositions 0.02 1.28 (0.05 ) (0.02 ) 1.22 Net income (loss) 0.35 1.84 0.82 (0.37 ) 2.64 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 January 1, 2017 Revenue $ 498,016 $ 536,242 $ 514,489 $ 566,770 $ 2,115,517 Gross profit 235,086 253,554 248,550 276,163 1,013,353 Restructuring and contract termination charges, net — 4,468 656 — 5,124 Operating income from continuing operations 60,577 66,266 75,781 80,442 283,066 Income from continuing operations before income taxes 49,491 60,873 64,518 69,186 244,068 Income from continuing operations 41,744 57,756 53,917 62,289 215,706 Income from discontinued operations and dispositions 5,722 6,101 4,210 2,560 18,593 Net income 47,466 63,857 58,127 64,849 234,299 Basic earnings per share: Income from continuing operations $ 0.38 $ 0.53 $ 0.49 $ 0.57 $ 1.97 Income from discontinued operations and dispositions 0.05 0.06 0.04 0.02 0.17 Net income 0.43 0.59 0.53 0.59 2.14 Diluted earnings per share: Income continuing operations $ 0.38 $ 0.53 $ 0.49 $ 0.57 $ 1.96 Income from discontinued operations and dispositions 0.05 0.06 0.04 0.02 0.17 Net income 0.43 0.58 0.53 0.59 2.12 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 ____________________________ (1) The fourth quarter of fiscal year 2017 includes a pre-tax gain of $2.1 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2016 includes a pre-tax loss of $15.3 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.

Nature of Operations and Acco32

Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Consolidation [Policy Text Block]	The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation.
Segment Reporting [Policy Text Block]
Fiscal Periods [Policy Text Block]	The Company's fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. Each of the fiscal years ended December 31, 2017 (" fiscal year 2017 ") and January 1, 2017 (" fiscal year 2016 ") included 52 weeks. The fiscal year ended January 3, 2016 (" fiscal year 2015 ") included 53 weeks. The additional week in fiscal year 2015 has been reflected in the Company's third quarter.
Subsequent Events [Policy Text Block]
Accounting Policies and Estimates [Policy Text Block]	Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Revenue Recognition [Policy Text Block]	Revenue Recognition: The Company’s product revenue is recorded when persuasive evidence of an arrangement exists, delivery has occurred, the price to the buyer is fixed or determinable, and collectability is reasonably assured. For products that include installation, and if the installation meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and installation revenue is recognized when the installation is complete. For revenue that includes customer-specified acceptance criteria, revenue is recognized after the acceptance criteria have been met. Certain of the Company’s products require specialized installation. Revenue for these products is deferred until installation is completed. Revenue from services is deferred and recognized over the contractual period, or as services are rendered. In limited circumstances, the Company has arrangements that include multiple elements that are delivered at different points of time, such as revenue from products and services with a remaining service or storage component, including cord blood processing and storage. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by a selling-price hierarchy. A deliverable in an arrangement qualifies as a separate unit of accounting if the delivered item has value to the customer on a stand-alone basis. A delivered item that does not qualify as a separate unit of accounting is combined with the other undelivered items in the arrangement and revenue is recognized for those combined deliverables as a single unit of accounting. The selling price used for each deliverable is based upon vendor-specific objective evidence ("VSOE") if such evidence is available, third-party evidence ("TPE") if VSOE is not available, and management's best estimate of selling price ("BESP") if neither VSOE nor TPE are available. TPE is the price of the Company's or any competitor's largely interchangeable products or services in stand-alone sales to similarly-situated customers. BESP is the price at which the Company would sell the deliverable if it were sold regularly on a stand-alone basis, considering market conditions and entity-specific factors. Revenue from software licenses and services was 4% of the Company's total revenue for fiscal year 2017 , and 5% for each of fiscal years 2016 and 2015 . The Company sells its software licenses with maintenance services and, in some cases, also with consulting services. For the undelivered elements, the Company determines VSOE of fair value to be the price charged when the undelivered element is sold separately. The Company determines VSOE for maintenance sold in connection with a software license based on the stated renewal rate method. The Company determines VSOE for consulting services by reference to the amount charged for similar engagements on a stand-alone basis. The Company recognizes revenue from software licenses sold together with maintenance and/or consulting services upon shipment using the residual method, provided that the above criteria have been met. If VSOE of fair value for the undelivered elements cannot be established, the Company defers all revenue from the arrangement until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered, or if the only undelivered element is maintenance, then the Company recognizes the entire fee ratably over the maintenance period. The Company recognizes revenue from the grant of certain intellectual property rights for patented technologies it owns. These rights typically include a combination of the following: the grant of a non-exclusive, retroactive and future license to patented technologies, a covenant-not-to-sue, the release of the licensee from certain claims, and the dismissal of any pending litigation. The intellectual property rights granted may be perpetual in nature, extending until the expiration of the related patents, or can be granted for a defined timeframe. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by the selling-price hierarchy. In the case where the agreement includes the dismissal of any pending litigation, the Company allocates between revenue and litigation settlement using the residual method. The Company recognizes revenue when the earnings process is complete and upon the execution of the agreement, when collectability is reasonably assured, or upon receipt of the minimum upfront fee for term agreement renewals, and when all other revenue recognition criteria have been met. Service revenues represent the Company’s service offerings including service contracts, field service including related time and materials, diagnostic testing, cord blood processing and storage, and training. Service revenues are recognized as the service is performed. Revenues for service contracts and storage contracts are recognized over the contract period. The Company sells products and accessories predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. Sales incentives related to distributor revenue are also the same as those for end-user customers.
Warranty Costs [Policy Text Block]	Warranty Costs : The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period.
Shipping and Handling Costs [Policy Text Block]	Shipping and Handling Costs: The Company reports shipping and handling revenue in revenue, to the extent they are billed to customers, and the associated costs in cost of product revenue.
Inventories [Policy Text Block]	Inventories : Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements.
Income Taxes [Policy Text Block]	Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings. The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense. See Note 6 below for additional details.
Property, Plant and Equipment [Policy Text Block]	Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 7 years. Certain tooling costs are capitalized and amortized over a 3 -year life, while repairs and maintenance costs are expensed.
Asset Retirement Obligations [Policy Text Block]	Asset Retirement Obligations : The Company records obligations associated with its lease obligations, the retirement of tangible long-lived assets and the associated asset retirement costs in accordance with authoritative guidance on asset retirement obligations. The Company reviews legal obligations associated with the retirement of long-lived assets that result from contractual obligations or the acquisition, construction, development and/or normal use of the assets. If it is determined that a legal obligation exists, regardless of whether the obligation is conditional on a future event, the fair value of the liability for an asset retirement obligation is recognized in the period in which it is incurred, if a reasonable estimate of fair value can be made. The fair value of the liability is added to the carrying amount of the associated asset, and this additional carrying amount is depreciated over the life of the asset. The difference between the gross expected future cash flow and its present value is accreted over the life of the related lease as interest expense. The amounts recorded in the consolidated financial statements are not material to any year presented.
Change in Accounting for Pension and Other Postretirement Benefits [Policy Text Block]	Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company immediately recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company's fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds.
Translation of Foreign Currencies [Policy Text Block]	Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive (loss) income, a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net
Business Combinations [Policy Text Block]	Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. Measurement period adjustments are made in the period in which the amounts are determined and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed.
Goodwill and Other Intangible Assets [Policy Text Block]	Goodwill and Other Intangible Assets: The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of a trade name that is not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships, and purchased technologies, which are being amortized over their estimated useful lives. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. In January 2017, the Company early adopted Accounting Standards Update No. 2017-04, Intangibles-Goodwill and Other Topic (Topic 350), Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). ASU 2017-04 amends Topic 350 by eliminating Step 2 from the goodwill impairment test and requires an entity to perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which the carrying value exceeds the reporting unit's fair value but not to exceed the total amount of goodwill allocated to that reporting unit. The Company will apply the provisions of ASU 2017-04 in its interim or annual goodwill impairment tests prospectively. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized . In addition, the Company evaluates the remaining useful life of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Amortizing intangible assets are reviewed for impairment when indicators of impairment are present. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 12 below for additional details.
Stock-Based Compensation [Policy Text Block]	Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 18 below.
Marketable Securities and Investments [Policy Text Block]	Marketable Securities and Investments: The cost of securities sold is based on the specific identification method. If securities are classified as available for sale, the Company records these investments at their fair values with unrealized gains and losses included in accumulated other comprehensive (loss) income. Under the cost method of accounting, equity investments in private companies are carried at cost and are adjusted for other-than-temporary declines in fair value, additional investments or distributions.
Cash Flows [Policy Text Block]	Cash and Cash Equivalents: The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments.
Environmental Matters [Policy Text Block]	Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted.
Research and Development Expense, Policy [Policy Text Block]	Research and Development: Research and development costs are expensed as incurred. The fair value of acquired IPR&D costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned.
Restructuring Charges [Policy Text Block]	Restructuring Charges: In recent fiscal years, the Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of its operations with its growth strategy, the integration of its business units and its productivity initiatives. In connection with these initiatives, the Company has recorded restructuring charges, as more fully described in Note 4 below. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Costs related to lease terminations are recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceases use.
New Accounting Pronouncement or Change in Accounting Principle, Description	Comprehensive Income: Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income.
Derivative Instruments and Hedging [Policy Text Block]	Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive (loss) income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements. The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of Accumulated Other Comprehensive Income ("AOCI"), as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815), Targeted Improvements to Accounting for Hedging Activities ("ASU 2017-12") , which amends the hedge accounting recognition and presentation requirements in Topic 815. ASU 2017-12 makes targeted changes to the existing hedge accounting model to better align an entity’s financial reporting for hedging relationships with the entity’s risk management activities, and to reduce the complexity of, and simplify the application of, the hedge accounting model. Specifically, ASU 2017-12 expands the types of transactions eligible for hedge accounting, eliminates the requirement to separately measure and present hedge ineffectiveness, simplifies the way assessments of hedge ineffectiveness may be performed, relaxes the documentation requirements for entering into hedging positions, provides targeted improvements to fair value hedges of interest rate risk, and permits an entity to exclude the change in the fair value of cross-currency basis spreads in currency swaps from the assessment of hedge effectiveness. The standard also requires entities to provide new disclosures about the impact fair value and cash flow hedges have on their income statements and about cumulative basis adjustments arising from fair value hedges. The provisions of this guidance are to be applied using a modified retrospective approach to existing hedging relationships as of the adoption date. However, the transition provisions allow for certain elections at the date of adoption and entities may choose to apply any of the provided elections. ASU 2017-12 is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The Company early adopted the provisions of this guidance beginning after December 31, 2017. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In May 2017, the FASB issued Accounting Standards Update No. 2017-09, Compensation - Stock Compensation (Topic 718), Scope of Modification Accounting ("ASU 2017-09") , which amends the scope of modification accounting for share-based payment arrangements. ASU 2017-09 provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under Topic 718. Specifically, an entity would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. If an entity modifies its awards and concludes that it is not required to apply modification accounting under the standard, it must still consider whether the modification affects its application of other guidance. Additionally, if a significant modification does not result in incremental compensation cost, entities are required to disclose the “lack of” incremental compensation cost resulting from such significant modification. The standard also removes the guidance in Topic 718 stating that modification accounting is not required when an entity adds an antidilution provision as long as that modification is not made in contemplation of an equity restructuring. The provisions of this guidance are to be applied on a prospective basis to awards modified on or after the effective date. ASU 2017-09 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In March 2017, the FASB issued Accounting Standards Update No. 2017-07, Compensation - Retirement Benefits (Topic 715), Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost ("ASU 2017-07") , which amends the requirements in Topic 715 related to the income statement presentation of the components of net periodic benefit cost for an entity’s sponsored defined benefit pension and other postretirement plans. ASU 2017-07 requires entities to (1) disaggregate the current-service-cost component from the other components of net benefit cost (the “other components”) and present it with other current employee compensation costs in their income statements and (2) present the other components elsewhere in their income statements and outside of income from operations, and disclose the income statement lines that contain the other components if they are not presented on appropriately described separate lines. Additionally, the standard requires that only the service-cost component of net benefit cost is eligible for capitalization (e.g., as part of inventory or property, plant, and equipment). The change in income statement presentation requires retrospective application, while the change in capitalized benefit cost is to be applied prospectively. ASU 2017-07 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The standard provides a practical expedient that permits entities to use the components of cost disclosed in prior years as a basis for the retrospective application of the new income statement presentation. Entities need to disclose the use of the practical expedient. The Company is evaluating the requirements of this guidance. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In January 2017, the FASB issued ASU 2017-04 , Intangibles-Goodwill and Other Topic (Topic 350), Simplifying the Test for Goodwill Impairment ("ASU 2017-04") , which amends Topic 350 to simplify the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 requires that an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize the impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider the income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. The provisions of this guidance are to be applied on a prospective basis. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. In January 2017, the Company early adopted ASU 2017-04 and will apply the provisions of this standard in its interim or annual goodwill impairment tests prospectively. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business ("ASU 2017-01"), which amends Topic 805 to provide a screen to determine when a set of assets and liabilities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. If the screen is not met, the standard (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace missing elements. The standard provides a framework to assist entities in evaluating whether both an input and a substantive process are present. The standard also provides a framework that includes two sets of criteria to consider that depend on whether a set has outputs and a more stringent criteria for sets without outputs. Lastly, the standard narrows the definition of the term "output" so that the term is consistent with how outputs are described in Topic 606, Revenue from Contracts with Customers . The provisions of this guidance are to be applied prospectively. ASU 2017-01 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted in limited circumstances. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Statement of Cash Flows (Topic 230), Restricted Cash ("ASU 2016-18"), which amends Topic 230 to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. The standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The provisions of this guidance are to be applied using a retrospective transition method to each period presented. ASU 2016-18 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In October 2016, the FASB issued Accounting Standards Update No. 2016-16, Income Taxes (Topic 740), Intra-entity Transfer of Assets Other than Inventory ("ASU 2016-16"). ASU 2016-16 removes the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. The standard requires entities to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The provisions of this guidance are to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. ASU 2016-16 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The Company is evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230 and other topics. The provisions of this guidance are to be applied using a retrospective transition method to each period presented, and if it is impracticable to apply the amendments retrospectively for some of the issues, ASU 2016-15 allows the amendments for those issues to be applied prospectively as of the earliest date practicable. ASU 2015-16 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). ASU 2016-13 changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The standard requires entities to use the expected loss impairment model and will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance sheet credit exposures. Entities are required to estimate the lifetime “expected credit loss” for each applicable financial asset and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The standard also amends the impairment model for available-for-sale (“AFS”) debt securities and requires entities to determine whether all or a portion of the unrealized loss on an AFS debt security is a credit loss. An entity will recognize an allowance for credit losses on an AFS debt security as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment. The provisions of this guidance are to be applied using a modified-retrospective approach. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. ASU 2016-13 is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. ASU 2016-02 also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The provisions of this guidance are effective for annual periods beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. ASU 2016-02 is to be applied using a modified retrospective approach. The Company is evaluating the requirements of this guidance and has not yet determined the impact of the adoption on its consolidated financial position, results of operations and cash flows. The Company does not intend to early adopt the provisions of this standard. In July 2015, the FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory . Under this new guidance, companies that use inventory measurement methods other than last-in, first-out or the retail inventory method should measure inventory at the lower of cost and net realizable value. The provisions of this guidance are to be applied prospectively and are effective for interim and annual periods beginning after December 15, 2016, with early adoption permitted. The Company adopted ASU 2015-11 at the beginning of the first quarter of fiscal year 2017. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). Under this new guidance, an entity should use a five-step process to recognize revenue, depicting the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. Subsequent to the issuance of the standard, the FASB decided to defer the effective date for one year to annual reporting periods beginning after December 15, 2017, with early adoption permitted for annual reporting periods beginning after December 15, 2016. In November 2017, the FASB also issued Accounting Standards Update No. 2017-14, Income Statement-Reporting Comprehensive Income (Topic 220), Revenue Recognition (Topic 605), and Revenue from Contracts with Customers (Topic 606) . ASU 2017-14 includes amendments to certain SEC paragraphs within the FASB Accounting Standards Codification ("Codification"). ASU 2017-14 amends the Codification to incorporate SEC Staff Accounting Bulletin No. 116 and SEC Interpretive Release on Vaccines for Federal Government Stockpiles (SEC Release No. 33-10403) to align existing SEC staff guidance with Revenue from Contracts with Customers (Topic 606). In May 2016, the FASB also issued Accounting Standards Update No. 2016-12, Revenue from Contracts with Customers (Topic 606), Narrow-Scope Improvements and Practical Expedients ("ASU 2016-12") , which amended its revenue recognition guidance in ASU 2014-09 on transition, collectibility, non-cash consideration, contract modifications and completed contracts at transition and the presentation of sales and other similar taxes collected from customers. In April 2016, the FASB also issued Accounting Standards Update No. 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing ("ASU 2016-10") , which amended its revenue recognition guidance in ASU 2014-09 on identifying performance obligations to allow entities to disregard items that are immaterial in the context of the contract, clarify when a promised good or service is separately identifiable (i.e., distinct within the context of the contract) and allow an entity to elect to account for the cost of shipping and handling performed after control of a good has been transferred to the customer as a fulfillment cost (i.e., an expense). ASU 2016-10 also clarifies how an entity should evaluate the nature of its promise in granting a license of intellectual property ("IP") and requires entities to classify IP in one of two categories: functional IP or symbolic IP, which will determine whether it recognizes revenue over time or at a point in time. ASU 2016-10 also address how entities should consider license renewals and restrictions and apply the exception for sales- and usage-based royalties received in exchange for licenses of IP. In March 2016, the FASB also issued Accounting Standards Update No. 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net) ("ASU 2016-08"), which amended the principal-versus-agent implementation guidance and illustrations in ASU 2014-09. ASU 2016-08 clarifies that an entity should evaluate when it is the principal or agent for each specified good or service promised in a contract with a customer. ASU 2017-14, ASU 2016-12, ASU 2016-10, ASU 2016-08 and ASU 2014-09 may be adopted either using a full retrospective approach or a modified retrospective approach. The standards were effective for the Company beginning on January 1, 2018. The Company did not early adopt these standards and adopted these standards using the modified retrospective approach. The most significant impact of the standards relates to the accounting for certain transactions with multiple elements or “bundled” arrangements. Specifically, for sales of software subscriptions or sales of licenses and maintenance, we will recognize the license revenue predominantly at the time of billing and delivery rather than recognizing the entire sales price ratably over the maintenance period, which is the Company's current practice. In addition, for certain sales of instruments that include customer-specified acceptance criteria, the Company will recognize revenue when the customer obtains control of the instrument which is predominantly at the time of delivery or when title has transferred to the customer, as the Company believes acceptance is perfunctory. The Company will also capitalize incremental commission fees as a result of obtaining contracts when these fees are recoverable and will amortize the assets based on the transfer of goods or services to which the assets relate which typically range from two to six years. The Company elected to apply the modified retrospective approach only to contracts not completed as of January 1, 2018. The adoption of the standards will result in an increase in the retained earnings at January 1, 2018 of approximately $9.3 million for the cumulative effect of initially applying the standards at January 1, 2018. In addition, the adoption of the standards will result in a reduction in deferred revenue of approximately $12.5 million , primarily driven by the upfront recognition of license revenue and certain multi-year software subscriptions, and an increase in deferred income taxes of approximately $3.2 million for the tax impact of the cumulative adjustments. The cumulative effect of recognizing instrument sales upon delivery or transfer of title and capitalizing the incremental commission fees are not material at January 1, 2018. The adoption of the standards will have no impact to cash from or used in operating, investing, or financing activities in the Company's consolidated statement of cash flows at January 1, 2018.

Business Combinations and Ass33

Business Combinations and Asset Purchases (Tables)	12 Months Ended
	Dec. 31, 2017
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Information [Table Text Block]	The following unaudited pro forma information presents the combined financial results for the Company and EUROIMMUN as if the acquisition of EUROIMMUN had been completed at the beginning of fiscal year 2016: December 31, January 1, (In thousands, except per share data) Pro Forma Statement of Operations Information (Unaudited): Revenue $ 2,562,580 $ 2,379,176 Income from continuing operations 143,459 156,210 Basic earnings per share: Income from continuing operations $ 1.31 $ 1.43 Diluted earnings per share: Income from continuing operations $ 1.29 $ 1.42
Fair Values of the Business Combinations and Allocations for the Acquisitions Completed	The total purchase price for the acquisitions in fiscal year 2016 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2016 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 72,497 Working capital and other adjustments (261 ) Less: cash acquired (2,152 ) Total $ 70,084 Identifiable assets acquired and liabilities assumed: Current assets $ 7,153 Property, plant and equipment 7,542 Identifiable intangible assets: Core technology 6,600 Trade names 570 Customer relationships 14,900 Goodwill 43,072 Deferred taxes (7,768 ) Liabilities assumed (1,985 ) Total $ 70,084 The total purchase price for the acquisitions in fiscal year 2015 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2015 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 75,285 Contingent consideration 56,878 Working capital and other adjustments 1,832 Less: cash acquired (3,864 ) Total $ 130,131 Identifiable assets acquired and liabilities assumed: Current assets $ 2,551 Property, plant and equipment 998 Identifiable intangible assets: Core technology 15,759 Trade names 200 Licenses 116 Customer relationships 3,073 IPR&D 75,700 Goodwill 53,112 Deferred taxes (18,528 ) Liabilities assumed (2,850 ) Total $ 130,131 The total purchase price for the acquisitions in fiscal year 2017 have been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: EUROIMMUN 2017 Other (In thousands) Fair value of business combination: Cash payments $ 1,413,780 $ 140,861 Other liability — 1,273 Less: cash acquired (25,018 ) (2,439 ) Total $ 1,388,762 $ 139,695 Identifiable assets acquired and liabilities assumed: Current assets $ 121,174 $ 16,268 Property, plant and equipment 129,964 11,356 Other assets 49,944 1,691 Identifiable intangible assets: Core technology 160,000 12,400 Trade names 36,000 3,000 Customer relationships 700,000 43,700 In-process research and development ("IPR&D") 1,400 — Goodwill 614,759 75,453 Deferred taxes (275,491 ) (15,414 ) Liabilities assumed (87,631 ) (8,759 ) Debt assumed (61,357 ) — Total $ 1,388,762 $ 139,695

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	The summary pre-tax operating results of the discontinued operations were as follows during the three fiscal years ended: December 31, January 1, January 3, (In thousands) Revenue $ 44,343 $ 146,217 $ 158,128 Cost of revenue 32,933 95,395 97,777 Selling, general and administrative expenses 5,869 13,657 11,712 Research and development expenses 4,891 14,368 13,391 Restructuring and contract termination charges, net — 568 43 Income from discontinued operations before income taxes $ 650 $ 22,229 $ 35,205
Schedule of Gains and Losses on Disposition of Discontinued Operations [Table Text Block]	The Company recorded the following pre-tax gains and losses, which have been reported as a net gain or loss on disposition of discontinued operations during the three fiscal years ended: December 31, January 1, January 3, (In thousands) Gain on disposition of the Medical Imaging business $ 179,615 $ — $ — Gain (loss) on disposition of Technical Services business — 1,753 (28 ) Loss on disposition of Fluid Sciences Segment — (1,134 ) — Gain (loss) on disposition of discontinued operations before income taxes $ 179,615 $ 619 $ (28 )
Schedule of carrying amounts of major classes of assets and liabilities included in discontinued operations [Table Text Block]	The carrying amounts of the major classes of assets and liabilities included in discontinued operations as of December 31, 2017 and January 1, 2017 consisted of the following: December 31, January 1, (In thousands) Current assets of discontinued operations: Accounts receivables $ — $ 28,400 Inventories — 26,977 Prepaid income taxes — 425 Other current assets — 3,183 Total current assets of discontinued operations — 58,985 Property, plant and equipment — 25,219 Intangible assets — 3,292 Goodwill — 38,794 Other assets, net — 1,084 Long-term assets of discontinued operations — 68,389 Total assets of discontinued operations $ — $ 127,374 Current liabilities of discontinued operations: Accounts payable $ — $ 16,770 Accrued restructuring and contract termination charges — 209 Accrued expenses and other current liabilities 2,102 9,992 Total current liabilities of discontinued operations 2,102 26,971 Deferred income taxes — 7,851 Long-term liabilities — 7,109 Total long-term liabilities — 14,960 Total liabilities of discontinued operations $ 2,102 $ 41,931

Restructuring and Contract Te35

Restructuring and Contract Terminaiton Charges, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the number of employees reduced, the initial restructuring or contract termination charges by operating segment, and the dates by which payments were substantially completed, or the expected dates by which payments will be substantially completed, for restructuring actions implemented during fiscal years 2017, 2016 and 2015 in continuing operations: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Diagnostics Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Severance Excess Facility (In thousands, except headcount data) Q4 2017 Plan 29 $ 255 $ 1,680 $ — $ — $ 1,935 Q1 FY2019 — Q3 2017 Plan 27 1,021 1,321 — — 2,342 Q4 FY2018 — Q1 2017 Plan 90 1,631 5,000 33 33 6,697 Q2 FY2018 Q2 FY2018 Q3 2016 Plan 22 41 1,779 — — 1,820 Q4 FY2017 — Q2 2016 Plan 72 561 4,106 — — 4,667 Q3 FY2017 — Q4 2015 Plan 174 1,315 9,980 — 285 11,580 Q1 FY2017 Q4 FY2017 Q2 2015 Plan 95 673 5,290 — — 5,963 Q2 FY2016 —
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the Company's restructuring accrual balances and related activity by restructuring plan, as well as contract termination accrual balances and related activity, during fiscal years 2017, 2016 and 2015 in continuing operations: Balance at December 28, 2014 2015 Charges and Changes in Estimates, Net 2015 Amounts Paid Balance at January 3, 2016 2016 Charges and Changes in Estimates, Net 2016 Amounts Paid Balance at January 1, 2017 2017 Charges and Changes in Estimates, Net 2017 Amounts Paid Balance at December 31, 2017 (In thousands) Severance: Q4 2017 Plan $ — $ — $ — $ — $ — $ — $ — $ 1,935 $ (16 ) $ 1,919 Q3 2017 Plan — — — — — — — 2,342 (270 ) 2,072 Q1 2017 Plan — — — — — — — 6,631 (4,133 ) 2,498 Q3 2016 Plan — — — — 1,820 (612 ) 1,208 (202 ) (1,006 ) — Q2 2016 Plan (1) — — — — 4,667 (3,231 ) 1,436 (829 ) (607 ) — Q4 2015 Plan (2) — 11,295 (925 ) 10,370 (953 ) (8,198 ) 1,219 (1,066 ) (153 ) — Q2 2015 Plan — 5,423 (4,322 ) 1,101 (533 ) (370 ) 198 (198 ) — — Facility: Q1 2017 Plan — — — — — — — 66 (33 ) 33 Q4 2015 Plan — 285 (26 ) 259 — (248 ) 11 — — 11 Previous Plans (3) 23,522 (3,539 ) (9,695 ) 10,288 35 (3,971 ) 6,352 727 (2,691 ) 4,388 Restructuring 23,522 13,464 (14,968 ) 22,018 5,036 (16,630 ) 10,424 9,406 (8,909 ) 10,921 Contract Termination 304 83 (255 ) 132 88 (103 ) 117 3,251 (320 ) 3,048 Total Restructuring and Contract Termination $ 23,826 $ 13,547 $ (15,223 ) $ 22,150 $ 5,124 $ (16,733 ) $ 10,541 $ 12,657 $ (9,229 ) $ 13,969 ____________________________ (1) During fiscal year 2017 , the Company recognized pre-tax restructuring reversals of $0.4 million each in the Discovery & Analytical Solutions and Diagnostics segments, related to lower than expected costs associated with workforce reductions for the Q2 2016 Plan. (2) During fiscal year 2017 , the Company recognized pre-tax restructuring reversals of $0.5 million each in the Discovery & Analytical Solutions and Diagnostics segments related, to lower than expected costs associated with workforce reductions for the Q4 2015 Plan. (3) During fiscal year 2017 , the Company recognized pre-tax restructuring charges of $0.3 million in the Discovery & Analytical Solutions and $0.4 million in the Diagnostics segments related to change in lease assumptions partially offset by lower than expected costs associated with workforce reductions for the Previous Plans.

Interest and Other Expense (I36

Interest and Other Expense (Income), Net (Tables)	12 Months Ended
	Dec. 31, 2017
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and other expense, net, consisted of the following for the fiscal years ended: December 31, January 1, January 3, Interest income $ (2,571 ) $ (702 ) $ (673 ) Interest expense 43,940 41,528 37,997 Losses (gains) on disposition of businesses and assets, net (see Note 3) 309 (5,562 ) — Other (income) expense, net (33,593 ) 3,734 4,795 Total interest and other expense, net $ 8,085 $ 38,998 $ 42,119

Income Taxes (Tables)

Income Taxes (Tables) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017
Income Tax Disclosure [Abstract]
Summary of Income Tax Contingencies [Table Text Block]	The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended: December 31, January 1, January 3, (In thousands) Unrecognized tax benefits, beginning of year $ 29,607 $ 28,143 $ 32,342 Gross increases—tax positions in prior periods 749 1,514 325 Gross decreases—tax positions in prior periods (828 ) (183 ) (2,305 ) Gross increases—current-period tax positions 2,346 3,547 — Settlements (324 ) — (441 ) Lapse of statute of limitations (1,371 ) (4,109 ) (1,077 ) Foreign currency translation adjustments 129 695 (701 ) Unrecognized tax benefits, end of year $ 30,308 $ 29,607 $ 28,143
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	The components of income (loss) from continuing operations before income taxes were as follows for the fiscal years ended: December 31, January 1, January 3, (In thousands) U.S. $ 3,743 $ 39,689 $ (21,510 ) Non-U.S. 292,975 204,379 230,317 Total $ 296,718 $ 244,068 $ 208,807
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of the provision for (benefit from) income taxes for continuing operations were as follows: Current Expense (Benefit) Deferred Expense (Benefit) Total (In thousands) Fiscal year ended December 31, 2017 Federal $ 62,003 $ 35,435 $ 97,438 State 3,332 (792 ) 2,540 Non-U.S. 45,639 (5,789 ) 39,850 Total $ 110,974 $ 28,854 $ 139,828 Fiscal year ended January 1, 2017 Federal $ 14 $ 2,994 $ 3,008 State 2,143 (575 ) 1,568 Non-U.S. 30,754 (6,968 ) 23,786 Total $ 32,911 $ (4,549 ) $ 28,362 Fiscal year ended January 3, 2016 Federal $ (10,952 ) $ (4,794 ) $ (15,746 ) State 2,613 (2,563 ) 50 Non-U.S. 37,963 (2,245 ) 35,718 Total $ 29,624 $ (9,602 ) $ 20,022
Schedule of Income Tax Expense (Benefit), Continuing Operations and Discontinued Operations [Table Text Block]	The total provision for income taxes included in the consolidated financial statements is as follows for the fiscal years ended: December 31, January 1, January 3, (In thousands) Continuing operations $ 139,828 $ 28,362 $ 20,022 Discontinued operations 44,522 4,255 11,537 Total $ 184,350 $ 32,617 $ 31,559
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended: December 31, January 1, January 3, (In thousands) Tax at statutory rate $ 103,851 $ 85,424 $ 73,082 Non-U.S. rate differential, net (65,836 ) (52,648 ) (47,994 ) U.S. taxation of multinational operations 5,408 6,941 1,732 State income taxes, net 1,810 1,509 80 Prior year tax matters (7,955 ) (9,621 ) (6,387 ) Federal tax credits (8,249 ) (7,189 ) (2,096 ) Change in valuation allowance 1,951 (2,755 ) 2,593 Non-deductible acquisition expense — 5,701 — Impact of federal tax reform 106,538 — — Others, net 2,310 1,000 (988 ) Total $ 139,828 $ 28,362 $ 20,022
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of December 31, 2017 and January 1, 2017 were as follows: December 31, January 1, (In thousands) Deferred tax assets: Inventory $ 6,376 $ 10,994 Reserves and accruals 26,657 24,669 Accrued compensation 17,333 26,715 Net operating loss and credit carryforwards 88,503 113,415 Accrued pension 34,682 37,005 Restructuring reserve 2,586 1,954 Deferred revenue 28,478 38,113 Unrealized foreign exchange loss 10,910 — All other, net — 682 Total deferred tax assets 215,525 253,547 Deferred tax liabilities: Postretirement health benefits (3,391 ) (4,785 ) Unrealized foreign exchange gain — (15,730 ) Depreciation and amortization (392,293 ) (130,176 ) All other, net (594 ) — Total deferred tax liabilities (396,278 ) (150,691 ) Valuation allowance (68,895 ) (65,640 ) Net deferred tax (liabilities) assets $ (249,648 ) $ 37,216
Schedule of Deferred Income Taxes, Domestic and Foreign [Table Text Block]	The components of net deferred tax (liabilities) assets as of December 31, 2017 and January 1, 2017 were as follows: December 31, January 1, (In thousands) U.S. $ 44,974 $ 52,604 Non-U.S. (294,622 ) (15,388 ) Total $ (249,648 ) $ 37,216
Components of net deferred tax asset recognized [Table Text Block]	The components of net deferred tax (liabilities) assets as of December 31, 2017 and January 1, 2017 were recognized in the consolidated balance sheets as follows: December 31, January 1, (In thousands) Other assets, net $ 67,280 $ 85,312 Long-term liabilities (316,928 ) (48,096 ) Total $ (249,648 ) $ 37,216
Deferred tax assets, other assets, net	$ 67,280	$ 85,312
Deferred tax liabilities, Long-term liabilities	(316,928)	(48,096)
Deferred Tax Liabilities, Net	$ 249,648
Deferred Tax Assets, Net		$ (37,216)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations	The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended: December 31, January 1, January 3, (In thousands) Number of common shares—basic 109,857 109,478 112,507 Effect of dilutive securities: Stock options 708 640 621 Restricted stock awards 294 195 187 Number of common shares—diluted 110,859 110,313 113,315 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 287 458 607

Inventories, Net (Tables)

Inventories, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Net Inventories	Inventories as of December 31, 2017 and January 1, 2017 consisted of the following: December 31, January 1, (In thousands) Raw materials $ 122,100 $ 79,189 Work in progress 18,452 6,561 Finished goods 211,123 161,097 Total inventories $ 351,675 $ 246,847

Property, Plant and Equipment40

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment [Table Text Block]	Property, plant and equipment, at cost, as of December 31, 2017 and January 1, 2017 , consisted of the following: December 31, January 1, (In thousands) Land $ 5,624 $ 4,250 Building and leasehold improvements 262,657 162,780 Machinery and equipment 362,638 260,873 Total property, plant and equipment 630,919 427,903 Accumulated depreciation (332,853 ) (282,409 ) Total property, plant and equipment, net $ 298,066 $ 145,494

Marketable Securities and Inv41

Marketable Securities and Investments (Tables)	12 Months Ended
	Dec. 31, 2017
Marketable Securities [Abstract]
Schedule of Investments, Noncurrent [Table Text Block]	Investments as of December 31, 2017 and January 1, 2017 consisted of the following: December 31, January 1, (In thousands) Marketable securities $ 2,208 $ 1,678 Cost method investments 10,783 — $ 12,991 $ 1,678
Available-for-sale Securities [Table Text Block]	Marketable securities classified as available for sale as of December 31, 2017 and January 1, 2017 consisted of the following: Market Value Gross Unrealized Holding Cost Gains (Losses) (In thousands) December 31, 2017 Equity securities $ 811 $ 1,161 $ — $ (350 ) Fixed-income securities 22 22 — — Other 1,375 1,438 — (63 ) $ 2,208 $ 2,621 $ — $ (413 ) January 1, 2017 Equity securities $ 598 $ 1,077 $ — $ (479 ) Fixed-income securities 22 22 — — Other 1,058 1,121 — (63 ) $ 1,678 $ 2,220 $ — $ (542 )

Goodwill and Intangible Asset42

Goodwill and Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for fiscal years 2017 and 2016 are as follows: Discovery & Analytical Solutions Diagnostics Consolidated Balance at January 3, 2016 $ 1,296,724 $ 940,139 $ 2,236,863 Foreign currency translation (16,602 ) (11,873 ) (28,475 ) Acquisitions, earnouts and other 23,814 15,764 39,578 Balance at January 1, 2017 1,303,936 944,030 2,247,966 Foreign currency translation 37,646 29,091 66,737 Acquisitions, earnouts and other 2,653 684,842 687,495 Balance at December 31, 2017 $ 1,344,235 $ 1,657,963 $ 3,002,198
Identifiable Intangible Asset Balances	Identifiable intangible asset balances at December 31, 2017 by category and by business segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated Patents $ 28,048 $ 11,911 $ 39,959 Less: Accumulated amortization (24,448 ) (10,637 ) (35,085 ) Net patents 3,600 1,274 4,874 Trade names and trademarks 29,950 51,024 80,974 Less: Accumulated amortization (20,022 ) (8,228 ) (28,250 ) Net trade names and trademarks 9,928 42,796 52,724 Licenses 43,061 10,239 53,300 Less: Accumulated amortization (34,620 ) (8,015 ) (42,635 ) Net licenses 8,441 2,224 10,665 Core technology 230,755 240,985 471,740 Less: Accumulated amortization (186,364 ) (58,552 ) (244,916 ) Net core technology 44,391 182,433 226,824 Customer relationships 233,573 907,938 1,141,511 Less: Accumulated amortization (116,696 ) (126,144 ) (242,840 ) Net customer relationships 116,877 781,794 898,671 IPR&D 5,569 82,456 88,025 Less: Accumulated amortization (4,059 ) (1,368 ) (5,427 ) Net IPR&D 1,510 81,088 82,598 Net amortizable intangible assets 184,747 1,091,609 1,276,356 Non-amortizable intangible assets: Trade name 70,584 — 70,584 Total $ 255,331 $ 1,091,609 $ 1,346,940 Identifiable intangible asset balances at January 1, 2017 by category and business segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated Patents $ 28,001 $ 11,900 $ 39,901 Less: Accumulated amortization (22,852 ) (9,556 ) (32,408 ) Net patents 5,149 2,344 7,493 Trade names and trademarks 28,563 11,523 40,086 Less: Accumulated amortization (15,927 ) (8,090 ) (24,017 ) Net trade names and trademarks 12,636 3,433 16,069 Licenses 49,831 7,936 57,767 Less: Accumulated amortization (38,745 ) (7,762 ) (46,507 ) Net licenses 11,086 174 11,260 Core technology 233,291 70,896 304,187 Less: Accumulated amortization (184,340 ) (49,380 ) (233,720 ) Net core technology 48,951 21,516 70,467 Customer relationships 259,419 123,884 383,303 Less: Accumulated amortization (119,342 ) (93,720 ) (213,062 ) Net customer relationships 140,077 30,164 170,241 IPR&D 5,569 72,946 78,515 Less: Accumulated amortization (3,445 ) (960 ) (4,405 ) Net IPR&D 2,124 71,986 74,110 Net amortizable intangible assets 220,023 129,617 349,640 Non-amortizable intangible assets: Trade name 70,584 — 70,584 Total $ 290,607 $ 129,617 $ 420,224

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt [Table Text Block]	The following table summarizes the maturities of the Company’s indebtedness as of December 31, 2017 : Sr. Unsecured Revolving Credit Facility Maturing 2021 Sr. Unsecured Term Loan Credit Facility 5.0% Sr. Notes Maturing 2021 1.875% Sr. Notes Maturing 2026 Other Debt Facilities Financing Lease Obligations Total (In thousands) 2018 $ — $ 200,000 $ — $ — $ 16,015 $ 1,370 $ 217,385 2019 — — — — 12,974 1,532 14,506 2020 — — — — 7,752 1,597 9,349 2021 625,000 — 500,000 — 9,248 1,664 1,135,912 2022 — — — — 4,664 1,639 6,303 2023 and thereafter — — — 600,700 9,562 28,109 638,371 Total before unamortized discount and debt issuance costs 625,000 200,000 500,000 600,700 60,215 35,911 2,021,826 Unamortized discount and debt issuance costs (3,339 ) — (3,417 ) (8,961 ) — — (15,717 ) Total $ 621,661 $ 200,000 $ 496,583 $ 591,739 $ 60,215 $ 35,911 $ 2,006,109

Accrued Expenses and Other Cu44

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Accounts Payable and Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses and other current liabilities as of December 31, 2017 and January 1, 2017 consisted of the following: December 31, January 1, (In thousands) Payroll and incentives $ 66,955 $ 61,474 Employee benefits 37,354 31,039 Deferred revenue 159,923 162,987 Federal, non-U.S. and state income taxes 10,800 8,189 Other accrued operating expenses 225,610 136,011 Total accrued expenses and other current liabilities $ 500,642 $ 399,700

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017
Pension Plans, Defined Benefit
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Components of Net Periodic Benefit Cost (Credit)	Net periodic pension (credit) cost for U.S. and non-U.S. plans included the following components for fiscal years ended: December 31, January 1, January 3, (In thousands) Service and administrative costs $ 4,951 $ 4,337 $ 4,332 Interest cost 16,707 18,638 20,696 Expected return on plan assets (26,401 ) (24,245 ) (26,021 ) Curtailment gain — — (907 ) Actuarial (gain) loss (7,085 ) 15,890 12,953 Amortization of prior service cost (195 ) (210 ) (238 ) Net periodic pension (credit) cost $ (12,023 ) $ 14,410 $ 10,815
Schedule of Net Funded Status		The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 31, 2017 and January 1, 2017 . December 31, 2017 January 1, 2017 Non-U.S. U.S. Non-U.S. U.S. (In thousands) Actuarial present value of benefit obligations: Accumulated benefit obligations $ 334,151 $ 308,713 $ 271,127 $ 300,650 Change in benefit obligations: Projected benefit obligations at beginning of year $ 279,522 $ 300,650 $ 276,960 $ 301,416 Service and administrative costs 2,201 2,750 2,262 2,075 Interest cost 4,870 11,836 6,205 12,433 Benefits paid and plan expenses (13,238 ) (20,032 ) (11,940 ) (19,424 ) Participants’ contributions 189 — 209 — Business acquisition (divestiture) 39,293 — (2,955 ) — Plan settlements — — (993 ) — Actuarial (gain) loss (1,486 ) 13,509 38,623 4,150 Effect of exchange rate changes 32,059 — (28,849 ) — Projected benefit obligations at end of year $ 343,410 $ 308,713 $ 279,522 $ 300,650 Change in plan assets: Fair value of plan assets at beginning of year $ 153,281 $ 243,817 $ 150,894 $ 244,693 Actual return on plan assets 15,866 29,642 32,581 18,548 Benefits paid and plan expenses (13,238 ) (20,032 ) (11,940 ) (19,424 ) Employer’s contributions 8,422 — 9,562 — Participants’ contributions 189 — 209 — Plan settlements — — (993 ) — Effect of exchange rate changes 15,216 — (27,032 ) — Fair value of plan assets at end of year $ 179,736 $ 253,427 $ 153,281 $ 243,817 Net liabilities recognized in the consolidated balance sheets $ (163,674 ) $ (55,286 ) $ (126,241 ) $ (56,833 ) Net amounts recognized in the consolidated balance sheets consist of: Noncurrent assets $ 26,591 $ — $ 12,944 $ — Current liabilities (7,017 ) — (6,033 ) — Noncurrent liabilities (183,248 ) (55,286 ) (133,152 ) (56,833 ) Net liabilities recognized in the consolidated balance sheets $ (163,674 ) $ (55,286 ) $ (126,241 ) $ (56,833 ) Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ (457 ) $ — $ (603 ) $ — Actuarial assumptions as of the year-end measurement date: Discount rate 1.99 % 3.56 % 2.06 % 4.06 % Rate of compensation increase 3.50 % None 3.64 % None Actuarial assumptions used to determine net periodic pension cost during the year were as follows: December 31, 2017 January 1, 2017 January 3, 2016 Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Discount rate 2.06 % 4.06 % 2.88 % 4.25 % 2.75 % 4.08 % Rate of compensation increase 3.64 % None 3.26 % None 3.28 % None Expected rate of return on assets 6.00 % 7.25 % 5.30 % 7.25 % 4.60 % 7.25 %
Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]		The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets: December 31, January 1, (In thousands) Pension Plans with Projected Benefit Obligations in Excess of Plan Assets Projected benefit obligations $ 190,265 $ 139,185 Fair value of plan assets — — Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets Accumulated benefit obligations $ 187,329 $ 136,197 Fair value of plan assets — —
Schedule of Allocation of Plan Assets		Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 31, 2017 and January 1, 2017 , and target asset allocations for fiscal year 2018 are as follows: Target Allocation Percentage of Plan Assets at December 30, 2018 December 31, 2017 January 1, 2017 Asset Category Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Equity securities 45-55% 40-50% 51 % 41 % 48 % 41 % Debt securities 45-55% 50-60% 49 % 59 % 51 % 59 % Other 0-5% 0-5% — % — % 1 % — % Total 100 % 100 % 100 % 100 % 100 % 100 %
Schedule of Changes in Fair Value of Plan Assets	The fair values of the Company’s pension plan assets as of December 31, 2017 and January 1, 2017 by asset category, classified in the three levels of inputs described in Note 21 to the consolidated financial statements are as follows: Fair Value Measurements at December 31, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 4,307 $ 4,307 $ — $ — Equity Securities: U.S. large-cap 30,008 30,008 — — International large-cap value 32,613 32,613 — — U.S. small mid-cap 2,104 2,104 — — Emerging markets growth 14,348 14,348 — — Equity index funds 90,838 — 90,838 — Domestic real estate funds 1,401 1,401 — — Commodity funds 7,387 7,387 — — Fixed income securities: Non-U.S. Treasury Securities 24,946 — 24,946 — Corporate and U.S. debt instruments 138,948 40,290 98,658 — Corporate bonds 27,571 — 27,571 — High yield bond funds 5,912 5,912 — — Other types of investments: Multi-strategy hedge funds 16,789 — — 16,789 Non-U.S. government index linked bonds 35,991 — 35,991 — Total assets measured at fair value $ 433,163 $ 138,370 $ 278,004 $ 16,789 Fair Value Measurements at January 1, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 6,079 $ 6,079 $ — $ — Equity Securities: U.S. large-cap 25,523 25,523 — — International large-cap value 28,267 28,267 — — U.S. small-cap 1,756 1,756 — — Emerging markets growth 12,144 12,144 — — Equity index funds 74,274 — 74,274 — Domestic real estate funds 1,401 1,401 — — Commodity funds 6,854 6,854 — — Fixed income securities: Non-U.S. Treasury Securities 22,059 — 22,059 — Corporate and U.S. debt instruments 133,406 35,971 97,435 — Corporate bonds 23,906 — 23,906 — High yield bond funds 5,636 5,636 — — Other types of investments: Multi-strategy hedge funds 23,790 — — 23,790 Non-U.S. government index linked bonds 32,003 — 32,003 — Total assets measured at fair value $ 397,098 $ 123,631 $ 249,677 $ 23,790
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets		A reconciliation of the beginning and ending Level 3 assets for fiscal years 2017, 2016 and 2015 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Venture Capital Funds Multi-strategy Hedge Funds Total (In thousands) Balance at December 28, 2014 $ 1 $ 23,332 $ 23,333 Unrealized gains — 83 83 Balance at January 3, 2016 1 23,415 23,416 Realized losses (1 ) — (1 ) Unrealized gains — 375 375 Balance at January 1, 2017 — 23,790 23,790 Sales — (8,189 ) (8,189 ) Realized gains — 1,542 1,542 Unrealized losses — (354 ) (354 ) Balance at December 31, 2017 $ — $ 16,789 $ 16,789
Schedule of Expected Benefit Payments		The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Non-U.S. U.S. (In thousands) 2018 $ 11,786 $ 18,593 2019 12,166 18,860 2020 12,566 19,125 2021 13,151 19,392 2022 13,275 19,630 2023-2026 71,963 97,295
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Components of Net Periodic Benefit Cost (Credit)		Net periodic postretirement medical benefit (credit) cost included the following components for the fiscal years ended: December 31, January 1, January 3, (In thousands) Service cost $ 92 $ 101 $ 108 Interest cost 125 142 143 Expected return on plan assets (1,114 ) (1,035 ) (1,062 ) Actuarial (gain) loss (741 ) (539 ) 971 Net periodic postretirement medical benefit (credit) cost $ (1,638 ) $ (1,331 ) $ 160
Schedule of Net Funded Status		The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of December 31, 2017 and January 1, 2017 . December 31, January 1, (In thousands) Actuarial present value of benefit obligations: Retirees $ 804 $ 907 Active employees eligible to retire 379 423 Other active employees 1,948 2,031 Accumulated benefit obligations at beginning of year 3,131 3,361 Service cost 92 101 Interest cost 125 142 Benefits paid (122 ) (145 ) Actuarial loss (gain) 187 (329 ) Change in accumulated benefit obligations during the year 282 (231 ) Retirees 688 804 Active employees eligible to retire 408 379 Other active employees 2,317 1,948 Accumulated benefit obligations at end of year $ 3,413 $ 3,131 Change in plan assets: Fair value of plan assets at beginning of year $ 15,453 $ 14,353 Actual return on plan assets 1,921 1,100 Fair value of plan assets at end of year $ 17,374 $ 15,453 Net assets recognized in the consolidated balance sheets $ 13,961 $ 12,322 Net amounts recognized in the consolidated balance sheets consist of: Noncurrent assets $ 13,961 $ 12,322 Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — Actuarial assumptions as of the year-end measurement date: Discount rate 3.60 % 4.11 % Actuarial assumptions used to determine net cost during the year are as follows: December 31, January 1, January 3, Discount rate 4.11 % 4.34 % 4.10 % Expected rate of return on assets 7.25 % 7.25 % 7.25 %
Schedule of Changes in Fair Value of Plan Assets		The fair values of the Company’s plan assets at December 31, 2017 and January 1, 2017 by asset category, classified in the three levels of inputs described in Note 21, are as follows: Fair Value Measurements at December 31, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 268 $ 268 $ — $ — Equity Securities: U.S. large-cap 2,057 2,057 — — International large-cap value 2,236 2,236 — — U.S. small mid-cap 144 144 — — Emerging markets growth 984 984 — — Domestic real estate funds 96 96 — — Commodity funds 506 506 — — Fixed income securities: Corporate debt instruments 9,526 2,762 6,764 — High yield bond funds 406 406 — — Other types of investments: Multi-strategy hedge funds 1,151 — — 1,151 Total assets measured at fair value $ 17,374 $ 9,459 $ 6,764 $ 1,151 Fair Value Measurements at January 1, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 319 $ 319 $ — $ — Equity Securities: U.S. large-cap 1,618 1,618 — — International large-cap value 1,792 1,792 — — U.S. small mid-cap 111 111 — — Emerging markets growth 770 770 — — Domestic real estate funds 89 89 — — Commodity funds 434 434 — — Fixed income securities: Corporate debt instruments 8,456 2,280 6,176 — High yield bond funds 356 356 — — Other types of investments: Multi-strategy hedge funds 1,508 — — 1,508 Total assets measured at fair value $ 15,453 $ 7,769 $ 6,176 $ 1,508
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets		A reconciliation of the beginning and ending Level 3 assets for fiscal years 2017, 2016 and 2015 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Multi-strategy Hedge Funds (In thousands) Balance at December 28, 2014 $ 1,341 Unrealized gains 33 Balance at January 3, 2016 1,374 Unrealized gains 134 Balance at January 1, 2017 1,508 Sales (562 ) Realized gains 229 Unrealized losses (24 ) Balance at December 31, 2017 $ 1,151
Schedule of Expected Benefit Payments		The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Postretirement Medical Plan (In thousands) 2018 $ 147 2019 166 2020 178 2021 195 2022 211 2023-2026 1,153

Warranty Reserves (Tables)

Warranty Reserves (Tables)	12 Months Ended
	Dec. 31, 2017
Product Warranties Disclosures [Abstract]
Warranty Reserve Activity	A summary of warranty reserve activity for the fiscal years ended December 31, 2017 , January 1, 2017 and January 3, 2016 is as follows: (In thousands) Balance at December 28, 2014 $ 9,593 Provision charged to income 15,792 Payments (14,936 ) Adjustments to previously provided warranties, net (146 ) Foreign currency translation and acquisitions (460 ) Balance at January 3, 2016 9,843 Provision charged to income 14,901 Payments (14,749 ) Adjustments to previously provided warranties, net (850 ) Foreign currency translation and acquisitions (133 ) Balance at January 1, 2017 9,012 Provision charged to income 13,700 Payments (14,245 ) Adjustments to previously provided warranties, net (815 ) Foreign currency translation and acquisitions 1,398 Balance at December 31, 2017 $ 9,050

Stock Plans (Tables)

Stock Plans (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Total Compensation Recognized Related to Outstanding Equity Awards	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s consolidated statements of operations for fiscal years 2017, 2016 and 2015 : December 31, January 1, January 3, (In thousands) Cost of product and service revenue $ 1,254 $ 1,031 $ 1,272 Research and development expenses 1,389 902 526 Selling, general and administrative expenses 22,778 15,225 15,480 Total stock-based compensation expense $ 25,421 $ 17,158 $ 17,278
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model	The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended: December 31, January 1, January 3, Risk-free interest rate 2.0 % 1.7 % 1.3 % Expected dividend yield 0.4 % 0.6 % 0.6 % Expected lives 5 years 5 years 5 years Expected stock volatility 22.4 % 25.2 % 26.5 %
Summary of Stock Option Activity	The following table summarizes stock option activity for the fiscal year ended December 31, 2017 : December 31, 2017 Number of Shares Weighted- Average Exercise Price (Shares in thousands) Outstanding at beginning of year 2,287 $ 37.64 Granted 464 53.94 Exercised (578 ) 31.16 Forfeited (19 ) 50.86 Outstanding at end of year 2,154 $ 42.77 Exercisable at end of year 1,229 $ 37.79
Summary of Restricted Stock Award Activity	The following table summarizes restricted stock award activity for the fiscal year ended December 31, 2017 : December 31, 2017 Number of Shares Weighted- Average Grant- Date Fair Value (Shares in thousands) Nonvested at beginning of year 521 $ 46.48 Granted 231 54.75 Vested (229 ) 46.11 Forfeited (27 ) 50.12 Nonvested at end of year 496 $ 50.30

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive (loss) income consisted of the following: Foreign Currency Translation Adjustment, net of tax Unrecognized Prior Service Costs, net of tax Unrealized (Losses) Gains on Securities, net of tax Accumulated Other Comprehensive Income (Loss) (In thousands) Balance, December 28, 2014 $ 23,332 $ 1,575 $ (107 ) $ 24,800 Current year change (70,178 ) (316 ) (262 ) (70,756 ) Balance, January 3, 2016 (46,846 ) 1,259 (369 ) (45,956 ) Current year change (54,077 ) (860 ) 32 (54,905 ) Balance, January 1, 2017 (100,923 ) 399 (337 ) (100,861 ) Current year change 54,341 (77 ) 79 54,343 Balance, December 31, 2017 $ (46,582 ) $ 322 $ (258 ) $ (46,518 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2017 and January 1, 2017 classified in one of the three classifications described above: Fair Value Measurements at December 31, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,208 $ 2,208 $ — $ — Foreign exchange derivative assets 1,431 — 1,431 — Foreign exchange derivative liabilities (23,638 ) — (23,638 ) — Contingent consideration (65,328 ) — — (65,328 ) Fair Value Measurements at January 1, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 1,678 $ 1,678 $ — $ — Foreign exchange derivative assets 1,208 — 1,208 — Foreign exchange derivative liabilities, net (1,370 ) — (1,370 ) — Contingent consideration (63,201 ) — — (63,201 )
Reconciliation of Beginning and Ending Level 3 Net Liabilities	A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: (In thousands) Balance at December 28, 2014 $ (91 ) Additions (57,353 ) Amounts paid and foreign currency translation 113 Change in fair value (included within selling, general and administrative expenses) (19 ) Balance at January 3, 2016 (57,350 ) Additions — Amounts paid and foreign currency translation 332 Reclassified to other current liabilities for milestone achieved 10,000 Change in fair value (included within selling, general and administrative expenses) (16,183 ) Balance at January 1, 2017 (63,201 ) Additions — Amounts paid and foreign currency translation 34 Change in fair value (included within selling, general and administrative expenses) (2,161 ) Balance at December 31, 2017 $ (65,328 )

Industry Segment and Geograph50

Industry Segment and Geographic Area Information (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations	Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended: December 31, January 1, January 3, (In thousands) Discovery & Analytical Solutions Product revenue $ 941,328 $ 934,098 $ 968,034 Service revenue 637,131 578,886 560,385 Total revenue 1,578,459 1,512,984 1,528,419 Operating income from continuing operations (1) 206,688 196,819 162,762 Diagnostics Product revenue 536,086 462,798 427,068 Service revenue 142,437 139,735 149,336 Total revenue 678,523 602,533 576,404 Operating income from continuing operations 149,636 149,577 146,478 Corporate Operating loss from continuing operations (2) (51,521 ) (63,330 ) (58,314 ) Continuing Operations Product revenue 1,477,414 1,396,896 1,395,102 Service revenue 779,568 718,621 709,721 Total revenue 2,256,982 2,115,517 2,104,823 Operating income from continuing operations 304,803 283,066 250,926 Interest and other expense, net (see Note 5) 8,085 38,998 42,119 Income from continuing operations before income taxes $ 296,718 $ 244,068 $ 208,807 ____________________________ (1) Legal costs for a particular case in the Discovery & Analytical Solutions segment were $2.7 million for fiscal year 2017 . (2) Activity related to the mark-to-market adjustment on postretirement benefit plans has been included in the Corporate operating loss from continuing operations, and in the aggregate constituted a pre-tax gain of $2.1 million in fiscal year 2017 , a pre-tax loss of $15.3 million in fiscal year 2016 , and pre-tax loss of $12.4 million in fiscal year 2015 .
Schedule of Depreciation, Amortization and Capital Expenditures	Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended December 31, 2017 : Depreciation and Amortization Expense Capital Expenditures December 31, January 1, January 3, December 31, January 1, January 3, (In thousands) (In thousands) Discovery & Analytical Solutions $ 72,590 $ 72,484 $ 74,177 $ 26,200 $ 21,486 $ 18,175 Diagnostics 31,204 25,339 29,728 11,262 8,556 6,854 Corporate 1,206 2,149 1,459 1,627 1,660 3,189 Continuing operations $ 105,000 $ 99,972 $ 105,364 $ 39,089 $ 31,702 $ 28,218 Discontinued operations $ 929 $ 6,266 $ 6,643 $ 182 $ 1,302 $ 1,414
Schedule of Total Assets by Segment	Total Assets December 31, January 1, January 3, (In thousands) Discovery & Analytical Solutions $ 2,744,370 $ 2,612,757 $ 2,546,583 Diagnostics 3,314,804 1,505,381 1,459,854 Corporate 32,289 31,171 28,497 Current and long-term assets of discontinued operations — 127,374 131,361 Total assets $ 6,091,463 $ 4,276,683 $ 4,166,295
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended December 31, 2017 and net long-lived assets based on physical location as of December 31, 2017 and January 1, 2017 : Revenue December 31, January 1, January 3, (In thousands) U.S. $ 837,018 $ 842,364 $ 854,336 International: China 374,931 336,728 296,908 United Kingdom 65,164 65,904 69,081 Germany 91,669 89,839 86,632 India 84,812 43,891 40,239 Italy 77,477 70,948 71,225 France 80,153 71,104 70,665 Japan 76,322 65,980 69,381 Other international 569,436 528,759 546,356 Total international 1,419,964 1,273,153 1,250,487 Total sales $ 2,256,982 $ 2,115,517 $ 2,104,823 Net Long-Lived Assets December 31, January 1, January 3, (In thousands) U.S. $ 210,116 $ 182,186 $ 165,827 International: Germany 88,249 1,292 1,187 China 64,815 36,458 34,494 United Kingdom 28,028 14,638 14,244 India 14,820 2,020 1,508 Finland 14,764 12,295 12,203 Italy 10,334 3,398 2,958 Singapore 9,240 6,820 7,679 Brazil 7,963 1,452 1,225 Netherlands 4,281 4,162 3,835 Sweden 3,869 2,645 1,247 Other international 19,565 7,684 6,619 Total international 265,928 92,864 87,199 Total net long-lived assets $ 476,044 $ 275,050 $ 253,026

Quarterly Financial Informati51

Quarterly Financial Information (Unaudited) Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	Selected quarterly financial information is as follows for the fiscal years ended: First Quarter Second Quarter Third Quarter Fourth Quarter (1) Year (In thousands, except per share data) December 31, 2017 Revenue $ 514,115 $ 546,962 $ 554,275 $ 641,630 $ 2,256,982 Gross profit 239,611 257,503 268,822 307,095 1,073,031 Restructuring and contract termination charges, net 9,651 — 3,269 (263 ) 12,657 Operating income from continuing operations 51,579 75,997 79,807 97,420 304,803 Income from continuing operations before income taxes 39,983 70,792 105,054 80,889 296,718 Income (loss) from continuing operations 36,062 62,726 96,546 (38,444 ) 156,890 Income (loss) from discontinued operations and dispositions 2,541 141,343 (5,468 ) (2,673 ) 135,743 Net income (loss) 38,603 204,069 91,078 (41,117 ) 292,633 Basic earnings per share: Income (loss) from continuing operations $ 0.33 $ 0.57 $ 0.88 $ (0.35 ) $ 1.43 Income (loss) from discontinued operations and dispositions 0.02 1.29 (0.05 ) (0.02 ) 1.24 Net income (loss) 0.35 1.86 0.83 (0.37 ) 2.67 Diluted earnings per share: Income (loss) from continuing operations $ 0.33 $ 0.57 $ 0.87 $ (0.35 ) $ 1.42 Income (loss) from discontinued operations and dispositions 0.02 1.28 (0.05 ) (0.02 ) 1.22 Net income (loss) 0.35 1.84 0.82 (0.37 ) 2.64 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 January 1, 2017 Revenue $ 498,016 $ 536,242 $ 514,489 $ 566,770 $ 2,115,517 Gross profit 235,086 253,554 248,550 276,163 1,013,353 Restructuring and contract termination charges, net — 4,468 656 — 5,124 Operating income from continuing operations 60,577 66,266 75,781 80,442 283,066 Income from continuing operations before income taxes 49,491 60,873 64,518 69,186 244,068 Income from continuing operations 41,744 57,756 53,917 62,289 215,706 Income from discontinued operations and dispositions 5,722 6,101 4,210 2,560 18,593 Net income 47,466 63,857 58,127 64,849 234,299 Basic earnings per share: Income from continuing operations $ 0.38 $ 0.53 $ 0.49 $ 0.57 $ 1.97 Income from discontinued operations and dispositions 0.05 0.06 0.04 0.02 0.17 Net income 0.43 0.59 0.53 0.59 2.14 Diluted earnings per share: Income continuing operations $ 0.38 $ 0.53 $ 0.49 $ 0.57 $ 1.96 Income from discontinued operations and dispositions 0.05 0.06 0.04 0.02 0.17 Net income 0.43 0.58 0.53 0.59 2.12 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 ____________________________ (1) The fourth quarter of fiscal year 2017 includes a pre-tax gain of $2.1 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2016 includes a pre-tax loss of $15.3 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.

Nature of Operations and Acco52

Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Narrative) (Details) (Details) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017plansegments	Jan. 01, 2017	Jan. 03, 2016	Jan. 01, 2018USD ($)
Number of Stock-based Compensation Plans | plan		1
Number of Operating Segments | segments		2
Operating Cycle		52		53
License and services revenue as a percentage of total revenue		4.50%	5.07%
Minimum [Member] | Building [Member]
Property, Plant and Equipment, Useful Life, Maximum		10 years
Minimum [Member] | Tools, Dies and Molds [Member]
Property, Plant and Equipment, Useful Life, Maximum		3 years
Maximum [Member] | Building [Member]
Property, Plant and Equipment, Useful Life, Maximum		40 years
Maximum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment, Useful Life, Maximum		7 years
Scenario, Forecast [Member]
Operating Cycle	52
Subsequent Event [Member] | Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption					$ 9.3
Tax impact of Cumulative Adjustments, Deferred Income Tax					3.2
Impact of New Accounting Principle, Deferred Revenue					(12.5)
Impact of New Accounting Principle, Cash Flows					$ 0

Business Combinations and Ass53

Business Combinations and Asset Purchases (Narrative) (Details)	3 Months Ended							6 Months Ended	12 Months Ended
	Dec. 31, 2017USD ($)employees	Oct. 01, 2017USD ($)	Jul. 02, 2017USD ($)	Apr. 02, 2017USD ($)	Jan. 01, 2017USD ($)	Oct. 02, 2016USD ($)	Apr. 03, 2016USD ($)	Jul. 03, 2016USD ($)	Dec. 31, 2017USD ($)employees$ / shares	Jan. 01, 2017USD ($)$ / shares	Jan. 03, 2016USD ($)
Business Acquisition [Line Items]
Revenue	$ 641,630,000	$ 554,275,000	$ 546,962,000	$ 514,115,000	$ 566,770,000	$ 514,489,000	$ 498,016,000	$ 536,242,000	$ 2,256,982,000	$ 2,115,517,000
Business Combination, Contingent Consideration, Liability, Current	(52,200,000)				(15,400,000)				(52,200,000)	(15,400,000)
Business Combination, Contingent Consideration, Liability, Noncurrent	13,100,000				47,800,000				13,100,000	47,800,000
Business Combination, Contingent Consideration, Liability, Total	65,328,000				63,200,000				$ 65,328,000	63,200,000
Business Combination, Contingent Consideration Arrangements, Maximum Period									1 year 9 months
Business Combination, Contingent Consideration Arrangements, Description									Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). The expected maximum earnout period for an acquisition with open contingency period do not exceed 1.75 years from the acquisition date, and the remaining weighted average expected earnout period at December 31, 2017 was 11 months.
Goodwill	3,002,198,000				2,247,966,000				$ 3,002,198,000	2,247,966,000	$ 2,236,863,000
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions									1 year
Business Combination, Contingent Consideration Arrangements, Weighted Average Period									11 years
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	83,000,000								$ 83,000,000
Business Acquisition and Divestiture, Transaction Costs									10,800,000	1,200,000	700,000
Tulip Diagnostics Private Limited [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	$ 1,713,000								$ 1,713,000
Weighted average amortization period (in years)									11 years 9 months
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									$ 127,280,000
EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	99.98%								99.98%
Business Acquisition, Pro Forma Revenue									$ 2,562,580,000	2,379,176,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	$ 121,174,000								121,174,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(87,631,000)								(87,631,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	129,964,000								129,964,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	49,944,000								49,944,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	1,388,762,000								1,388,762,000
Intangible Assets, Gross (Excluding Goodwill)	897,400,000								897,400,000
Business Acquisition, Cost of Acquired Entity, Cash Paid									1,413,780,000
Business Combination, Consideration Transferred, Liabilities Incurred									$ 0
Weighted average amortization period (in years)									16 years 1 month
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual									$ 13,500,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual									(1,000,000)
Business Acquisition, Transaction Costs	$ 9,800,000								$ 9,800,000
Entity Number of Employees | employees	2,400								2,400
Goodwill	$ 614,759,000								$ 614,759,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(275,491,000)								(275,491,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(61,357,000)								(61,357,000)
Cash Acquired									(25,018,000)
Business Combination, Consideration Transferred									1,388,762,000
Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax									$ 143,459,000	$ 156,210,000
Business Acquisition, Pro Forma Earnings Per Share, Basic | $ / shares									$ 1.31	$ 1.43
Business Acquisition, Pro Forma Earnings Per Share, Diluted | $ / shares									$ 1.29	$ 1.42
Fiscal Year 2017 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									$ 142,134,000
Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Aggregate Revenue from Immaterial Acquisitions									38,500,000
Operating Income (Loss) From Immaterial Acquisitions									0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	16,268,000								16,268,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(8,759,000)								(8,759,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	11,356,000								11,356,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	1,691,000								1,691,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	139,695,000								139,695,000
Business Acquisition, Cost of Acquired Entity, Cash Paid									140,861,000
Business Combination, Consideration Transferred, Liabilities Incurred									1,273,000
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									14,844,000
Goodwill	75,453,000								75,453,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(15,414,000)								(15,414,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	0								0
Cash Acquired									(2,439,000)
Business Combination, Consideration Transferred									139,695,000
2016 Acquisitions (excluding Bioo) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments										$ 8,800,000
Fiscal Year 2016 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets					7,153,000					7,153,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities					(1,985,000)					(1,985,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					7,542,000					7,542,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					70,084,000					70,084,000
Intangible Assets, Gross (Excluding Goodwill)					22,100,000					22,100,000
Business Acquisition, Cost of Acquired Entity, Cash Paid										$ 72,497,000
Weighted average amortization period (in years)										9 years 5 months
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments										$ 72,300,000
Goodwill					43,072,000					43,072,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total					(7,768,000)					(7,768,000)
Working capital and other adjustments										(261,000)
Cash Acquired										(2,152,000)
Business Combination, Consideration Transferred										70,084,000
Bioo Scientific Corporation [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	140,000								140,000
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments										63,500,000
Goodwill	(2,576,000)								(2,576,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(516,000)								(516,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	2,200,000								2,200,000
Fiscal Year 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets											2,551,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities											(2,850,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment											998,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net											130,131,000
Business Acquisition, Cost of Acquired Entity, Cash Paid											75,285,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount											9,200,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value											(56,878,000)
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments											77,117,000
Goodwill											53,112,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total											(18,528,000)
Working capital and other adjustments											1,832,000
Cash Acquired											(3,864,000)
Business Combination, Consideration Transferred											130,131,000
Vanadis Diagnostics AB [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value									(65,300,000)		56,878,000
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments											35,141,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High											93,000,000
2015 Acquisitions (excluding Vanadis) [Domain]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments											41,976,000
Core Technology [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	160,000,000								160,000,000
Core Technology [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	12,400,000								12,400,000
Core Technology [Member] | Fiscal Year 2016 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					6,600,000					$ 6,600,000
Core Technology [Member] | Fiscal Year 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											15,759,000
Weighted average amortization period (in years)										9 years
Trade Names [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	36,000,000								36,000,000
Trade Names [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	3,000,000								3,000,000
Trade Names [Member] | Fiscal Year 2016 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					570,000					$ 570,000
Trade Names [Member] | Fiscal Year 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											200,000
Licenses [Member] | Fiscal Year 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											116,000
Customer Relationships [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	700,000,000								700,000,000
Customer Relationships [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	43,700,000								43,700,000
Customer Relationships [Member] | Fiscal Year 2016 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					14,900,000					14,900,000
Customer Relationships [Member] | Fiscal Year 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											3,073,000
In Process Research and Development [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	1,400,000								1,400,000
In Process Research and Development [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	0								0
In Process Research and Development [Member] | Fiscal Year 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											75,700,000
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,657,963,000				944,030,000				1,657,963,000	944,030,000	940,139,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	1,344,235,000				$ 1,303,936,000				1,344,235,000	$ 1,303,936,000	$ 1,296,724,000
Euro Member Countries, Euro | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									1,200,000,000
United States of America, Dollars | Tulip Diagnostics Private Limited [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	25,200,000								25,200,000
United States of America, Dollars | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									1,413,780,000
United States of America, Dollars | EUROIMMUM [Member] | Term Loan Credit Facility, 12 Months Maturity [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									200,000,000
United States of America, Dollars | EUROIMMUM [Member] | Line of Credit, Maturing August 11, 2021 [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									710,000,000
United States of America, Dollars | EUROIMMUM [Member] | Cash and Cash Equivalents [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									503,780,000
India, Rupees | Tulip Diagnostics Private Limited [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 1,600,000,000								$ 1,600,000,000

Business Combinations and Ass54

Business Combinations and Asset Purchases (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Jan. 03, 2016	Jan. 01, 2017
Business Acquisition [Line Items]
Goodwill	$ 3,002,198,000	$ 2,236,863,000	$ 2,247,966,000
Fiscal Year 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		75,285,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value		56,878,000
Working capital and other adjustments		1,832,000
Less: cash acquired		3,864,000
Business Combination, Consideration Transferred		130,131,000
Current assets		2,551,000
Property, plant and equipment		998,000
Goodwill		53,112,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total		(18,528,000)
Liabilities assumed		(2,850,000)
Total		130,131,000
EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	1,413,780,000
Less: cash acquired	25,018,000
Business Combination, Consideration Transferred	1,388,762,000
Current assets	121,174,000
Property, plant and equipment	129,964,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	49,944,000
Goodwill	614,759,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(275,491,000)
Liabilities assumed	(87,631,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(61,357,000)
Total	1,388,762,000
Core Technology [Member] | Fiscal Year 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		15,759,000
Core Technology [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	160,000,000
Trade Names [Member] | Fiscal Year 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		200,000
Trade Names [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	36,000,000
Customer Relationships [Member] | Fiscal Year 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		3,073,000
Customer Relationships [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	700,000,000
Licenses [Member] | Fiscal Year 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		116,000
In Process Research and Development [Member] | Fiscal Year 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		75,700,000
In Process Research and Development [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	1,400,000
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,657,963,000	940,139,000	944,030,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	$ 1,344,235,000	$ 1,296,724,000	$ 1,303,936,000

Discontinued Operations Narrati

Discontinued Operations Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net	$ 0	$ 28,400
Gain (loss) on disposition of discontinued operations before income taxes	179,615	619	$ (28)
(Benefit from) provision for income taxes on discontinued operations and dispositions	44,522	4,255	11,537
Disposal Group, Including Discontinued Operation, Inventory, Current	0	26,977
Disposal Group, Including Discontinued Operation, Other Assets, Current	0	3,183
Disposal Group, Including Discontinued Operation, Prepaid income taxes, Current [Abstract]	0	425
Disposal Group, Including Discontinued Operation, Assets, Current	0	58,985
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent	0	25,219
Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent	0	3,292
Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent	0	38,794
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent	0	1,084
Disposal Group, Including Discontinued Operation, Assets, Noncurrent	0	68,389
Disposal Group, Including Discontinued Operation, Assets	0	127,374
Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current [Abstract]	0	16,770
Disposal Group, Including Discontinued Operation, Accrued restructuring and contract termination charges, Current	0	209
Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current	2,102	9,992
Disposal Group, Including Discontinued Operation, Liabilities, Current	2,102	26,971
Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities, Noncurrent	0	7,851
Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent	0	7,109
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent	0	14,960
Disposal Group, Including Discontinued Operation, Liabilities	2,102	41,931
Technical Services Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on disposition of discontinued operations before income taxes	0	1,753	(28)
Fluid Sciences Segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on disposition of discontinued operations before income taxes	0	(1,134)	0
Other Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Disposition of Assets		(1,600)
PerkinElmer Labs, Inc. [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration		20,000
Gain (Loss) on Disposition of Business	$ 1,100	$ 7,100
Capital loss on disposition of a business		7,300
Tax effect of disposition of a business		2,500
Medical Imaging Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Period of Continuing Involvement after Disposal	12 months
Gain (loss) on disposition of discontinued operations before income taxes	$ 179,615	$ 0	$ 0
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	43,131
Disposal Group, Including Discontinued Operation, Consideration	277,400
Disposal Group, Including Discontinued Operation, Working Capital Adjustment	4,200
Suzhou PerkinElmer Medical Laboratory Co. Ltd [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on disposition of discontinued operations before income taxes	(1,108)
Disposal Group, Including Discontinued Operation, Consideration	$ 2,300

Summary Operating Results of Di

Summary Operating Results of Discontinued Operations for the Periods Prior to Disposition (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue	$ 44,343	$ 146,217	$ 158,128
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	32,933	95,395	97,777
Disposal Group, Including Discontinued Operation, General and Administrative Expense	5,869	13,657	11,712
Disposal Group, Including Discontinued Operations, Research and development expenses	4,891	14,368	13,391
Disposal Group, Including Discontinued Operations, Restructuring and contract termination charges, net	0	568	43
Loss from discontinued operations before income taxes	$ 650	$ 22,229	$ 35,205

Restructuring and Contract Te57

Restructuring and Contract Termination Charges, Net (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended	12 Months Ended
	Dec. 31, 2017	Oct. 01, 2017	Jul. 02, 2017	Apr. 02, 2017	Jan. 01, 2017	Oct. 02, 2016	Apr. 03, 2016	Jul. 03, 2016	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016	Dec. 28, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	$ (263)	$ 3,269	$ 0	$ 9,651	$ 0	$ 656	$ 0	$ 4,468	$ 12,657	$ 5,124	$ 13,547
Accrued restructuring and contract termination costs	13,969				10,541				13,969	10,541	22,150	$ 23,826
Accrued restructuring and contract termination costs	8,759				7,479				8,759	7,479
Restructuring Reserve, Noncurrent	2,300				3,100				2,300	3,100
Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Accrued restructuring and contract termination costs	$ 3,048				$ 117				3,048	117	132	$ 304
Discovery & Analytical Solutions [Member] | Contract Termination [Member] | 2017 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net									$ 3,612
Discovery & Analytical Solutions [Member] | Contract Termination [Member] | 2016 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net										$ 88
Discovery & Analytical Solutions [Member] | Contract Termination [Member] | 2015 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net											$ 83

Restructuring and Contract Te58

Restructuring and Contract Termination Charges, Net Restructuring and Contract Termination Charges, Net (Schedule of Initial Charges) (Details) $ in Thousands

3 Months Ended

6 Months Ended

12 Months Ended

Dec. 31, 2017USD ($)employees

Oct. 01, 2017USD ($)employees

Jul. 02, 2017USD ($)

Apr. 02, 2017USD ($)employees

Jan. 01, 2017USD ($)

Oct. 02, 2016USD ($)employees

Jul. 03, 2016USD ($)employees

Apr. 03, 2016USD ($)

Jan. 03, 2016USD ($)employees

Jun. 28, 2015USD ($)employees

Jul. 03, 2016USD ($)

Dec. 31, 2017USD ($)

Jan. 01, 2017USD ($)

Jan. 03, 2016USD ($)

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

$ (263)

$ 3,269

$ 0

$ 9,651

$ 0

$ 656

$ 0

$ 4,468

$ 12,657

$ 5,124

$ 13,547

Q4 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

29

Restructuring and contract termination charges, net

$ 1,935

Q3 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

27

Restructuring and contract termination charges, net

$ 2,342

Q1 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

90

Restructuring and contract termination charges, net

$ 6,697

Q3 2016 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

22

Restructuring and contract termination charges, net

$ 1,820

Q2 2016 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

72

Restructuring and contract termination charges, net

$ 4,667

Q4 2015 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

174

Restructuring and contract termination charges, net

$ 11,580

Q2 2015 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

95

Restructuring and contract termination charges, net

$ 5,963

Diagnostics [Member] | Severance [Member] | Q4 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

255

Diagnostics [Member] | Severance [Member] | Q3 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

1,021

Diagnostics [Member] | Severance [Member] | Q1 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

1,631

Diagnostics [Member] | Severance [Member] | Q3 2016 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

41

Diagnostics [Member] | Severance [Member] | Q2 2016 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

561

Diagnostics [Member] | Severance [Member] | Q4 2015 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

1,315

Diagnostics [Member] | Severance [Member] | Q2 2015 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

673

Diagnostics [Member] | Facility Closing [Member] | Q4 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Diagnostics [Member] | Facility Closing [Member] | Q3 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Diagnostics [Member] | Facility Closing [Member] | Q1 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

33

Diagnostics [Member] | Facility Closing [Member] | Q3 2016 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Diagnostics [Member] | Facility Closing [Member] | Q2 2016 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Diagnostics [Member] | Facility Closing [Member] | Q4 2015 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Diagnostics [Member] | Facility Closing [Member] | Q2 2015 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Discovery & Analytical Solutions [Member] | Severance [Member] | Q4 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

1,680

Discovery & Analytical Solutions [Member] | Severance [Member] | Q3 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

1,321

Discovery & Analytical Solutions [Member] | Severance [Member] | Q1 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

5,000

Discovery & Analytical Solutions [Member] | Severance [Member] | Q3 2016 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

1,779

Discovery & Analytical Solutions [Member] | Severance [Member] | Q2 2016 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

4,106

Discovery & Analytical Solutions [Member] | Severance [Member] | Q4 2015 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

9,980

Discovery & Analytical Solutions [Member] | Severance [Member] | Q2 2015 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

5,290

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q4 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

$ 33

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2016 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q2 2016 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q4 2015 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

$ 285

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q2 2015 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

$ 0

Restructuring and Contract Te59

Restructuring and Contract Termination Charges, Net (Schedule of Restructuring Plan Activity) (Details) - USD ($) $ in Thousands	3 Months Ended										6 Months Ended	12 Months Ended
	Dec. 31, 2017	Oct. 01, 2017	Jul. 02, 2017	Apr. 02, 2017	Jan. 01, 2017	Oct. 02, 2016	Jul. 03, 2016	Apr. 03, 2016	Jan. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Dec. 31, 2017		Jan. 01, 2017	Jan. 03, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Current Other	$ 2,900											$ 2,900
Restructuring Reserve [Roll Forward]
Beginning balance				$ 10,541				$ 22,150			$ 22,150	10,541		$ 22,150	$ 23,826
Restructuring Charges and Changes in Estimates												12,657		5,124	13,547
Amounts paid and foreign currency translation												(9,229)		(16,733)	(15,223)
Ending balance	13,969				$ 10,541				$ 22,150			13,969		10,541	22,150
Restructuring and contract termination charges, net	(263)	$ 3,269	$ 0	9,651	0	$ 656		0			4,468	12,657		5,124	13,547
Employee Severance and Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				10,424				22,018			22,018	10,424		22,018	23,522
Restructuring Charges and Changes in Estimates												9,406		5,036	13,464
Amounts paid and foreign currency translation												(8,909)		(16,630)	(14,968)
Ending balance	10,921				10,424				22,018			10,921		10,424	22,018
Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				117				132			132	117		132	304
Restructuring Charges and Changes in Estimates												3,251		88	83
Amounts paid and foreign currency translation												(320)		(103)	(255)
Ending balance	3,048				117				132			3,048		117	132
Q4 2017 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	1,935
Q4 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				0			0	0		0	0
Restructuring Charges and Changes in Estimates												1,935		0	0
Amounts paid and foreign currency translation												(16)		0	0
Ending balance	1,919				0				0			1,919		0	0
Q3 2017 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		2,342
Q3 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				0			0	0		0	0
Restructuring Charges and Changes in Estimates												2,342		0	0
Amounts paid and foreign currency translation												(270)		0	0
Ending balance	2,072				0				0			2,072		0	0
Q1 2017 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				6,697
Q1 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				0			0	0		0	0
Restructuring Charges and Changes in Estimates												6,631		0	0
Amounts paid and foreign currency translation												(4,133)		0	0
Ending balance	2,498				0				0			2,498		0	0
Q1 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				0			0	0		0	0
Restructuring Charges and Changes in Estimates												66		0	0
Amounts paid and foreign currency translation												(33)		0	0
Ending balance	33				0				0			33		0	0
Q3 2016 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net						1,820
Q3 2016 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				1,208				0			0	1,208		0	0
Restructuring Charges and Changes in Estimates												(202)			0
Amounts paid and foreign currency translation												(1,006)			0
Ending balance	0				1,208				0			0		1,208	0
Q2 2016 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net							$ 4,667
Q2 2016 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				1,436				0			0	1,436		0	0
Restructuring Charges and Changes in Estimates												(829)		4,667	0
Amounts paid and foreign currency translation												(607)		(3,231)	0
Ending balance	0				1,436				0			0		1,436	0
Q4 2015 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net									11,580
Q4 2015 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				1,219				10,370			10,370	1,219		10,370	0
Restructuring Charges and Changes in Estimates												(1,066)		(953)	11,295
Amounts paid and foreign currency translation												(153)		(8,198)	(925)
Ending balance	0				1,219				10,370			0		1,219	10,370
Q4 2015 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				11				259			259	11		259	0
Restructuring Charges and Changes in Estimates												0		0	285
Amounts paid and foreign currency translation												0		(248)	(26)
Ending balance	11				11				259			11		11	259
Q2 2015 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net										$ 5,963
Q2 2015 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				198				1,101			1,101	198		1,101	0
Restructuring Charges and Changes in Estimates												(198)	[1]	(533)	5,423	[1]
Amounts paid and foreign currency translation												0		(370)	(4,322)
Ending balance	0				198				1,101			0		198	1,101
Previous restructuring and integration plans [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				6,352				$ 10,288			$ 10,288	6,352		10,288
Restructuring Charges and Changes in Estimates												727		35	(3,539)
Amounts paid and foreign currency translation												(2,691)		(3,971)	(9,695)
Ending balance	4,388				$ 6,352				10,288			4,388		$ 6,352	$ 10,288
Diagnostics [Member] | 2017 Contract Termination Charges [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net												517
Diagnostics [Member] | Q4 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	255
Diagnostics [Member] | Q4 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	0
Diagnostics [Member] | Q3 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		1,021
Diagnostics [Member] | Q3 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		0
Diagnostics [Member] | Q1 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				1,631
Diagnostics [Member] | Q1 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				33
Diagnostics [Member] | Q3 2016 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net						41
Diagnostics [Member] | Q3 2016 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net						0
Diagnostics [Member] | Q2 2016 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												(400)
Restructuring and contract termination charges, net							561
Diagnostics [Member] | Q2 2016 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net							0
Diagnostics [Member] | Q4 2015 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												(500)
Restructuring and contract termination charges, net									1,315
Diagnostics [Member] | Q4 2015 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net									0
Diagnostics [Member] | Q2 2015 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net										673
Diagnostics [Member] | Q2 2015 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net										0
Diagnostics [Member] | Previous restructuring and integration plans [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												400
Diagnostics [Member] | Previous restructuring and integration plans [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												0
Discovery & Analytical Solutions [Member] | 2017 Contract Termination Charges [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net												3,612
Discovery & Analytical Solutions [Member] | Q4 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	1,680
Discovery & Analytical Solutions [Member] | Q4 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	$ 0
Discovery & Analytical Solutions [Member] | Q3 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		1,321
Discovery & Analytical Solutions [Member] | Q3 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		$ 0
Discovery & Analytical Solutions [Member] | Q1 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				5,000
Discovery & Analytical Solutions [Member] | Q1 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				$ 33
Discovery & Analytical Solutions [Member] | Q3 2016 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net						1,779
Discovery & Analytical Solutions [Member] | Q3 2016 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net						$ 0
Discovery & Analytical Solutions [Member] | Q2 2016 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												(400)
Restructuring and contract termination charges, net							4,106
Discovery & Analytical Solutions [Member] | Q2 2016 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net							$ 0
Discovery & Analytical Solutions [Member] | Q4 2015 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												(500)
Restructuring and contract termination charges, net									9,980
Discovery & Analytical Solutions [Member] | Q4 2015 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net									$ 285
Discovery & Analytical Solutions [Member] | Q2 2015 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net										5,290
Discovery & Analytical Solutions [Member] | Q2 2015 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net										$ 0
Discovery & Analytical Solutions [Member] | Previous restructuring and integration plans [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												0
Discovery & Analytical Solutions [Member] | Previous restructuring and integration plans [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												300
Discovery & Analytical Solutions and Diagnostcs [Member] | Q4 2015 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												$ (500)
[1]	_

Interest and Other Expense (I60

Interest and Other Expense (Income), Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Foreign Currency Transaction Gain (Loss), before Tax	$ (29,200)	$ (1,500)	$ 25,300
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	(4,500)	5,400	(20,600)
Gain on disposition of businesses and assets, net	309	(5,562)	0
Interest income	(2,571)	(702)	(673)
Interest expense	43,940	41,528	37,997
Other expense, net	(33,593)	3,734	4,795
Total interest and other expense, net	$ 8,085	$ 38,998	$ 42,119

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Income Tax Contingency [Line Items]
Income Tax Holiday, Aggregate Dollar Amount	$ (10,100)	$ (11,400)	$ (8,300)
Impact of benefits derived from tax holidays on earnings per share, basic	$ 0.09	$ (0.10)	$ (0.07)
Impact of benefits derived from tax holidays on earnings per share, diluted	$ (0.09)	$ (0.10)	$ (0.07)
Valuation Allowance, Amount	$ 68,895	$ 65,640
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning of period	29,607	28,143	$ 32,342
Gross increases - tax positions in prior period	749	1,514	325
Gross decreases - tax positions in prior period	(828)	(183)	(2,305)
Gross increases - current-period tax positions	2,346	3,547	0
Settlements	(324)	0	(441)
Lapse of statute of limitations	(1,371)	(4,109)	(1,077)
Foreign currency translation adjustments	129	695	(701)
Unrecognized tax benefits, end of period	30,308	29,607	28,143
Interest on income taxes accrued	1,900
Interest on income taxes expense	(300)	(100)
Income tax penalties expense	(1,600)
Income tax penalties accrued	2,200
Uncertain tax benefits if recognized that could affect the continuing operations effective tax rate	28,600
Unrecognized Tax Benefits Expected To Be Resolved With In A Year	3,100
Foreign earnings invested outside U.S.	$ 1,420,600
Open Tax Years by Major Tax Jurisdiction, Begin Date	2,010
Tax Adjustments, Settlements, and Unusual Provisions	$ 98,600	(9,600)	(6,400)
Excess tax benefit from exercise of common stock options	0	0	2,435
2017 Tax Cuts and Jobs Act [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Income Tax Expense on Repatriated Earnings	85,000
Tax Adjustments, Settlements, and Unusual Provisions	106,538	$ 0	$ 0
Remeasurement of net deferred tax assets [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount	21,500
Other Tax Matters [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions	5,100
General Business [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Credit Carryforward, Amount	100
State and Local Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	198,600
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Credit Carryforward, Amount	6,000
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	263,100
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Credit Carryforward, Amount	100
Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	$ 40,600
China [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Income Tax Holiday, Termination Date	12/31/2019
Singapore [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Income Tax Holiday, Termination Date	12/31/2018

Income Taxes Income Before Inco

Income Taxes Income Before Income taxes (Details) - USD ($) $ in Thousands	3 Months Ended								6 Months Ended	12 Months Ended
	Dec. 31, 2017	[1]	Oct. 01, 2017	Jul. 02, 2017	Apr. 02, 2017	Jan. 01, 2017	Oct. 02, 2016	Apr. 03, 2016	Jul. 03, 2016	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Income Tax Contingency [Line Items]
U.S.										$ 3,743	$ 39,689	$ (21,510)
Non-U.S.										292,975	204,379	230,317
Income from continuing operations before income taxes	$ 80,889		$ 105,054	$ 70,792	$ 39,983	$ 69,186	$ 64,518	$ 49,491	$ 60,873	$ 296,718	$ 244,068	$ 208,807
[1]	The fourth quarter of fiscal year 2017 includes a pre-tax gain of $2.1 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2016 includes a pre-tax loss of $15.3 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.

Income Taxes Components of the

Income Taxes Components of the Provision (Benefits from) Income Tax (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Income Tax Contingency [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount	$ (65,836)	$ (52,648)	$ (47,994)
Federal current	62,003	14	(10,952)
Federal deferred expense (benefit)	35,435	2,994	(4,794)
Federal total	97,438	3,008	(15,746)
State current	3,332	2,143	2,613
State deferred expense (benefit)	(792)	(575)	(2,563)
State total	2,540	1,568	50
Non-U.S. current	45,639	30,754	37,963
Non-U.S.deferred expense benefit	(5,789)	(6,968)	(2,245)
Non-U.S. total	39,850	23,786	35,718
Total current	110,974	32,911	29,624
Total deferred expense (benefit)	28,854	(4,549)	(9,602)
Total	139,828	28,362	20,022
Discontinued operations	44,522	4,255	11,537
Total provision for income taxes	184,350	32,617	31,559
Singapore, Finland, Netherlands and China [Member]
Income Tax Contingency [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount	$ 55,900	$ 48,200	$ 36,100

Income Taxes Reconciliation of

Income Taxes Reconciliation of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Income Tax Contingency [Line Items]
Tax at statutory rate	$ 103,851	$ 85,424	$ 73,082
Non-U.S. rate differential, net	(65,836)	(52,648)	(47,994)
U.S. taxation of multinational operations	5,408	6,941	1,732
State income taxes, net	1,810	1,509	80
Prior year tax matters	(7,955)	(9,621)	(6,387)
Federal tax credits	(8,249)	(7,189)	(2,096)
Change in valuation allowance	1,951	(2,755)	2,593
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount	0	5,701	0
Tax Adjustments, Settlements, and Unusual Provisions	98,600	(9,600)	(6,400)
Other, net	2,310	1,000	(988)
Total	139,828	28,362	20,022
Singapore, Finland, Netherlands and China [Member]
Income Tax Contingency [Line Items]
Non-U.S. rate differential, net	55,900	48,200	36,100
2017 Tax Cuts and Jobs Act [Member]
Income Tax Contingency [Line Items]
Tax Adjustments, Settlements, and Unusual Provisions	$ 106,538	$ 0	$ 0

Income Taxes Components of Defe

Income Taxes Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017
Income Tax Contingency [Line Items]
Inventory	$ 6,376	$ 10,994
Reserves and accruals	26,657	24,669
Accrued compensation	17,333	26,715
Net operating loss and credit carryforwards	88,503	113,415
Accrued pension	34,682	37,005
Restructuring reserve	2,586	1,954
Deferred revenue	28,478	38,113
Deferred Tax Assets, Unrealized Currency Losses	10,910	0
All other, net	0	682
Deferred Tax Assets, Gross	215,525	253,547
Postretirement health benefits	(3,391)	(4,785)
Deferred Tax Liabilities, Unrealized Currency Transaction Gains	0	(15,730)
Depreciation and amortization	(392,293)	(130,176)
Deferred Tax Liabilities, Other	(594)	0
Total deferred tax liabilities	(396,278)	(150,691)
Valuation allowance	(68,895)	(65,640)
Net deferred tax liabilities		(37,216)
Deferred Tax Liabilities, Net	249,648
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	(3,300)
Domestic Country [Member]
Income Tax Contingency [Line Items]
Net deferred tax liabilities	(44,974)	(52,604)
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Deferred Tax Liabilities, Net	$ 294,622	$ 15,388

Income Taxes Summary of Loss an

Income Taxes Summary of Loss and Tax Credit Carryforwards (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017
Income Tax Contingency [Line Items]
Valuation Allowance, Amount	$ 68,895	$ 65,640
State and Local Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	198,600
Tax Credit Carryforward, Amount	6,000
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	263,100
Tax Credit Carryforward, Amount	100
Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	40,600
General Business [Member]
Income Tax Contingency [Line Items]
Tax Credit Carryforward, Amount	$ 100
Minimum [Member] | Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Tax Credit Carryforward, Expiration Date	Jan. 1, 2018
Maximum [Member] | Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Tax Credit Carryforward, Expiration Date	Dec. 31, 2037

Earnings Per Share (Schedule of

Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Earnings Per Share [Abstract]
Number of common shares-basic	109,857	109,478	112,507
Effect of dilutive securities, Stock options	708	640	621
Effect of dilutive securities, Restricted stock	294	195	187
Number of common shares-diluted	110,859	110,313	113,315
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	287	458	607

Accounts Receivable, Net (Detai

Accounts Receivable, Net (Details) - USD ($) $ in Millions	Dec. 31, 2017	Jan. 01, 2017
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]
Reserves for doubtful accounts	$ 31.3	$ 29.2

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jan. 01, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 122,100	$ 79,189
Work in progress	18,452	6,561
Finished goods	211,123	161,097
Total inventories	$ 351,675	$ 246,847

Property, Plant and Equipment70

Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 630,919	$ 427,903
Accumulated depreciation	(332,853)	(282,409)
Total property, plant and equipment, net	298,066	145,494
Depreciation expense	31,300	28,500	$ 28,700
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	5,624	4,250
Building and leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	262,657	162,780
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 362,638	$ 260,873

Marketable Securities and Inv71

Marketable Securities and Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Schedule of Available-for-sale Securities [Line Items]
Unrealized gains (losses) on securities, net of tax	$ 79	$ 32	$ (262)
Marketable securities	2,208	1,678
Cost Method Investments	$ 10,783	0
Cost Method Investments, Percentage of Equity Purchased	18.00%
Marketable Securities and Investments	$ 12,991	1,678
Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	1,161	1,077
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	811	598
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(350)	(479)
Fixed Income Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	22	22
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	22	22
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0	0
Available-for-sale Securities, Other [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	1,438	1,121
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	1,375	1,058
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(63)	(63)
Available-for-sale Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	2,621	2,220
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	2,208	1,678
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	$ (413)	$ (542)

Goodwill and Intangible Asset72

Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016	Dec. 29, 2013	Dec. 30, 2012
Goodwill and Intangible Assets Net [Line Items]
Change in any one of the input assumptions for the various reporting units	10.00%
Total amortization expense related to finite-lived intangible assets	$ 73,700	$ 71,500	$ 76,600
Future Amortization Expense, Year One	139,100
Future Amortization Expense, Year Two	145,700
Future Amortization Expense, Year Three	147,400
Future Amortization Expense, Year Four	132,000
Future Amortization Expense, Year Five	119,800
Finite-Lived Intangible Assets, Net	1,276,356	349,640
Goodwill	$ 3,002,198	2,247,966	2,236,863
Impairment Testing Date	1/2/2017
Minimum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	0.00%
Discount rates for reporting units	9.00%
Maximum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	3.00%
Discount rates for reporting units	13.50%
Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	$ 52,724	16,069
Licenses [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	10,665	11,260
Discovery & Analytical Solutions [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	184,747	220,023
Goodwill	1,344,235	1,303,936	1,296,724
Discovery & Analytical Solutions [Member] | Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	9,928	12,636
Discovery & Analytical Solutions [Member] | Licenses [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	8,441	11,086
Diagnostics [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	1,091,609	129,617
Goodwill	1,657,963	944,030	$ 940,139
Diagnostics [Member] | Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	42,796	3,433
Diagnostics [Member] | Licenses [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	2,224	174
Other Asset Acquisitions [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net				$ 7,000	$ 6,800
Prepaid Royalties	72,800			$ 40,300	$ 25,000
Prepaid Royalties, Other Current Asset	5,100
Prepaid Royalties, Other Assets	67,700
Payments of Additional Prepaid Royalties	5,100	9,400
Other Asset Acquisitions extension [Member]
Goodwill and Intangible Assets Net [Line Items]
Prepaid Royalties		$ 6,000
Informatics [Member]
Goodwill and Intangible Assets Net [Line Items]
Goodwill	$ 217,200

Goodwill and Intangible Asset73

Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017
Changes in the carrying amount of goodwill
Foreign currency translation	$ 66,737	$ (28,475)
Acquisitions, earn outs and other	687,495	39,578
Ending balance	3,002,198	2,247,966
Diagnostics [Member]
Changes in the carrying amount of goodwill
Foreign currency translation	29,091	(11,873)
Acquisitions, earn outs and other	684,842	15,764
Ending balance	1,657,963	944,030
Discovery & Analytical Solutions [Member]
Changes in the carrying amount of goodwill
Foreign currency translation	37,646	(16,602)
Acquisitions, earn outs and other	2,653	23,814
Ending balance	$ 1,344,235	$ 1,303,936

Goodwill and Intangible Asset74

Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jan. 01, 2017
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	$ 1,276,356	$ 349,640
Totals	1,346,940	420,224
Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	39,959	39,901
Less: Accumulated amortization	(35,085)	(32,408)
Net amortizable intangible assets	4,874	7,493
Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	80,974	40,086
Less: Accumulated amortization	(28,250)	(24,017)
Net amortizable intangible assets	52,724	16,069
Non-amortizing intangible assets	70,584	70,584
Licenses [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	53,300	57,767
Less: Accumulated amortization	(42,635)	(46,507)
Net amortizable intangible assets	10,665	11,260
Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	471,740	304,187
Less: Accumulated amortization	(244,916)	(233,720)
Net amortizable intangible assets	226,824	70,467
Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	1,141,511	383,303
Less: Accumulated amortization	(242,840)	(213,062)
Net amortizable intangible assets	898,671	170,241
In Process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	88,025	78,515
Less: Accumulated amortization	(5,427)	(4,405)
Net amortizable intangible assets	82,598	74,110
Diagnostics [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	1,091,609	129,617
Totals	1,091,609	129,617
Diagnostics [Member] | Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	11,911	11,900
Less: Accumulated amortization	(10,637)	(9,556)
Net amortizable intangible assets	1,274	2,344
Diagnostics [Member] | Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	51,024	11,523
Less: Accumulated amortization	(8,228)	(8,090)
Net amortizable intangible assets	42,796	3,433
Non-amortizing intangible assets	0	0
Diagnostics [Member] | Licenses [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	10,239	7,936
Less: Accumulated amortization	(8,015)	(7,762)
Net amortizable intangible assets	2,224	174
Diagnostics [Member] | Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	240,985	70,896
Less: Accumulated amortization	(58,552)	(49,380)
Net amortizable intangible assets	182,433	21,516
Diagnostics [Member] | Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	907,938	123,884
Less: Accumulated amortization	(126,144)	(93,720)
Net amortizable intangible assets	781,794	30,164
Diagnostics [Member] | In Process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	82,456	72,946
Less: Accumulated amortization	(1,368)	(960)
Net amortizable intangible assets	81,088	71,986
Discovery & Analytical Solutions [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	184,747	220,023
Totals	255,331	290,607
Discovery & Analytical Solutions [Member] | Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	28,048	28,001
Less: Accumulated amortization	(24,448)	(22,852)
Net amortizable intangible assets	3,600	5,149
Discovery & Analytical Solutions [Member] | Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	29,950	28,563
Less: Accumulated amortization	(20,022)	(15,927)
Net amortizable intangible assets	9,928	12,636
Non-amortizing intangible assets	70,584	70,584
Discovery & Analytical Solutions [Member] | Licenses [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	43,061	49,831
Less: Accumulated amortization	(34,620)	(38,745)
Net amortizable intangible assets	8,441	11,086
Discovery & Analytical Solutions [Member] | Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	230,755	233,291
Less: Accumulated amortization	(186,364)	(184,340)
Net amortizable intangible assets	44,391	48,951
Discovery & Analytical Solutions [Member] | Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	233,573	259,419
Less: Accumulated amortization	(116,696)	(119,342)
Net amortizable intangible assets	116,877	140,077
Discovery & Analytical Solutions [Member] | In Process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	5,569	5,569
Less: Accumulated amortization	(4,059)	(3,445)
Net amortizable intangible assets	$ 1,510	$ 2,124

Debt (Details)

Debt (Details) € in Millions	Jul. 19, 2016USD ($)	Oct. 25, 2011USD ($)	Apr. 02, 2017	Dec. 31, 2017USD ($)	Dec. 30, 2012USD ($)	Dec. 31, 2017EUR (€)	Jan. 01, 2017USD ($)	Aug. 11, 2016USD ($)	Jul. 19, 2016EUR (€)	Sep. 30, 2012USD ($)
Basis spread on variable rate			1.30%
Unamortized discount and debt issuance costs				$ (15,717,000)
Maturities of Long-term Debt [Abstract]
2,017				217,385,000
2,018				14,506,000
2,019				9,349,000
2,020				1,135,912,000
2,021				6,303,000
Thereafter				638,371,000
Long-term Debt Before Unamortized Discount				2,021,826,000
Total				2,006,109,000
Other Long-term Debt, Current				217,306,000			$ 1,172,000
Line of Credit, Maturing August 11, 2021 [Member]
Unsecured revolving credit facility, amount				1,000,000,000				$ 1,000,000,000
Line of Credit Facility, Remaining Borrowing Capacity				363,600,000
Letters of credit issued and outstanding				$ 11,400,000
Interest rate terms under amended senior unsecured revolving credit facility				The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%.
Weighted average interest rates under amended senior unsecured revolving credit facility				The Eurocurrency margin as of December 31, 2017 was 110 basis points. The weighted average Eurocurrency interest rate as of December 31, 2017 was 1.56%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 2.66%, which was the interest applicable to the borrowings outstanding under the Eurocurrency rate as of December 31, 2017
Aggregate borrowings under the amended facility				$ 625,000,000
Unamortized discount and debt issuance costs				(3,339,000)
Unamortized Debt Issuance Expense				3,300,000			4,300,000
Maturities of Long-term Debt [Abstract]
2,017				0
2,018				0
2,019				0
2,020				625,000,000
2,021				0
Thereafter				0
Long-term Debt Before Unamortized Discount				625,000,000
Total				$ 621,661,000			0
Line of Credit, Maturing August 11, 2021 [Member] | Base Rate Option Three [Member] | Line of Credit [Member]
Basis spread on variable rate				1.00%
Line of Credit, Maturing August 11, 2021 [Member] | Eurocurrency Rate [Member]
Basis spread on variable rate				1.10%
Line of Credit, Maturing August 11, 2021 [Member] | Eurocurrency Rate [Member] | Line of Credit [Member]
Basis spread on variable rate				1.10%
Line of Credit, Maturing August 11, 2021 [Member] | Base Rate Option Two [Member] | Line of Credit [Member]
Basis spread on variable rate				0.50%
Line of Credit, Maturing December 16, 2016 [Member] | Eurocurrency Rate [Member]
Description of variable rate basis				Eurocurrency margin
Line of Credit, Maturing December 16, 2016 [Member] | Base Rate Option Two [Member]
Description of variable rate basis				Federal Funds
2021 Notes [Member]
Interest rate terms under amended senior unsecured revolving credit facility				Interest on the 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest.
Unsecured senior notes, interest rate percent		5.00%
Unsecured senior notes, face value		$ 500,000,000
Gross proceeds from the issuance of debt instrument		$ 496,900,000
Senior unsecured notes issuance as percentage of principal amount		99.372%
Unamortized discount and debt issuance costs				$ (3,417,000)
Unamortized Debt Issuance Expense				2,000,000			2,500,000
Debt Instrument, Redemption Percentage Upon Change of Control and Downgrade of Debt Instrument		101.00%
Maturities of Long-term Debt [Abstract]
2,017				0
2,018				0
2,019				0
2,020				500,000,000
2,021				0
Thereafter				0
Long-term Debt Before Unamortized Discount				500,000,000
Total				$ 496,583,000			495,800,000
2021 Notes [Member] | Treasury Rate [Member]
Basis spread on variable rate				0.45%
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Debt Instrument, Maturity Date	Jul. 19, 2026
Unsecured senior notes, interest rate percent									1.875%
Gross proceeds from the issuance of debt instrument	$ 492,300,000
Senior unsecured notes issuance as percentage of principal amount									99.118%
Unamortized discount and debt issuance costs				$ (8,961,000)
Unamortized Debt Issuance Expense				4,300,000			4,800,000
Debt Instrument, Redemption Percentage Upon Change of Control and Downgrade of Debt Instrument	101.00%
Maturities of Long-term Debt [Abstract]
2,017				0
2,018				0
2,019				0
2,020				0
2,021				0
Thereafter				600,700,000
Long-term Debt Before Unamortized Discount				600,700,000
Total				591,739,000			517,800,000
Financing Lease Obligations [Member]
Additional Financing Lease Obligations					$ 11,500,000
Unamortized discount and debt issuance costs				0
Maturities of Long-term Debt [Abstract]
2,017				1,370,000
2,018				1,532,000
2,019				1,597,000
2,020				1,664,000
2,021				1,639,000
Thereafter				28,109,000
Long-term Debt Before Unamortized Discount				35,911,000
Total				35,911,000
Other Long-term Debt				35,900,000			37,100,000			$ 29,300,000
Other Long-term Debt, Current				1,400,000			1,200,000
Other Long-term Debt, Noncurrent				$ 34,500,000			$ 35,900,000
Term Loan Credit Facility, 12 Months Maturity [Member]
Debt Instrument, Maturity Date				Dec. 18, 2018
Short-term Debt, Terms				twelve months
Short-term Debt, Maximum Amount Outstanding During Period				$ 200,000,000
Interest rate terms under amended senior unsecured revolving credit facility				The interest rates under the senior unsecured term loan credit facility are based on the Eurocurrency rate or the base rate at the time of the borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) an adjusted one-month Libor plus 1.00%. The Eurocurrency margin as of December 31, 2017 was 110 basis points.
Weighted average interest rates under amended senior unsecured revolving credit facility				The weighted average Eurocurrency interest rate as of December 31, 2017 was 1.56%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 2.66%, which was the interest applicable to the borrowings outstanding under the Eurocurrency rate as of December 31, 2017
Unamortized discount and debt issuance costs				$ 0
Term Loan Credit Facility, Maximum Borrowing Capacity				200,000,000
Maturities of Long-term Debt [Abstract]
2,017				200,000,000
2,018				0
2,019				0
2,020				0
2,021				0
Thereafter				0
Long-term Debt Before Unamortized Discount				200,000,000
Total				$ 200,000,000
Term Loan Credit Facility, 12 Months Maturity [Member] | Base Rate Option Three [Member]
Basis spread on variable rate				1.00%
Term Loan Credit Facility, 12 Months Maturity [Member] | Base Rate Option Two [Member]
Basis spread on variable rate				0.50%
Other Debt Facilities - EUROIMMUN [Member]
Interest rate terms under amended senior unsecured revolving credit facility				The bank loans in the aggregate amount of $44.8 million bear fixed interest rates between 1.1% and 7.9% and bank loans in the aggregate amount of $12.4 million bear variable interest rates based on the Euribor rate plus a margin between 1.3% and 1.5%.
Unamortized discount and debt issuance costs				$ 0
Maturities of Long-term Debt [Abstract]
2,017				16,015,000
2,018				12,974,000
2,019				7,752,000
2,020				9,248,000
2,021				4,664,000
Thereafter				9,562,000
Long-term Debt Before Unamortized Discount				60,215,000
Total				$ 60,215,000
Other Long-term Debt | €						€ 60.2
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €						47.8
Long-term Debt, Percentage Bearing Variable Interest, Amount | €						€ 12.4
Other Debt Facilities - EUROIMMUN [Member] | Minimum [Member]
Unsecured senior notes, interest rate percent				0.10%		0.10%
Other Debt Facilities - EUROIMMUN [Member] | Maximum [Member]
Unsecured senior notes, interest rate percent				7.90%		7.90%
Other Debt Facilities - EUROIMMUN [Member] | Euribor Rate [Member] | Maximum [Member]
Basis spread on variable rate			1.50%
Other Unsecured Revolving Debt Facilities [Member]
Other Unsecured Revolving Credit Facility				$ 2,700,000
Interest rate terms under amended senior unsecured revolving credit facility				The unsecured revolving debt facilities bear fixed interest rates between 0.05% and 1.95% and will mature in 2018.
Other Unsecured Revolving Debt Facilities [Member] | Minimum [Member]
Unsecured senior notes, interest rate percent				0.05%		0.05%
Other Unsecured Revolving Debt Facilities [Member] | Maximum [Member]
Unsecured senior notes, interest rate percent				1.95%		1.95%
Other Secured Bank Loan [Member]
Interest rate terms under amended senior unsecured revolving credit facility				The secured bank loan of $0.3 million bears a fixed annual interest rate of 1.95% and is repaid in monthly installments until 2027.
Unsecured senior notes, interest rate percent				1.95%		1.95%
Maturities of Long-term Debt [Abstract]
Secured Debt | €						€ 0.3
Euro Member Countries, Euro | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Unsecured senior notes, face value | €									€ 500
Euro Member Countries, Euro | Other Debt Facilities - EUROIMMUN [Member]
Maturities of Long-term Debt [Abstract]
Other Long-term Debt | €						47.6
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member]
Maturities of Long-term Debt [Abstract]
Other Long-term Debt | €						57.2
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €						44.8
Secured Debt | €						15
Unsecured Debt | €						€ 42.2
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member] | Minimum [Member]
Unsecured senior notes, interest rate percent				1.10%		1.10%
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member] | Maximum [Member]
Unsecured senior notes, interest rate percent				7.90%		7.90%

Accrued Expenses and Other Cu76

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jan. 01, 2017
Accounts Payable and Accrued Liabilities, Current [Abstract]
Payroll and incentives	$ 66,955	$ 61,474
Employee benefits	37,354	31,039
Deferred revenue	159,923	162,987
Federal, non-U.S. and state income taxes	10,800	8,189
Other accrued operating expenses	225,610	136,011
Total accrued expenses and other current liabilities	$ 500,642	$ 399,700

Employee Benefit Plans (Schedul

Employee Benefit Plans (Schedule of Net Benefit Costs, Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment			$ (816)
Service cost	$ 4,951	$ 4,337	4,332
Interest cost	16,707	18,638	20,696
Expected return on plan assets	(26,401)	(24,245)	(26,021)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment	0	0	907
Actuarial loss (gain)	(7,085)	15,890	12,953
Amortization of prior service cost	(195)	(210)	(238)
Net periodic benefit cost	$ (12,023)	$ 14,410	10,815
Other Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial loss (gain)			$ 821

Employee Benefit Plans (Sched78

Employee Benefit Plans (Schedule of Net Funded Status, Pension Plans) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Apr. 01, 2018	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016	Dec. 28, 2014
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Benefit Obligation		$ 190,265	$ 139,185
Change in benefit obligations:
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change		2,600	5,500	$ 6,800
Change in plan assets:
Employer's contributions			9,562
Actuarial assumptions as of the year-end measurement date:
Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Fair Value of Plan Assets		0	0
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Projected Benefit Obligation		187,329	136,197
Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Fair Value of Plan Assets		0	0
Foreign Plan [Member]
Change in plan assets:
Employer's contributions		8,400	$ 9,562	14,908
UNITED STATES
Change in plan assets:
Employer's contributions				20,000
UNITED STATES | Subsequent Event [Member]
Change in plan assets:
Employer's contributions	$ 15,000
Other Pension Plan [Member]
Change in benefit obligations:
Actuarial loss (gain)				(821)
Actuarial assumptions as of the year-end measurement date:
Rate of compensation increase			3.64%
Foreign Plan [Member]
Actuarial present value of benefit obligations: [Abstract]
Accumulated benefit obligations		334,151	$ 271,127
Change in benefit obligations:
Projected benefit obligations at beginning of year	343,410	279,522	276,960
Service cost		2,201	2,262
Interest cost		4,870	6,205
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant		189	209
Defined Benefit Plan, Benefit Obligation, Divestiture			2,955
Defined Benefit Plan, Benefit Obligation, Business Combination		39,293
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change		0	(993)
Actuarial loss (gain)		(1,486)	38,623
Effect of exchange rate changes		32,059	(28,849)
Projected benefit obligations at end of year		343,410	279,522	276,960
Change in plan assets:
Fair value of plan assets at beginning of year	179,736	153,281	150,894
Actual return on plan assets		15,866	32,581
Benefits paid and plan expenses		(13,238)	(11,940)
Employer's contributions		8,422
Defined Benefit Plan, Plan Assets, Payment for Settlement		0	(993)
Participant's contributions		189	209
Effect of exchange rate changes		15,216	(27,032)
Fair value of plan assets at end of year		179,736	153,281	$ 150,894
Net amounts recognized in the consolidated balance sheets consist of:
Net amounts recognized in the consolidated balance sheets		(163,674)	(126,241)
Assets for Plan Benefits, Defined Benefit Plan		26,591	12,944
Current liabilities		(7,017)	(6,033)
Noncurrent liabilities		(183,248)	(133,152)
Net amounts recognized in accumulated other comprehensive income consist of:
Prior service cost		$ (457)	$ (603)
Actuarial assumptions as of the year-end measurement date:
Discount rate		1.99%	2.06%	2.88%	2.75%
Rate of compensation increase		3.50%	3.64%	3.26%	3.28%
Expected rate of return on assets			6.00%	5.30%	4.60%
Defined Benefit Plan, Benefit Obligation, Benefits Paid		$ 13,238	$ 11,940
UNITED STATES
Actuarial present value of benefit obligations: [Abstract]
Accumulated benefit obligations		308,713	300,650
Change in benefit obligations:
Projected benefit obligations at beginning of year	308,713	300,650	301,416
Service cost		2,750	2,075
Interest cost		11,836	12,433
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant		0	0
Defined Benefit Plan, Benefit Obligation, Divestiture		0	0
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change		0	0
Actuarial loss (gain)		13,509	4,150
Effect of exchange rate changes		0	0
Projected benefit obligations at end of year		308,713	300,650	$ 301,416
Change in plan assets:
Fair value of plan assets at beginning of year	$ 253,427	243,817	244,693
Actual return on plan assets		29,642	18,548
Benefits paid and plan expenses		(20,032)	(19,424)
Employer's contributions		0	0
Defined Benefit Plan, Plan Assets, Payment for Settlement		0	0
Participant's contributions		0	0
Effect of exchange rate changes		0	0
Fair value of plan assets at end of year		253,427	243,817	$ 244,693
Net amounts recognized in the consolidated balance sheets consist of:
Net amounts recognized in the consolidated balance sheets		(55,286)	(56,833)
Assets for Plan Benefits, Defined Benefit Plan		0	0
Current liabilities		0	0
Noncurrent liabilities		(55,286)	(56,833)
Net amounts recognized in accumulated other comprehensive income consist of:
Prior service cost		$ 0	$ 0
Actuarial assumptions as of the year-end measurement date:
Discount rate		3.56%	4.06%	4.25%	4.08%
Rate of compensation increase		0.00%	0.00%	0.00%	0.00%
Expected rate of return on assets			7.25%	7.25%	7.25%
Defined Benefit Plan, Benefit Obligation, Benefits Paid		$ 20,032	$ 19,424

Employee Benefit Plans (Sched79

Employee Benefit Plans (Schedule of Allocation of Plan Assets, Pension Plans) (Details)	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		100.00%	100.00%
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		100.00%	100.00%
Minimum [Member] | Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage		45.00%
Minimum [Member] | Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage		40.00%
Minimum [Member] | Debt Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage		45.00%
Minimum [Member] | Debt Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage		50.00%
Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage		0.00%
Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage		0.00%
Maximum [Member] | Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage		55.00%
Maximum [Member] | Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage		50.00%
Maximum [Member] | Debt Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage		55.00%
Maximum [Member] | Debt Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage		60.00%
Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage		5.00%
Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage		5.00%
Other Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		0.00%	1.00%
Other Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		0.00%	0.00%
Debt Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		49.00%	51.00%
Debt Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		59.00%	59.00%
Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		51.00%	48.00%
Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		41.00%	41.00%
Scenario, Forecast [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Allocation Percentage	1
Scenario, Forecast [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Allocation Percentage	1

Employee Benefit Plans (Sched80

Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($) $ in Thousands	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016	Dec. 28, 2014
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 433,163	$ 397,098
Equity Securities, U.S. Small-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,104	1,756
Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,307	6,079
Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30,008	25,523
Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	32,613	28,267
Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14,348	12,144
Equity Securities, Equity Index Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	90,838	74,274
Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,401	1,401
Equity Securities, Commodity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7,387	6,854
Foreign Government Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	24,946	22,059
Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	138,948	133,406
Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	27,571	23,906
Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,912	5,636
Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	16,789	23,790
Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	35,991	32,003
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	138,370	123,631
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Small-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,104	1,756
Fair Value, Inputs, Level 1 [Member] | Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,307	6,079
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30,008	25,523
Fair Value, Inputs, Level 1 [Member] | Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	32,613	28,267
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14,348	12,144
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Equity Index Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,401	1,401
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Commodity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7,387	6,854
Fair Value, Inputs, Level 1 [Member] | Foreign Government Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	40,290	35,971
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,912	5,636
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	278,004	249,677
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Small-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Equity Index Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	90,838	74,274
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Commodity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Foreign Government Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	24,946	22,059
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	98,658	97,435
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	27,571	23,906
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	35,991	32,003
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	16,789	23,790	$ 23,416	$ 23,333
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Small-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Equity Index Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Commodity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Foreign Government Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	16,789	23,790	23,415	23,332
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Venture Capital Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0	$ 1	$ 1
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	$ 0

Employee Benefit Plans (Sched81

Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Other Postretirement Benefits Plan [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	$ 15,453	$ 14,353
Realized gains (losses)	741	539	$ (971)
Fair value of plan assets at end of year	17,374	15,453	14,353
Other Postretirement Benefits Plan [Member] | Multi-strategy hedge funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,508
Fair value of plan assets at end of year	1,151	1,508
Pension Plans, Defined Benefit
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	397,098
Fair value of plan assets at end of year	433,163	397,098
Pension Plans, Defined Benefit | Multi-strategy hedge funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	23,790
Fair value of plan assets at end of year	16,789	23,790
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefits Plan [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,508
Fair value of plan assets at end of year	1,151	1,508
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefits Plan [Member] | Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchases, Sales, and Settlements	(562)
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,508	1,374	1,341
Realized gains (losses)	229
Unrealized gains (losses)	(24)	134	33
Fair value of plan assets at end of year	1,151	1,508	1,374
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchases, Sales, and Settlements	(8,189)
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	23,790	23,416	23,333
Realized gains (losses)	1,542	(1)
Unrealized gains (losses)	(354)	375	83
Fair value of plan assets at end of year	16,789	23,790	23,416
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | Venture Capital Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchases, Sales, and Settlements	0
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	0	1	1
Realized gains (losses)	0	(1)
Unrealized gains (losses)	0	0	0
Fair value of plan assets at end of year	0	0	1
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchases, Sales, and Settlements	8,189
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	23,790	23,415	23,332
Realized gains (losses)	1,542	0
Unrealized gains (losses)	(354)	375	83
Fair value of plan assets at end of year	$ 16,789	$ 23,790	$ 23,415

Employee Benefit Plans (Sched82

Employee Benefit Plans (Schedule of Expected Benefit Payments, Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016	Dec. 30, 2018
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Contributions by Employer		$ 9,562
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
2,018	$ 11,786
2,019	12,166
2,020	12,566
2,021	13,151
2,022	13,275
2023-2026	71,963
Defined Benefit Plan, Plan Assets, Contributions by Employer	8,400	$ 9,562	$ 14,908
Foreign Plan [Member] | Scenario, Forecast [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in next fiscal year				$ 8,800
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
2,018	18,593
2,019	18,860
2,020	19,125
2,021	19,392
2,022	19,630
2023-2026	$ 97,295
Defined Benefit Plan, Plan Assets, Contributions by Employer			$ 20,000

Employee Benefit Plans (Sched83

Employee Benefit Plans (Schedule of Net Benefit Costs, Other Postretirement Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 4,951	$ 4,337	$ 4,332
Interest cost	16,707	18,638	20,696
Expected return on plan assets	(26,401)	(24,245)	(26,021)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment	0	0	907
Actuarial loss (gain)	7,085	(15,890)	(12,953)
Amortization of prior service cost	(195)	(210)	(238)
Net periodic benefit cost	(12,023)	14,410	10,815
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	92	101	108
Interest cost	125	142	143
Expected return on plan assets	(1,114)	(1,035)	(1,062)
Defined Benefit Plan, Amortization of Gain (Loss)	(741)	(539)	971
Actuarial loss (gain)	187	(329)
Net periodic benefit cost	$ (1,638)	$ (1,331)	$ 160

Employee Benefit Plans (Sched84

Employee Benefit Plans (Schedule of Net Funded Status, Other Postretirement Benefit Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	4.11%	4.34%	4.10%
Change in benefit obligations:
Projected benefit obligations at beginning of year	$ 3,131	$ 3,361
Service cost	92	101	$ 108
Interest cost	125	142	143
Defined Benefit Plan, Benefit Obligation, Benefits Paid	122	145
Actuarial loss (gain)	187	(329)
Change in accumulated benefit obligations during the year	282	(231)
Projected benefit obligations at end of year	3,413	3,131	3,361
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	15,453	14,353
Actual return on plan assets	1,921	1,100
Fair value of plan assets at end of year	17,374	15,453	$ 14,353
Net amounts recognized in the consolidated balance sheets	13,961	12,322
Assets for Plan Benefits, Defined Benefit Plan	13,961	12,322
Prior service cost	$ 0	$ 0
Discount rate	3.60%	4.11%
Expected rate of return on assets	7.25%	7.25%	7.25%
Retirees [Member]
Change in benefit obligations:
Projected benefit obligations at beginning of year	$ 804	$ 907
Projected benefit obligations at end of year	688	804	$ 907
Active Employees Eligible to Retire [Member]
Change in benefit obligations:
Projected benefit obligations at beginning of year	379	423
Projected benefit obligations at end of year	408	379	423
Other Active Employees [Member]
Change in benefit obligations:
Projected benefit obligations at beginning of year	1,948	2,031
Projected benefit obligations at end of year	$ 2,317	$ 1,948	$ 2,031

Employee Benefit Plans (Sched85

Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Other Postretirement Benefit Plans) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016	Dec. 28, 2014
Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 433,163	$ 397,098
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	17,374	15,453	$ 14,353
Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	138,370	123,631
Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9,459	7,769
Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	278,004	249,677
Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,764	6,176
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	16,789	23,790	23,416	$ 23,333
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,151	1,508
Cash [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,307	6,079
Cash [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	268	319
Cash [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,307	6,079
Cash [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	268	319
Cash [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Cash [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Cash [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Cash [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30,008	25,523
Equity Securities, U.S. Large-cap [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,057	1,618
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30,008	25,523
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,057	1,618
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	32,613	28,267
Equity Securities, International large-cap value[Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,236	1,792
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	32,613	28,267
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,236	1,792
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Equity Index Funds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	90,838	74,274
Equity Securities, Equity Index Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	984	770
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	984	770
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	90,838	74,274
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Domestic Real Estate Funds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,401	1,401
Equity Securities, Domestic Real Estate Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	96	89
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,401	1,401
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	96	89
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Commodity Funds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7,387	6,854
Equity Securities, Commodity Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	506	434
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7,387	6,854
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	506	434
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, Corporate Debt Instruments [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	138,948	133,406
Fixed Income Funds, Corporate Debt Instruments [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9,526	8,456
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	40,290	35,971
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,762	2,280
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	98,658	97,435
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,764	6,176
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, Corporate Bonds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	27,571	23,906
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	27,571	23,906
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,912	5,636
Fixed Income Funds, High Yield Bonds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	406	356
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,912	5,636
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	406	356
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	16,789	23,790
Other Types of Investments, Multi-strategy hedge funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,151	1,508
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	16,789	23,790	23,415	23,332
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,151	1,508	1,374	1,341
Other Types of Investments, Venture Capital Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0	$ 1	$ 1
Equity Securities, U.S. Small-cap [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,104	1,756
Equity Securities, U.S. Small-cap [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	144	111
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,104	1,756
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	144	111
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	$ 0

Employee Benefit Plans (Sched86

Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Other Postretirement Benefit Plans) (Details) - Other Postretirement Benefits Plan [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	$ 15,453	$ 14,353
Realized gains (losses)	741	539	$ (971)
Fair value of plan assets at end of year	17,374	15,453	14,353
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	1,508
Fair value of plan assets at end of year	1,151	1,508
Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	1,508
Fair value of plan assets at end of year	1,151	1,508
Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchases, Sales, and Settlements	(562)
Fair value of plan assets at beginning of year	1,508	1,374	1,341
Realized gains (losses)	229
Unrealized gains (losses)	(24)	134	33
Fair value of plan assets at end of year	$ 1,151	$ 1,508	$ 1,374

Employee Benefit Plans (Sched87

Employee Benefit Plans (Schedule of Expected Benefit Payments, Other Postretirement Benefits) (Details) - USD ($) $ in Thousands	Dec. 30, 2018	Dec. 31, 2017
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
2,018		$ 11,786
2,019		12,166
2,020		12,566
2,021		13,151
2,022		13,275
2023-2026		71,963
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
2,018		18,593
2,019		18,860
2,020		19,125
2,021		19,392
2,022		19,630
2023-2026		97,295
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
2,018		147
2,019		166
2,020		178
2,021		195
2,022		211
2023-2026		$ 1,153
Scenario, Forecast [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	$ 8,800

Employee Benefit Plans (Savings

Employee Benefit Plans (Savings Plan) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, 401(k) Savings Plan, Employer Contribution Match of Employees Eligible Compensation	100.00%
Defined Benefit Plan, 401(k) Savings Plan, Maximum Employee Match Percent for Employer Match	5.00%
Defined Benefit, 401(k) Savings Plan Expense	$ 12.5	$ 12.8

Employee Benefit Plans (Supplem

Employee Benefit Plans (Supplemental Executive Retirement Plan) (Details) - Supplemental Employee Retirement Plans, Defined Benefit [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligation	$ 23.7	$ 21.8
Fair value of plan assets	1.4	1.1
Pension expense	$ 3.2	$ 1.6	$ (1.6)

Employee Benefit Plans (Nonqual

Employee Benefit Plans (Nonqualified Deferred Compensation Plans) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Jan. 01, 2017
Management [Member]
Defined Benefit Plan Disclosure [Line Items]
Deferred Compensation Arrangement with Individual, Recorded Liability	$ 1	$ 0.9

Contingencies (Details)

Contingencies (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)years	Jan. 01, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
Management's estimate of total cost of ultimate disposition of known environmental matters | $	$ 9.4	$ 9.9
Number of years over which estimated environmental cost will be paid | years	10

Warranty Reserves (Details)

Warranty Reserves (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)years	Jan. 01, 2017USD ($)	Jan. 03, 2016USD ($)
Warranty reserve activity
Period of warranty protection beyond date of sale (in years) | years	1
Balance beginning of period	$ 9,012	$ 9,843	$ 9,593
Provision charged to income	13,700	14,901	15,792
Payments	(14,245)	(14,749)	(14,936)
Adjustments to previously provided warranties, net	(815)	(850)	(146)
Foreign currency and acquisitions	1,398	(133)	(460)
Balance end of period	$ 9,050	$ 9,012	$ 9,843

Stock Plans (Narrative) (Detail

Stock Plans (Narrative) (Details)	12 Months Ended
	Dec. 31, 2017USD ($)plan$ / sharesshares	Jan. 01, 2017USD ($)$ / sharesshares	Jan. 03, 2016USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock-based Compensation Plans | plan	1
Total income tax benefit recognized for stock-based compensation	$ 14,500,000	$ 10,500,000	$ 5,800,000
Stock-based compensation costs capitalized as part of inventory	300,000
Options related excess tax benefit, classified as a financing cash activity	0	0	2,435,000
Aggregate intrinsic value for stock options outstanding	$ 65,400,000
Weighted average remaining contractual term of options (in years)	4 years
Aggregate intrinsic value for stock options exercisable	$ 43,400,000
Weighted average remaining contractual term of options exercisable (in years)	2 years 11 months
Number of shares vested and expected to vest in the future | shares	2,200,000
Aggregate intrinsic value of vested and expected to vest stock options	$ 65,400,000
Weighted average remaining contractual term for options vested and expected to vest	4 years 1 month
Total pre-tax stock-based compensation expense	$ 25,421,000	$ 17,158,000	$ 17,278,000
Deferred compensation liability	$ 11,700,000
Performance Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	$ 52.69	$ 42.79	$ 46.83
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares	15,139	19,584	8,860
Total pre-tax stock-based compensation expense	$ 8,700,000	$ 2,700,000	$ 4,000,000
Shares/units granted | shares	49,845	72,164	66,509
Awards/units outstanding | shares	164,481
Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	$ 63.14	$ 54.58	$ 51.01
Total pre-tax stock-based compensation expense	$ 800,000	$ 800,000
Shares/units granted | shares	1,598	1,821	1,953
Stock award program for non-employees Directors, fair market value	$ 100,000	$ 100,000
Stock Awards [Member] | New Non-employee Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares/units granted | shares	820
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	$ 54.75
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares	27,000
Fair value of restricted stock awards vested	$ 10,600,000	8,400,000	$ 7,800,000
Total pre-tax stock-based compensation expense	10,300,000	$ 9,300,000	$ 8,400,000
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	$ 13,200,000
Shares/units granted | shares	231,000
Awards/units outstanding | shares	496,000	521,000
Weighted-average period for recognition of unrecognized compensation cost, years	1 year 4 months
Option vesting period (in years)	3 years
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan | shares	5,000,000
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	$ 67.09	$ 49.67	$ 47.08
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date	95.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate	10.00%
Shares/units granted | shares	36,769	49,578	78,294
Shares available for grant under employee stock purchase plan | shares	900,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of options | $ / shares	$ 11.83	$ 10.20	$ 11.02
Total intrinsic value of options exercised	$ 17,600,000	$ 16,600,000	$ 25,900,000
Cash received from option exercises	18,000,000	14,400,000	14,900,000
Total pre-tax stock-based compensation expense	4,700,000	$ 4,400,000	$ 4,100,000
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	$ 6,000,000
Weighted-average period for recognition of unrecognized compensation cost, years	2 years
Option vesting period (in years)		3 years
Stock Options Expiration Period After Date of Grant		7 years
Performance Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	$ 52.78
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares	0
Total pre-tax stock-based compensation expense	$ 900,000
Shares/units granted | shares	54,337
Awards/units outstanding | shares	54,337
Two Thousand Nine Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan | shares	10,000,000

Stock Plans (Summary of Total C

Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 25,421	$ 17,158	$ 17,278
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,254	1,031	1,272
Research and development expenses [Member ]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,389	902	526
Selling, general and administrative and other expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 22,778	$ 15,225	$ 15,480

Stock Plans (Weighted-Average A

Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details)	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate	2.00%	1.70%	1.30%
Expected dividend yield	0.40%	0.60%	0.60%
Expected lives, years	5 years	5 years	5 years
Expected stock volatility	22.40%	25.20%	26.50%

Stock Plans (Summary of Stock O

Stock Plans (Summary of Stock Option Activity) (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Stock option activity
Shares outstanding at beginning of the year	2,287
Shares granted	464
Shares exercised	(578)
Shares forfeited	(19)
Shares outstanding at end of year	2,154
Shares exercisable at end of year	1,229
Number of shares vested and expected to vest in the future	2,200
Weighted-average price, outstanding at beginning of year (per share) | $ / shares	$ 37.64
Weighted-average price, granted (per share) | $ / shares	53.94
Weighted-average price, exercised (per share) | $ / shares	31.16
Weighted-average price, forfeited (per share) | $ / shares	50.86
Weighted-average price, outstanding at end of year (per share) | $ / shares	42.77
Weighted-average price, exercisable at end of year (per share) | $ / shares	$ 37.79

Stock Plans (Summary of Restric

Stock Plans (Summary of Restricted Stock Award Activity) (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Restricted Stock Units (RSUs) [Member]
Restricted stock award activity
Performance factor percentage minimum	0.00%
Performance factor percentage maximum	200.00%
Restricted Stock Awards [Member]
Restricted stock award activity
Nonvested at beginning of year | shares	521
Shares, granted | shares	231
Shares, vested | shares	(229)
Shares, forfeited | shares	(27)
Nonvested at end of year | shares	496
Weighted-average grant-date fair value, nonvested at beginning of year (per share) | $ / shares	$ 46.48
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	54.75
Weighted-average grant-date fair value, vested (per share) | $ / shares	46.11
Weighted-average grant-date fair value, forfeited (per share) | $ / shares	50.12
Weighted-average grant-date fair value, nonvested at end of year (per share) | $ / shares	$ 50.30

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended									6 Months Ended		12 Months Ended
	Apr. 01, 2018	Dec. 31, 2017	Oct. 01, 2017	Jul. 02, 2017	Apr. 02, 2017	Jan. 01, 2017	Oct. 02, 2016	Jul. 03, 2016	Apr. 03, 2016	Jul. 01, 2018	Jul. 03, 2016	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016	Jul. 27, 2016
Schedule of Stockholders' Equity [Line Items]
Stock repurchase program, number of shares authorized to be repurchased															8,000,000
Cash dividends (per share)		$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07		$ 0.07	$ 0.28	$ 0.28
Aggregate cost of repurchased common stock to satisfy statutory tax withholding obligation requirements												$ 4,400	$ 3,600	$ 4,400
Number of common stock repurchased in open market												0
Stock repurchase program, number of shares remained available for repurchase		8,000,000										8,000,000
Repurchased shares of common stock to satisfy statutory tax withholding obligation requirements												78,644	75,198	95,129
Dividends accrued		$ 7,700										$ 7,700
Unrecognized prior service costs, net of tax												$ (77)	$ (860)	$ (316)
Dividends Payable, Date Declared		Oct. 27, 2017
Dividends Payable, Date to be Paid												Feb. 9, 2018
Subsequent Event [Member]
Schedule of Stockholders' Equity [Line Items]
Cash dividends (per share)	$ 0.07
Dividends Payable, Date Declared	Jan. 25, 2018
Dividends Payable, Date to be Paid										May 10, 2018

Stockholders' Equity (Component

Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016	Dec. 28, 2014
Cumulative Translation Adjustment Summary [Roll Forward]
Foreign currency translation adjustment, net of tax, beginning of year	$ (100,923)	$ (46,846)	$ 23,332
Current year change	54,341	(54,077)	(70,178)
Foreign currency translation adjustment, net of tax, end of year	(46,582)	(100,923)	(46,846)
Unrecognized prior service costs, net of tax	322	399	1,259	$ 1,575
Unrecognized prior service costs, net of tax, current year change	(77)	(860)	(316)
Unrealized (losses) gains on securities, net of tax	(258)	(337)	(369)	(107)
Unrealized (losses) gains on securities, net of tax, current year change	79	32	(262)
Other comprehensive income (loss)	54,343	(54,905)	(70,756)
Accumulated other comprehensive income (loss)	$ (46,518)	$ (100,861)	$ (45,956)	$ 24,800

Derivatives And Hedging Acti100

Derivatives And Hedging Activities (Details) SEK in Thousands, $ in Thousands, € in Millions	3 Months Ended	12 Months Ended
	Apr. 01, 2018USD ($)	Dec. 31, 2017USD ($)	Jan. 01, 2017USD ($)	Jan. 03, 2016USD ($)	Dec. 31, 2017EUR (€)	Jan. 01, 2017EUR (€)	Jan. 01, 2017SEK	Jan. 03, 2016EUR (€)
Derivative [Line Items]
Proceeds from Derivative Instrument, Investing Activities		$ 36,541	$ 0	$ 0
Company's business conducted outside United States		60.00%
Payments for (Proceeds from) Hedge, Financing Activities		$ 13,824	1,900	(18,706)
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months			$ 0
European And Asian Currencies [Member]
Derivative [Line Items]
Maximum maturity period for foreign exchange contracts, in months		12 months
Duration of foreign currency derivative contract, days		30 days	30 days
Fair Value Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount		$ 212,100	$ 137,500	$ 127,300
Net Investment Hedging [Member]
Derivative [Line Items]
Derivatives used in Net Investment Hedge, Increase (Decrease), Gross of Tax		(73,000)	(23,800)
Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, Gain on Derivative		36,500
Proceeds from Derivative Instrument, Investing Activities		36,500
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure		(1,431)	(1,208)
Notional Amount of SEK Derivatives [Member] | Cash Flow Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount | SEK							SEK 969,529
Notional Amount of US Dollar Derivatives [Member] | Cash Flow Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount		1,253,000	$ 8,700
Notional Amount of Euro Derivatives [Member] | Cash Flow Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount | €					€ 57.2	€ 58.6		€ 107.4
Net Investment Hedging [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments		$ 496,100
Subsequent Event [Member]
Derivative [Line Items]
Derivatives used in Net Investment Hedge, Increase (Decrease), Gross of Tax	$ 2,100

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) € in Millions	3 Months Ended	12 Months Ended
	Apr. 02, 2017	Dec. 31, 2017USD ($)	Jan. 03, 2016USD ($)	Dec. 31, 2017EUR (€)	Jan. 01, 2017USD ($)	Aug. 11, 2016USD ($)	Jul. 19, 2016USD ($)	Jul. 19, 2016EUR (€)	Dec. 28, 2014USD ($)	Sep. 30, 2012USD ($)	Oct. 25, 2011USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 83,000,000
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value		65,328,000	$ 57,350,000		$ 63,201,000				$ 91,000
Long-term Debt		$ 2,006,109,000
Debt Instrument, Basis Spread on Variable Rate	1.30%
Business Combination, Contingent Consideration Arrangements, Maximum Period		1 year 9 months
Business Combination, Contingent Consideration Arrangements, Weighted Average Period		11 years
Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt		$ 60,215,000
Other Long-term Debt | €				€ 60.2
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €				47.8
Long-term Debt, Percentage Bearing Variable Interest, Amount | €				€ 12.4
Line of Credit, Maturing August 11, 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured revolving credit facility, amount		1,000,000,000				$ 1,000,000,000
Long-term Debt		621,661,000			0
Revolving credit facility outstanding balance		625,000,000
Unamortized Debt Issuance Expense		3,300,000			4,300,000
Term Loan Credit Facility, 12 Months Maturity [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term Debt, Maximum Amount Outstanding During Period		200,000,000
Long-term Debt		200,000,000
Term Loan Credit Facility, Maximum Borrowing Capacity		200,000,000
2021 Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, face value											$ 500,000,000
Long-term Debt		496,583,000			495,800,000
Debt Instrument, Interest Rate, Stated Percentage											5.00%
Discount on senior unsecured notes		(1,400,000)			(1,700,000)						$ (3,100,000)
Unamortized Debt Issuance Expense		2,000,000			2,500,000
Unsecured senior notes, fair value		536,600,000			539,200,000
Financing Lease Obligations [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt		35,911,000
Other Long-term Debt		35,900,000			37,100,000					$ 29,300,000
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt		591,739,000			517,800,000
Debt Instrument, Interest Rate, Stated Percentage							1.875%	1.875%
Discount on senior unsecured notes		(4,700,000)			(4,500,000)		$ (4,400,000)
Unamortized Debt Issuance Expense		$ 4,300,000			4,800,000
Minimum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		0.10%		0.10%
Maximum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		7.90%		7.90%
Vanadis Diagnostics AB [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired			32,000,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			$ 93,000,000
Vanadis Diagnostics AB [Member] | Minimum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Projected milestone date		2,018	2,016
Fair Value Inputs, Discount Rate		2.30%	3.10%
Conditional probability of success		90.00%	85.00%	90.00%
Cumulative probability of success		65.80%	53.00%	65.80%
Vanadis Diagnostics AB [Member] | Maximum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Projected milestone date		2,019	2,019
Fair Value Inputs, Discount Rate		8.40%	11.30%
Conditional probability of success		95.00%	95.00%	95.00%
Cumulative probability of success		95.00%	90.00%	95.00%
Euro Member Countries, Euro | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Long-term Debt | €				€ 47.6
Euro Member Countries, Euro | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, face value | €								€ 500
Unsecured senior notes, fair value		$ 508,900,000			$ 507,500,000

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016	Dec. 28, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	$ 65,328	$ 63,201	$ 57,350	$ 91
Fair Value, Measurements, Recurring [Member] | Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	(2,208)	(1,678)
Foreign Currency Contract, Asset, Fair Value Disclosure	1,431	1,208
Foreign exchange derivative liabilities, net	(23,638)	(1,370)
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	65,328	63,201
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	(2,208)	(1,678)
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Foreign exchange derivative liabilities, net	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	0	0
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Foreign Currency Contract, Asset, Fair Value Disclosure	1,431	1,208
Foreign exchange derivative liabilities, net	(23,638)	(1,370)
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	0	0
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Foreign exchange derivative liabilities, net	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	$ 65,328	$ 63,201

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance beginning of period	$ (63,201)	$ (57,350)	$ (91)
Additions	0	0	(57,353)
Payments	(34)	(332)	(113)
Reclassified to other current liabilities for milestone achieved		10,000
Change in fair value (included within selling, general and administrative expenses)	(2,161)	(16,183)	(19)
Balance end of period	$ (65,328)	$ (63,201)	$ (57,350)

Leases (Details)

Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016	Dec. 28, 2014	Dec. 29, 2013	Aug. 22, 2013
Sale Leaseback Transaction [Line Items]
Sale Leaseback Transaction, Description of Accounting for Leaseback	The lease is accounted for as an operating lease and the excess of the net proceeds over the net carrying amount of the property are being amortized on a straight-line basis over the initial lease term of 15 years.
Sale Leaseback Transaction, Date				8/22/2013
Sale Leaseback Transaction, Gross Proceeds					$ 47.6
Sale Leaseback Transaction, Lease Terms					15 years
Sale Leaseback Transaction, Current Period Gain Recognized	$ 1.8
Sale Leaseback Transaction, Deferred Gain, Gross						$ 26.5
Sale Leaseback Transaction, Deferred Gain, Net	18.8	$ 20.6
Sales Leaseback Transaction, Short-Term Deferred Gain	1.8	1.8
Sales Leaseback Transaction, Long-Term Deferred Gain	17	18.8
Rental expense charged to continiuing operations	54	$ 52	$ 52.4
Minimum rental commitments in next fiscal year	57
Minimum rental commitments due in two years	37.2
Minimum rental commitments due in three year	27.4
Minimum rental commitments due in four years	22
Minimum rental commitments due in five years	13.5
Minimum rental commitments due in six years and thereafter	$ 59.6

Schedule of Sales and Operating

Schedule of Sales and Operating Income from Continuing Operations by Operating Segment (Details) $ in Thousands		3 Months Ended								6 Months Ended	12 Months Ended
		Dec. 31, 2017USD ($)	[1]	Oct. 01, 2017USD ($)	Jul. 02, 2017USD ($)	Apr. 02, 2017USD ($)	Jan. 01, 2017USD ($)	Oct. 02, 2016USD ($)	Apr. 03, 2016USD ($)	Jul. 03, 2016USD ($)	Dec. 31, 2017USD ($)segments	Jan. 01, 2017USD ($)	Jan. 03, 2016USD ($)
Schedule of Segment Reporting Information, by Segment [Line Items]
Operating income from continuing operations		$ 97,420		$ 79,807	$ 75,997	$ 51,579	$ 80,442	$ 75,781	$ 60,577	$ 66,266	$ 304,803	$ 283,066	$ 250,926
Number of Operating Segments | segments											2
Sales Revenue, Goods, Net											$ 1,477,414	1,396,896	1,395,102
Service revenue											779,568	718,621	709,721
Total revenue											2,256,982	2,115,517	2,104,823
Interest and other expense (income), net											8,085	38,998	42,119
Income from continuing operations before income taxes		$ 80,889		$ 105,054	$ 70,792	$ 39,983	$ 69,186	$ 64,518	$ 49,491	$ 60,873	296,718	244,068	208,807
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market											(2,100)	15,300	12,400
Change in allocation of functional Costs, Effect on operating income (loss)												10,668	10,906
Diagnostics [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Operating income from continuing operations											149,636	149,577	146,478
Sales Revenue, Goods, Net											536,086	462,798	427,068
Service revenue											142,437	139,735	149,336
Total revenue											678,523	602,533	576,404
Discovery & Analytical Solutions [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Operating income from continuing operations	[2]										206,688	196,819	162,762
Sales Revenue, Goods, Net											941,328	934,098	968,034
Service revenue											637,131	578,886	560,385
Total revenue											1,578,459	1,512,984	1,528,419
Corporate [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Operating income from continuing operations	[3],[4]										(51,521)	$ (63,330)	$ (58,314)
Particular Discovery & Analytical Solutions Case [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Legal Fees											$ 2,700
[1]	The fourth quarter of fiscal year 2017 includes a pre-tax gain of $2.1 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2016 includes a pre-tax loss of $15.3 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.
[2]	Legal costs for a particular case in the Discovery & Analytical Solutions segment were $2.7 million for fiscal year 2017.
[3]	Activity related to the mark-to-market adjustment on postretirement benefit plans has been included in the Corporate operating loss from continuing operations, and in the aggregate constituted a pre-tax gain of $2.1 million in fiscal year 2017, a pre-tax loss of $15.3 million in fiscal year 2016, and pre-tax loss of $12.4 million in fiscal year 2015.
[4]	{F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjY2MzI5NzExNzJkMjQ5NDk4MjQ4ZThlYzRhOTNmM2Y2fFRleHRTZWxlY3Rpb246RTkwOUMxQjMxNDkzODBFOEEzRjQ5NjIwODM3NUU0QkEM}

Industry Segment and Geograp106

Industry Segment and Geographic Area Information Schedule of Depreciation, Amortization and Capital Expenditures (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Segment Reporting Information [Line Items]
Depreciation and amortization expense	$ 105,000	$ 99,972	$ 105,364
Diagnostics [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	31,204	25,339	29,728
Capital expenditures	11,262	8,556	6,854
Discovery & Analytical Solutions [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	72,590	72,484	74,177
Capital expenditures	26,200	21,486	18,175
Corporate [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	1,206	2,149	1,459
Capital expenditures	1,627	1,660	3,189
Continuing Operations [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	105,000	99,972	105,364
Capital expenditures	39,089	31,702	28,218
Discontinued Operations [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	929	6,266	6,643
Capital expenditures	$ 182	$ 1,302	$ 1,414

Industry Segment and Geograp107

Industry Segment and Geographic Area Information Schedule of Total Assets by Segment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Schedule of Total Assets, by segment [Line Items]
Assets	$ 6,091,463	$ 4,276,683
Diagnostics [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	3,314,804	1,505,381	$ 1,459,854
Discovery & Analytical Solutions [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	2,744,370	2,612,757	2,546,583
Corporate [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	32,289	31,171	28,497
Net current and long-term assets of discontinued operations [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	$ 0	$ 127,374	131,361
Total assets [Member]
Schedule of Total Assets, by segment [Line Items]
Assets			$ 4,166,295

Industry Segment and Geograp108

Industry Segment and Geographic Area Information Schedule of Revenue by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Sales by Geographic Area [Line Items]
Total sales	$ 2,256,982	$ 2,115,517	$ 2,104,823
UNITED STATES
Sales by Geographic Area [Line Items]
Total sales	837,018	842,364	854,336
CHINA
Sales by Geographic Area [Line Items]
Total sales	374,931	336,728	296,908
UNITED KINGDOM
Sales by Geographic Area [Line Items]
Total sales	65,164	65,904	69,081
GERMANY
Sales by Geographic Area [Line Items]
Total sales	91,669	89,839	86,632
INDIA
Sales by Geographic Area [Line Items]
Total sales	84,812	43,891	40,239
ITALY
Sales by Geographic Area [Line Items]
Total sales	77,477	70,948	71,225
FRANCE
Sales by Geographic Area [Line Items]
Total sales	80,153	71,104	70,665
JAPAN
Sales by Geographic Area [Line Items]
Total sales	76,322	65,980	69,381
Other International [Member]
Sales by Geographic Area [Line Items]
Total sales	569,436	528,759	546,356
Total international [Member]
Sales by Geographic Area [Line Items]
Total sales	$ 1,419,964	$ 1,273,153	$ 1,250,487

Industry Segment and Geograp109

Industry Segment and Geographic Area Information Schedule of Long-Lived Assets by Geographic Location (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	$ 476,044	$ 275,050	$ 253,026
UNITED STATES
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	210,116	182,186	165,827
CHINA
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	64,815	36,458	34,494
UNITED KINGDOM
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	28,028	14,638	14,244
INDIA
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	14,820	2,020	1,508
FINLAND
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	14,764	12,295	12,203
SINGAPORE
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	9,240	6,820	7,679
BRAZIL
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	7,963	1,452	1,225
NETHERLANDS
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	4,281	4,162	3,835
ITALY
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	10,334	3,398	2,958
SWEDEN
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	3,869	2,645	1,247
GERMANY
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	88,249	1,292	1,187
Other International [Member]
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	19,565	7,684	6,619
Total international [Member]
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	$ 265,928	$ 92,864	$ 87,199

Quarterly Financial Informat110

Quarterly Financial Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended									6 Months Ended	12 Months Ended
	Dec. 31, 2017		Oct. 01, 2017	Jul. 02, 2017	Apr. 02, 2017	Jan. 01, 2017	Oct. 02, 2016	Jul. 03, 2016	Apr. 03, 2016	Jul. 03, 2016	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Quarterly Financial Data [Abstract]
Revenue	$ 641,630		$ 554,275	$ 546,962	$ 514,115	$ 566,770	$ 514,489		$ 498,016	$ 536,242	$ 2,256,982	$ 2,115,517
Gross profit	307,095		268,822	257,503	239,611	276,163	248,550		235,086	253,554	1,073,031	1,013,353
Restructuring and contract termination charges, net	(263)		3,269	0	9,651	0	656		0	4,468	12,657	5,124	$ 13,547
Operating income from continuing operations	97,420	[1]	79,807	75,997	51,579	80,442	75,781		60,577	66,266	304,803	283,066	250,926
Income from continuing operations before income taxes	80,889	[1]	105,054	70,792	39,983	69,186	64,518		49,491	60,873	296,718	244,068	208,807
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	(2,673)		(5,468)	141,343	2,541	2,560	4,210		5,722	6,101	135,743	18,593	23,640
Operating income from continuing operations	(38,444)	[1]	96,546	62,726	36,062	62,289	53,917		41,744	57,756	156,890	215,706	188,785
Net income	$ (41,117)	[1]	$ 91,078	$ 204,069	$ 38,603	$ 64,849	$ 58,127		$ 47,466	$ 63,857	$ 292,633	$ 234,299	$ 212,425
Basic earnings per share:
Income from continuing operations	$ (0.35)	[1]	$ 0.88	$ 0.57	$ 0.33	$ 0.57	$ 0.49		$ 0.38	$ 0.53	$ 1.43	$ 1.97	$ 1.68
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share	(0.02)		(0.05)	1.29	0.02	0.02	0.04		0.05	0.06	1.24	0.17	0.21
Net income	(0.37)	[1]	0.83	1.86	0.35	0.59	0.53		0.43	0.59	2.67	2.14	1.89
Diluted earnings per share:
Income from continuing operations	(0.35)	[1]	0.87	0.57	0.33	0.57	0.49		0.38	0.53	1.42	1.96	1.67
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share	(0.02)		(0.05)	1.28	0.02	0.02	0.04		0.05	0.06	1.22	0.17	0.21
Net income	(0.37)	[1]	0.82	1.84	0.35	0.59	0.53		0.43	0.58	2.64	2.12	$ 1.87
Cash dividends per common share	$ 0.07		$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.28	$ 0.28
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market											$ (2,100)	$ 15,300	$ 12,400
Tax Adjustments, Settlements, and Unusual Provisions											98,600	(9,600)	(6,400)
Diagnostics [Member]
Quarterly Financial Data [Abstract]
Operating income from continuing operations											$ 149,636	$ 149,577	$ 146,478
[1]	The fourth quarter of fiscal year 2017 includes a pre-tax gain of $2.1 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2016 includes a pre-tax loss of $15.3 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.